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Abstract
Acute leukaemia is the most common form of childhood cancer and is the 
primary cause of cancer-related mortality in children. The major initiating 
event in infant leukaemia is rearrangement of the Mil gene at 1 lq23, and 
such leukaemias have a poor survival rate.
Chromosomal translocations occur commonly in leukaemia and an in-frame 
fusion gene is created with altered properties to the original genes involved. 
Translocations of chromosome 1 lq23 result in the fusion of Mil to a variety 
of partners genes. Mil-Aft results from t(9;l 1), Mll-A/4 from t(4; 11) and 
Mll-Enl from t( 11; 19) and are thought to cause aberrant transcriptional 
regulation.
To identify candidate target genes of t( 11; 19), MLL-ENL has been over­
expressed in 32D cells, an immortalised myeloid progenitor cell line. The 
actions of MLL-ENL on cell survival following growth factor withdrawal, 
and on G-CSF mediated differentiation have been studied. Potential 
transcriptional targets of MLL-AF9 and MLL-ENL have been identified 
using microarray technology. Ten genes were identified as possible 
candidate target genes of the MLL-ENL protein that might be involved in 
leukaemogenesis. Of particular interest were Gatal and HTm4 which have 
a role in haematopoiesis and cell cycle regulation. shRNA constructs were 
generated to knock down MLL-ENL and allow validation of the potential 
target genes.
The mechanism of leukaemic transformation by MLL-ENL has also been 
investigated. In leukaemia, fusion proteins may contribute to 
haematological malignancy in various ways, though the main routes are 
thought to be either a gain-of-function or dominant negative action. In order
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to determine the mechanism by which a MLL fusion protein immortalizes 
murine haematopoietic progenitor cells (HPC), a system was developed 
where MLL-ENL was expressed in murine HPCs in the absence of both 
alleles of Mil. The experiments were carried out using murine HPCs from 
conditional Mil knockout mice generated in our laboratory where the wild- 
type Mil allele is flanked by LoxP sites at exons 9 and 10, and can be 
inactivated following Cre-mediated recombination. The ability of cells to 
undergo sequential re-plating in methylcellulose was used as an indication 
of immortalization. These experiments now definitively show that the 
MLL-ENL fusion protein acts in a gain-of-function manner.
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1 In troduction
1.1 Haematopoiesis
Understanding the general aspects of normal blood cell formation is 
important when considering the ways in which a leukaemic cell may arise. 
Haematopoiesis is a highly ordered and complex process by which all 
mature blood cells are generated from a small subset of pluripotent 
haematopoietic stem cells (HSC). These mature blood cells consist of 
erythrocytes and platelets, leukocytes comprising granulocytes and 
monocytes, and lymphocytes. Developmental control of the different blood 
cell lineages involves progenitor cell exposure to haematopoietic cytokines 
or growth regulators, as well as the regulated expression of genes by 
transcription factors (Engel and Murre 1999).
The initial sites of haematopoiesis within mammalian embryos are the yolk 
sac blood island, para-aortic splanchnopleura (P-Sp), and aorto-gonado- 
mesonephros region (AGM) (Medvinsky and Dzierzak 1996, Zon 1995). In 
the mouse embryo where this process has been most extensively studied, 
primitive haematopoiesis begins on embryonic day 7 (E7) with a burst of 
primitive nucleated erythrocytes that arise from the bi-potential 
haemangioblast which is capable of forming embryonic blood cells as well 
as blood vessels from endothelial cells (Moore and Metcalf 1970). Primitive 
haematopoiesis continues in the P-Sp from E7.5 to E9.5, and then in the 
AGM from E10.5-E11.5. HSC capable of long term repopulation of the 
entire adult haematopoietic system are generated at this stage but require a 
subsequent maturation step within the foetal liver which remains the main 
organ of definitive haematopoiesis, until bone marrow engraftment can be 
achieved and definitive haematopoiesis continues after birth (Baron and 
Fraser 2005, Keller, et al 1999).
17
Of importance to normal development and theories regarding 
leukaemogenesis is the capacity of stem cells to self-renew and regulate the 
relative balance between self-renewal and differentiation. Mouse 
multipotent progenitors can be divided into long-term (LT-) and short-term 
(ST-) HSC with the potential to renew, as well as multipotent progenitors 
(MPP) without detectable self-renewal potential (Spangrude, et al 1988). 
The classical model for haematopoietic commitment and blood lineage 
development is shown schematically in Figure 1.1 A. In this model the first 
and decisive lineage commitment step occurs in LT-HSC. This results in 
the generation of daughter cells with increased lineage commitment, and 
more limited ability to self-renew, termed ST-HSC (Akashi, et al 2000, 
Reya, et al 2001, Shizuru, et al 2005). The ST-HSC gives rise to the MPP 
which gives rise to either the common lymphoid or common myeloid 
progenitors (CLP and CMP respectively), with the capacities for 
differentiation into more limited cell types (Akashi, et al 2000, Shizuru, et 
al 2005). The CLP is capable of generating natural killer (NK) cells which 
lack typical immunophenotypic markers of T- or B-cells and are capable of 
lysing a variety of tumour or virus infected cells without any obvious 
antigenic stimulation (Kondo, et al 1997). The CLP also gives rise to both T 
and B lymphocyte progenitors (pro-T and pro-B cells respectively) with 
subsequent generation of T and B lymphocytes. The CMP give rise to 
granulocyte-macrophage- progenitors (GMP) and megakaryocyte-erythroid 
progenitors (MEP). The GMP gives rise to mature granulocytes 
(neutrophils, eosinophils and basophils), and monocytes, while mature 
erythrocytes and platelet-producing megakaryocytes are derived from the 
MEP (Akashi, et al 2000).
More recently this classical model of haematopoietic commitment has been 
challenged in the light of further investigation into the molecular pathways 
involved. ST-HSC which co-expressed high levels of the FMS-like tyrosine 
kinase 3 (FLT3) receptor appeared to sustain granulocyte, monocyte, and
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lymphocyte potentials, but were restricted in their ability to produce 
significant erythroid and megakaryocyte progeny (Adolfsson, et al 2005). 
The alternative model proposed is that the ST-HSC develops into a 
lymphoid primed multipotent progenitor (LMPP) following the loss of its 
megakaryocyte and erythroid potential. Cells retaining this potential derived 
from the ST-HSC are termed MEP. The LMPP then generates a CLP 
following loss of its GM potential. Cells retaining GM potential are derived 
from the LMPP and are termed GMP. Caveats of this proposed model, 
however, are that there needs to be a demonstration that LMPP do give rise 
to GMP, and that it is yet to be determined whether the proportion of GMP 
arising through the alternative pathway is similar to that arising from the 
classical route as implied by the model (Hock and Orkin 2005). This 
proposed model of haematopoietic lineage commitment is incorporated into 
the classical model by the authors and a composite model is shown in 
Figure 1.1B, which suggests that GMP are derived from either the LMPP or 
the CMP, and that both the latter two cell types co-exist.
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Figure 1.1 Pathways of haematopoietic cell commitment.
A shows the traditional model of haematopoiesis in which long-term 
haematopoietic stem cells (LT-HSC) give rise to short-term haematopoietic 
stem cells (ST-HSC) with a more limited self-renewal capacity. ST-HSC 
give rise to multipotent progenitors (MPP) which give rise to the common 
myeloid progenitor (CMP) and common lymphoid progenitor (CLP). 
Myeloid and lymphoid mature cell types respectively are derived from 
these progenitors. MEP: megakaryocyte-erythrocyte progenitor, GMP: 
granulocyte-macrophage progenitor.
B shows a composite model (Adolfsson, et al 2005) in which ST-HSC give 
rise to the lymphoid primed multi-potent progenitor (LMPP) and CMP. The 
LMPP gives rise to both the CLP and GMP. Mature cells arise from the 
MEP, GMP and CLP as previously shown.
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1.2 Transcriptional regulation of haematopoietic 
development
The ability to manipulate the mouse genome via homologous recombination 
into embryonic stem (ES) cells has defined the role of a number of genes in 
the transcriptional control of haematopoiesis, particularly in determining 
self-renewal ability of HSC and lineage commitment (reviewed in (Baron 
and Fraser 2005, Engel and Murre 1999).
The haemangioblast is the common progenitor that gives rise to primitive 
haematopoietic cells and endothelial cells, and requires expression of the 
stem cell leukaemia (SCL) transcription factor in addition to the vascular 
endothelial growth factor (VEGF) receptor if angioblast fate is not to occur 
(Ema, et al 2003). Development and localization of embryonic HSC 
appears to involve different factors to those which govern the function of 
mature HSC in the adult. Primitive haematopoiesis results in the production 
of transient large nucleated erythroblasts, megakaryocytes and immature 
macrophages, and is stimulated by VEGF signalling. SCL and LIM domain 
only 2 (LM02) are essential transcriptional regulators of early 
haematopoiesis (Robb, eta l 1995, Warren, et al 1994), while globin 
transcription factor 1 (GATA1) and GATA2 functions overlap (Fujiwara, et 
al 2004) . Transcriptional regulation of definitive haematopoiesis requires 
acute myeloid leukaemia 1 (AML1), subunit b of core binding factor 
(CBF/B), and expression of the myeloblastosis oncogene cmyb which, if 
mutated, cause widespread defects in definitive haematopoiesis but do not 
affect primitive erythropoiesis (Okuda, et al 1996), and loss of GATA2 
expression at this point cannot be compensated by GATA1 (Fujiwara, et al 
2004). However, in contrast to the continued expression of other factors 
required to determine and maintain lineage identity and function, 
expression of SCL in HSC and MPP does not contribute to HSC 
engraftment, self-renewal and differentiation into myeloid and lymphoid
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lineages (Mikkola, et al 2003b). A related transcription factor, 
lymphoblastomic leukaemia 1 (LYL1), however, is required for normal 
HSC function as well as B-cell differentiation, and Lyll null fetal liver and 
bone marrow cells fail in their competitive reconstituting abilities (Capron, 
et al 2006). Interestingly, Scl and Lyll are regulated by the same E26 avian 
leukaemia oncogene (ETS) and GATA factors, and may explain the mild 
phenotype of Scl null HSC when Lyll expression is intact (Chan, et al 
2007).
The development of distinct lineages from MPP is controlled by cell- 
restricted transcription factors and exposure to haematopoietic cytokines, 
and deregulation of normal transcription is implicated in the development 
of leukaemias associated with chromosomal translocations (Rabbitts, et al 
1999). Gene targeting studies and enforced expression in cells capable of 
differentiation have allowed the identification of factors that essentially 
determine or influence lineage commitment from MPP.
1.2.1 Transcription factors involved in myeloid and lymphoid 
lineage determination
As well as being required for the definitive development of all 
haematopoietic lineages, AML1 and CBF/B are required for the normal 
differentiation and proliferation of myeloid and lymphoid cells. Both genes 
are commonly rearranged in t(8;21) and inversion (16) acute myeloid 
leukaemia (AML), and in t(12;21) common acute lymphoblastic leukaemia 
(ALL) (Lo Coco, et al 1997, McHale and Smith 2004). PU.l belongs to the 
ETS-family of transcriptional regulators and determines HSC self-renewal 
as well directing lineage development by binding to the promoters of many 
myeloid genes including the macrophage colony-stimulating factor (M- 
CSF) receptor, granulocyte-macrophage (GM)-CSF receptor alpha, and the 
alpha sub-unit CD1 lb of the integrin Macl (Dakic, et al 2005, 
Gangenahalli, et al 2005, Iwasaki, et al 2005). In B cells, it regulates the
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immunoglobulin lambda 2-4 and kappa 3' enhancers, and J chain promoters 
(reviewed in (Gangenahalli, et al 2005).
GATA1 and friend of Gatal (FOG1) are essential transcription factors in 
erythroid and megakaryocytic lineages (Orkin 1992, Shivdasani, et al 
1997), and both GATA1 and GATA2 may interact with PU.l to inhibit its 
function. Overexpression of GATA1 in early myeloid cells blocks myeloid 
development (Visvader, et al 1992). Pathway inhibition also results in 
myeloid development, and over expression of PU.l can block erythroid 
development in proerythroblasts and result in erythroblast immortalisation 
and in erythroleukaemia in mice (Moreau-Gachelin, et al 1996). This 
suggests an ability of a particular transcription factor to upregulate lineage- 
specific target genes in a cell capable of differentiation into more than one 
lineage, depending on the degree of expression of that particular 
transcription factor compared to another. In a model of myeloid 
development by PU.l, both PU.l and GATA1 are expressed at low levels in 
CMP and specific upregulation of PU.l is associated with a decrease in 
GATA1 expression due to direct binding of GATA1 by PU.l. Activation of 
specific genes by PU.l results in increased proliferation, differentiation and 
suppression of apoptosis of myeloid progenitors in a programme of myeloid 
lineage commitment (Zhang, et al 1999, Zhang, et al 2000). The 
amplification of specific transcriptional programmes associated with a 
specific lineage, with associated repression of those of other lineages, in the 
presence of specific transcription factors, is likely to be the mechanism by 
which MPP become committed to specific lineages.
CCAAT/enhancer binding proteins (C/EBP) are upregulated during 
myelopoiesis and C/EBPe is a regulator of terminal differentiation of 
eosinophils and functional maturation of neutrophils (reviewed in 
(Yamanaka, et al 1998). C/EBPa protein is present at high levels in the 
myeloblastic murine 32Dcl3 cell line which is used in this study, and this
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protein is regulated during differentiation by G-CSF. Upon G-CSF 
treatment the levels of C/EBPa increase 2-fold within 24 hours, and are 
maintained for several days before falling to low levels by day 6 of 
differentiation (Scott, et al 1992). G-CSF treatment is also used in this 
study to examine effects of oncogene expression on differentiation.
B cell development involves lineage determination through co-ordinated 
transcriptional regulation, together with pre-B cell receptor selection, and 
subsequent B cell tolerance during the immature-to-mature B cell transition 
(reviewed in (Busslinger 2004, Hayakawa, et al 1997, Schebesta, et al 
2002). Illustrative examples of transcription factors involved in B cell 
development are described below.
Gene targeting studies show that the initiation of B-cell development in the 
bone marrow depends on the B-cell specific, basic helix-loop-helix 
transcription factor E2A and early B-cell factor EBF (Zhuang, et al 2004, 
Zhuang, et al 1994). These proteins regulate B-cell specific activator 
protein (BSAP), the transcription factor encoded by the Pax5 gene, which is 
critical to B-cell development in suppressing alternative lineage cell fates 
early in development, and Pax5 null pro-B cells can generate both myeloid 
and T lineage cells. Studies using a Pax5 conditional knockout mouse has 
revealed that PAX5 expression must be maintained through the pro-B stage, 
as loss of PAX5 results in committed pro-B cells reverting to multi-lineage 
potential cells (Nutt, et al 1999, Rolink, et al 1999). The t( 17; 19) 
translocation results in the formation of the E2a-hepatic leukaemic factor 
(Hlfl fusion gene in which the expression of HLF is aberrantly driven by the 
E2a promoter, implicating the deregulation of these genes in a rare 
childhood pro-B ALL (reviewed in (Seidel and Look 2001).
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1.2.2 The structure and function of the MLL gene in normal 
haematopoiesis
The mixed lineage leukaemia (Mil) gene spans 90 kb of chromosome 
1 lq23, has 38 exons (Nilson, et al 1996), and codes for a protein of 3969 
amino acids (Tkachuk, et al 1992). The Mil gene and its protein product are 
shown in Figure 1.2.
The MLL protein product shows structural similarities to Drosophila 
Trithorax (TRX) protein, with strong homology shared in the SET 
(Su(var)3-9, enhancer-of-zest) and PHD (plant homeodomain) domains 
(Tkachuk, et al 1992), and these domains are associated with a role in 
transcriptional regulation by modification of chromatin (Fair, et al 2001). 
The PHD domain mediates transcriptional repression through its binding of 
peptidyl-prolyl isomerase E (Cyp33), and other well-characterised domains 
are also implicated in the regulation of chromatin structure and 
transcription.
Three AT hook domains located in the amino terminus of MLL bind DNA 
that has AT-rich regions with a particular cruciform or bent tertiaiy 
structure rather than doing so in a sequence specific manner (Aravind and 
Landsman 1998). Two nuclear localisation domains in the amino terminal 
region confer a punctate nuclear expression pattern on the MLL protein 
(Yano, et al 1997). The DNA methyltransferase homology domain (MT) 
provides DNA binding ability in addition to the AT hook domains, enabling 
MLL to bind unmethylated CpG (cytidine and guanine separated by 
phosphate) sequences with high specificity (Birke, et al 2002) and direct 
methylation of these sequences would normally result in transcriptional 
silencing. Transcription is repressed during interaction of the DNA 
methyltransferase domain with an active promoter in reporter assays and 
thought to be mediated by interaction with histone deacetylases or the 
polycomb group proteins histone periodic control 2 (HPC2) and murine
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leukaemia viral oncogene homologue (BMI1) (Prasad, et al 1995, Xia, et al 
2003, Zeleznik-Le, et al 1994) and may involve chromatin modification by 
MLL. A transactivation domain (TAD) is located between the PHD and 
SET domains (Prasad, et al 1995) and facilitates the binding of MLL to the 
cAMP binding protein (CBP) to enhance transcriptional activation by 
promoting its binding with cAMP response element binding (CREB) (Ernst, 
et al 2001).
The MLL protein has a predicted molecular weight of 430kDa, though 
actually migrates at ~500kDa, and is proteolytically processed by Taspasel 
in vivo at a conserved site between the PHD and transactivation domains to 
generate two polypeptides of 180 and 320 kDa (Hsieh, et al 2003), where 
the N-terminal polypeptide retains transcriptional repression properties and 
the C-terminal domain contains transcriptional activation properties. 
Although the cleavage of MLL separates the transrepression and 
transactivation domains of MLL, immunoprecipitation of either polypeptide 
isolates almost identical protein complexes, suggesting MLL exists as a 
heterodimer in part of a single complex, and not as two separate complexes 
(Hsieh, et al 2003, Nakamura, et al 2002, Yokoyama, et al 2002). A mouse 
knockout model of Taspase 1 provides evidence that dimerisation of MLL 
is important for normal MLL function, and the majority of 
Taspase /"A mice die at approximately 2 days post-partum (Takeda, et al 
2006). Full length MLL is still present in murine embryonic fibroblasts but 
the cleaved MLL protein cannot be detected. The lethality seen in this 
model is not similar to the early embryonic death seen in M/^'mice ((Yagi, 
et al 1998, Yu, et al 1995), and suggests that the residual full length MLL 
has some normal function that maintains the mice to a later stage of survival 
(Takeda, et al 2006).
MLL is now known to be part of a super-complex containing proteins 
associated with other complexes such as SWI/SNF, NuRD, Sin3A, TFIID
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and the yeast SET1 homologues as well as the hSNF2H protein, which 
acetylate, deacetylate and methylate histones thus regulating gene 
transcription (Nakamura, et al 2002). The SWI/SNF complex and hSNF2H 
are involved in chromatin remodelling, the NuRD complex has histone 
deacetylase and nucleosome remodelling activity, the Sin3A complex has a 
histone deacetylase function, and the TFIID complex acts in transcriptional 
activation (Lemon, et al 2001).
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Figure 1.2 Structure of the wiid-type MLL protein and schematic view 
of an MLL fusion protein.
The 430 kDa MLL protein is proteolytically processed by Taspase 1 in vivo 
at a conserved cleavage site between the PHD and transactivation domains 
to generate two polypeptides of 180 and 300 kDa, where the N-terminal 
polypeptide retains transcriptional repression properties and the C-terminal 
domain contains transcriptional activation properties. These fragments 
interact in vivo via the FYRN domain of p300 and the FYRC domain of 
pi 80. Cleavage at the breakpoint region and fusion of the N-terminal 
fragment with a nuclear or cytoplasmic partner protein results in an aberrant 
fusion protein.
AT hooks: AT hook DNA binding motifs, SNL 1 and 2: speckled nuclear 
localization signals 1 and 2, CxxC (MT): cysteine-rich motif homologous to 
DNA methyltransferase and MBD1, PHD 1-3: PHD fingers 1, 2 and 3, 
BROMO: BROMO domain, FYRN: F/Y-rich region, N-terminus, FYRC: 
F/Y-rich region, C-terminus, TAD: transactivation domain, SET: SET 
domain. Regions structurally conserved with Trithorax of Drosophila are 
indicated by the (TRX) label. Reproduced from (Li, et al 2005).
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A further complex has been identified in which MLL is contained with 
Menin, Host Cell Factor (HCF) 1 and 2, ASH2L1, RBBP5 and WDR5 
(Hughes, et al 2004, Yokoyama, et al 2004). The components of this 
complex have only two proteins in common with the previously identified 
complex and differences in complex composition may be due to alterations 
in cellular environment (Yokoyama, et al 2004). The pivotal role of Menin 
in regulating MLL target genes including homeobox (Hox) genes is 
described in Chapter 1.5.3 and it appears that all the components of the 
complex bind to the promoter of Hoxa9 only when MLL is present 
(Nakamura, et al 2002).The role of the proteins within the supercomplex 
appear to have a significant role in the transcriptional activation properties 
of MLL through a chromatin remodeling function which may have 
implications for the way in which MLL fusion proteins function in human 
leukaemia.
MLL is expressed in haematopoietic and a variety of non-haematopoietic 
tissues (Butler, et al 1997). The normal function of MLL has been 
examined by gene targeting studies which show striking abnormalities of 
haematopoiesis and a number of defects in non-haematopoietic tissues in 
MLL knockout mice (Yagi, et al 1998, Yu, et al 1998, Yu, et al 1995). Both 
haematopoietic and non-haematopoietic defects in MLL knockout models 
appear to be due to aberrant regulation of Hox genes by MLL. Hox genes 
are key regulators of haematopoiesis as well as of the mammalian body 
plan, determining the axial skeleton, hind brain and limb development 
during embryogenesis (Boncinelli, et al 1989, Grier, et al 2005, Lawrence 
and Largman 1992).
M il''' mice die between E l0.5 and 14.5 (Hess, et al 1997, Yagi, et al 1998, 
Yu, et al 1998, Yu, et al 1995). These mice show axial skeletal 
abnormalities, anaemia and thrombocytopoenia and a marked decrease in
30
the number of haematopoietic cell precursors in the yolk sac, although all 
cell types are present (Hess, et al 1997, Yu, et al 1995).
Investigation into the role of MLL in definitive haematopoiesis has 
previously shown that M il''' ES cells are unable to contribute to the foetal 
liver haematopoietic stem cell population in chimaeric mice (Ernst, et al 
2004a). Cells expressing the receptor tyrosine kinase cKIT that were 
present in the AGM of M il''' mice did not have normal expression of HSC 
cell surface marker, and cells derived from the El 1.5 AGM region of Mil ~lm 
mice were unable to reconstitute recombinant activating 2 {Rag-2'1') mice, 
while those derived from M il+l' mice were unable to generate HSC at 
normal frequencies (Ernst, et al 2004a). These studies suggested that MLL 
is required for primitive haematopoietic cells to generate normally 
functioning HSC, either directly or by promoting their ability to undergo 
maturation in the fetal liver. However, the absolute requirement for MLL 
has been challenged more recently by studies which show that grossly 
normal haematopoiesis involving all cell lineages is observed in adult mice 
in which Mil is deleted in haematopoietic cells only (McMahon, et al 2007 
manuscript submitted). However, in competitive repopulation assays, Mil 
deficient bone marrow cells were unable to compete with wild type cells, 
again suggesting that Mil is needed for the correct development of foetal 
liver haematopoiesis and also to retain self-renewal potential in adult 
haematopoietic cells (McMahon, et al 2007 manuscript submitted).
The role of MLL in driving proliferation of haematopoietic progenitors is 
shown by the reduced ability of M/-deficient yolk sac and fetal liver cells 
to establish normal colony formation in vitro (Hess, et al 1997, Yagi, et al
1998). A reduction in the size of all colony forming units was observed, 
while the cell phenotype within each unit was preserved and identical to 
those from M il+l' or M i l embryos. Thus, MLL does not appear to be 
required for late-stage differentiation of these progenitors. However,
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although M il''' ES cells were able to generate normal embryoid bodies to 
give rise to a haemangioblast with the ability to commit to both 
haematopoietic and endothelial cells, MLL was required for the early 
differentiation and proliferation of haematopoietic cells derived from M il''' 
mesoderm, and such haematopoietic cells failed to form haematopoietic 
colonies in vitro (Ernst, et al 2004a, Ernst, et al 2004b).
Analysis of Hox gene expression identifies the role of MLL in maintaining, 
but not initiating the expression of these genes. Hoxa7 and Hoxc8 genes are 
initially expressed normally but not sustained (Yu, et al 1998), and MLL 
has also been shown to maintain the expression of Hoxa9, HoxalO, Hoxb4, 
Hoxb5, Hoxb6, Hoxb8, Hoxc6 and Hoxc9 (Ernst, et al 2004b, Hanson, et al 
1999). Heterozygous mutant embryos show a one-segment posterior shift in 
Hoxc8 expression (Hanson, et al 1999). The actions of Polycomb group 
proteins, such as BMI1 which also has a SET domain, antagonise Trithorax 
group proteins, and alter chromatin structure to repress transcription of 
target genes (Kennison 1995, Orlando 2003, Schumacher and Magnuson
1997). In contrast to Mil mutants, embryos deficient for Bmil show a one- 
segment anterior shift in Hoxc8 expression and some of the defects 
associated with MU'1' mice can be reversed by loss of Bmil gene expression 
(Hanson, et al 1999). These studies propose a definitive role for MLL in 
normal haematopoiesis through its regulation of Hox genes, which in turn 
are essential to this process.
1.2.3 The role of Hox genes in regulating haematopoiesis
Hox genes are critical to normal haematopoietic development and are 
maintained by normal MLL protein expression, such that failure to express 
a subset of Hox genes may underlie the haematopoietic defect in Mil 
knockout mice (Yagi, et al 1998, Yu, et al 1995). Aberrant Hox gene 
expression is seen in microarray studies of over-expressed MLL-fusion 
proteins in vitro (Antonchuk, et al 2001, Armstrong, et al 2002, Debemardi,
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et al 2003, Tsutsumi, et al 2003, Yeoh, et al 2002), and is associated with 
the development of leukaemia in mouse models of MLL fusion leukaemias, 
and their importance as potential targets of MLL fusion proteins in causing 
leukaemia is investigated as part of this study. An understanding of the role 
of Hox gene expression in normal haematopoiesis and its relation to normal 
MLL function may inform an understanding of the way in which aberrant 
Hox gene expression may result from MLL-fusion expression and 
contribute to leukaemia.
Homeotic mutations in Drosophila result in one body segment being 
transformed into another, and give rise to the term Homeobox. This 
conserved 180 nucleotide region shared by the genes involved in these 
mutations encodes a 60 amino acid DNA-binding motif, and forms a helix- 
tum-helix structure, known as the homeodomain (Gehring, et al 1994). The 
development of the Drosophila embryo is guided by the precise temporal 
and spatial pattern of expression of these homeobox genes. The homeotic 
cluster of homeobox genes (HOM-C) is expressed in ordered domains, from 
3' to 5', to parallel the anterior to posterior development of the axial body 
plan. Mammalian homeobox-containing genes that are expressed in 
haematopoietic cells include the hexapeptide group including the Hox genes 
containing an N-terminal 6-amino acid protein interaction domain, the POU 
group containing an N-terminal POU domain, the LIM group with an N- 
terminal LIM domain in addition to the homeodomain, and the TALE group 
including PBX and Meis proteins with homeodomains containing three 
extra amino acids. Homeobox proteins bind to DNA with increased affinity 
in combination with partner proteins such as PBX.
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Figure 1.3 The genomic organisation of mammalian Hox genes.
Four conserved clusters, labelled A, B, C and D, containing 9 to 11 genes 
are organized on four different chromosomes, and each gene is numbered 
according to its 3' to 5' order on the chromosome. The thirteen paralog 
groups have a particularly high sequence identity among one another. The 
genes are expressed in temporal and spatial overlapping patterns along the 
body axes during murine embryogenesis to specify axial spine, limb, 
gastrointestinal and genitourinary development, and are expressed in a 3' to 
5' direction. Reproduced from (Carroll 2000).
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The genomic organization of the 39 mammalian Hox genes is shown in 
Figure 1.3. Four conserved clusters, labelled A, B, C and D, containing 9 to 
11 genes are organized on four different chromosomes (Boncinelli, et al 
1989). Each gene is numbered according to its 3' to 5' order on the 
chromosome, such as Hoxal, Hoxb2 and so forth. Genes that are in the 
same position on different clusters, such as Hoxa4, Hoxb4, Hoxc4 belong to 
the same paralog group, and there are thirteen paralog groups, and have a 
particularly high sequence identity among one another. Mammalian Hox 
genes have significant sequence identity to those of the single HOM-C 
cluster found in insects, suggesting a strong evolutionary pressure to 
maintain the clustered genomic organization of homeobox genes. These 
genes are expressed in temporal and spatial overlapping patterns along the 
body axes during murine embryogenesis to specify axial spine, limb, 
gastrointestinal and genitourinary development, and are expressed in a 3' to 
5’ direction. Hox A mice show multiple developmental abnormalities, and 
these abnormalities tend to be restricted to the most anterior region of the 
deleted gene’s usual domain of expression, the defects affect several 
different tissues in the same region, and unlike Drosophila, true 
transformation of one body part into another does not occur, but rather a 
loss of structures (Boncinelli, et al 1989, Lawrence and Largman 1992).
The normal stem cell and committed progenitor compartment of normal 
bone marrow expresses multiple genes of the HOXA, HOXB and HOXC 
clusters (Giampaolo, et al 1994, Moretti, et al 1994, Sauvageau, et al 1994), 
and Hox gene expression is highest in the most primitive subpopulation 
(Sauvageau, et al 1994). Genes that are located at the 3' region of the 
clusters are down regulated at the committed progenitor stage, while those 
at the 5f end are maintained until cells are undergoing the later stages of 
differentiation (Kawagoe 1999). Such genes include Hoxa9, Hoxb9, and 
HoxalO (Sauvageau, et al 1994) whose aberrant expression is implicated in 
leukaemogenesis described below.
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Murine models suggest that HOXA, HOXB, and HOXC cluster genes are 
expressed in early mouse yolk sac at the same time as the onset of 
haematopoiesis (McGrath and Palis 1997). Loss-of-function studies of 
Hoxa9 show that haematopoiesis is affected at the level of the stem cell as 
well as the committed progenitor. Hoxa9 deficient mice were viable and 
fertile with only mild skeletal defects, but defective haematopoiesis of T 
and B cells and granulocytes occurred (Lawrence, et al 1997). In vivo 
assays suggested that Hoxa9 knockout mice had defects in their HSC with a 
ten-fold greater defect in ability to reconstitute the bone marrow 
compartment of sublethally-irradiated syngeneic mice compared to wild- 
type bone marrow (Lawrence, et al 1997).
Failure to down-regulate 3' Hox genes appears to result in a failure of cell 
differentiation and causes cell transformation. Retroviral transduction 
experiments to over-express specific Hox genes showed that Hoxa 10 over­
expression was associated with large numbers of megakaiyocyte/blast 
progenitors which evolved into AML (Thorsteinsdottir, et al 2002, 
Thorsteinsdottir, et al 1997). A marked reduction in pre-B-cell progenitors 
was also observed as well as a loss of committed macrophage progenitors 
suggesting that down-regulation of Hoxa 10 is required for B cell 
development and myeloid differentiation (Thorsteinsdottir, et al 2002, 
Thorsteinsdottir, et al 1997). Similarly, over-expression of Hoxa9 also 
results in the development of AML following an expansion of HSC and 
myeloid precursors (Kroon, et al 1998, Thorsteinsdottir, et al 2002), and 
again a role for Hoxa9 in blocking HPC differentiation is suggested. 
Retroviral over-expression of Hoxb3 blocks both B- and T-cell 
development and causes a myeloproliferative disorder that progresses to 
AML (Sauvageau, et al 1995). In contrast, over-expression of Hoxb4, 
resulted in only mild elevations in the myeloid and B-cell compartments 
with no effect on cell differentiation and no development of leukaemia, but
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did appear to positively regulate the expansion of the HSC pool 
(Antonchuk, et al 2001, Sauvageau, et al 1995, Thorsteinsdottir, et al
1999). HoxA, HoxB and HoxC gene expression is reduced in the deficient 
number of haematopoietic cells derived from embryoid bodies lacking Mil, 
and these cells are unable to divide and differentiate normally to form 
colonies. The ability of cells to differentiate, is restored by re-expression of 
Hoxa9, Hoxa 10 and Hoxb4 genes with subsequent colony phenotype 
depending on the individual gene re-expressed (Ernst, et al 2004b). This 
suggests that individual Hox genes are able to rescue the ability of cells to 
differentiate in the absence of Mil, but are redundant in terms of conferring 
a proliferative function upon these cells.
1.3 Chromosomal translocations in paediatric acute 
leukaemia
The main subtypes of ALL and AML in childhood involve a variety of 
genetic alterations and are characterised by gross chromosomal changes 
which may be numerical, or structural in the form of translocations. 
Chromosomal translocations involve illegitimate recombination events or 
the juxtaposition of normally separated genes. Such a process can result in 
the deregulation of an oncogene by association with a powerful active 
regulatory element, as in the case of the cMYC oncogene juxtaposed with 
the immunoglobulin heavy chain enhancer.
Alternatively, and more commonly in leukaemogenesis, an in-frame fusion 
gene is created with altered properties to the original genes involved, and 
which usually has activated kinase activity or properties of novel 
transcriptional regulation (Greaves 2003, Greaves and Wiemels 2003).
Such fusion genes are formed as a result of a number of chromosomal 
translocations in paediatric leukaemia, which include translocations of 
chromosome 1 lq23 resulting in the fusion of MLL to one of up to 50 known
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partners genes. These fusion genes are associated with approximately 80% 
of infant leukaemias and confer a very poor survival in ALL cases (Pui, et 
al 2002), and are also associated with the majority of therapy-related 
leukaemias (Pui and Relling 2000). The fusion genes MLL-AF4, MLL-ENL 
and MLL-AF9 are the three most frequently found in childhood leukaemias. 
MLL-AF4 fusions are almost exclusively associated with ALL, MLL-ENL 
found in both AML and ALL cases, while MLL-AF9 is mainly associated 
with AML, reflecting a tumour tropism which may allow clues to the 
biology of these leukaemias.
The main repair mechanism underlying aberrant recombination is thought 
to be non-homologous end-joining (Greaves and Wiemels 2003). In 
addition, it is known that inhibitors of topoisomerase II interfere with the 
re-ligation of DNA double strand breaks induced during chromosomal 
replication by topoisomerase II, thus exposing DNA free ends to allow 
translocations to occur. Most therapy-related leukaemias are MLL- 
rearranged leukaemias which have developed following previous treatment 
with topoisomerase II inhibitors for earlier malignancies. This, together 
with an association of maternal exposure to naturally occurring 
topoisomerase II inhibitors and MZZ-rearranged infant leukaemias suggests 
that 1 lq23 translocations occur in utero as a result of interference with 
DNA repair (Alexander, et al 2001).
Other fusion genes arise from translocations associated with paediatric 
leukaemia. These are shown in Table 1.
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Table 1 Chromosomal translocations and respective fusion genes found 
in paediatric leukaemia.
Disease Translocation Fusion protein
ALL t(9;22)(q34;ql 1) BCR-ABL
(12;21)(pl3;q22) TEL-AML
t( 1; 19)(q23 ;p 13) E2A-PBX1
t( 17; 19)(q22;p 13) E2A-HLF
AML inv (16) CBFp-MYHl 1
t(8;21)(q22;q22) AML-1-ETO
t(15;17)(q22;ql 1.2) PML-RARa
1.4 Neoplastic transformation and leukaemogenesis 
1.4.1 Evolution of the m alignant clone
The malignant transformation of cells to cause cancer is thought to follow a 
model in which there is the sequential accumulation of multiple genetic 
aberrations in a cell. This initially causes a limited expansion of the progeny 
of a single cell, and subsequent mutations result in new clonal outgrowth 
with a deregulated program of differentiation, proliferation or survival 
(Cavenee and White 1995, Greaves and Wiemels 2003). This model is 
illustrated in Figure 1.4. Only some of the acquired genetic aberrations in 
the final tumour will be critical to the transforming process, and identifying 
these initiating events will increase an understanding of disease biology and 
opportunities to develop targeted therapies.
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Figure 1.4 Model of malignant transformation in which clonal 
outgrowth results from the accumulation of multiple genetic 
aberrations.
The emergence of a cancer cell is thought to arise via a process of clonal 
evolution in which a daughter cell aquires a cancer-promoting mutation, 
passes it on to its progeny and all future generations. At some point, one of 
the descendants acquires a second mutation, and each later descendent 
acquires sequential ones. Eventually a cell accumulates enough mutations 
to cross the threshold to cancer.
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MLL translocations may follow the model of malignant transformation 
described with secondary mutations necessary for transformation, or it may 
be that the MLL-translocation is the only event required to cause 
leukaemia. Studies have shown that a malignant clone develops in utero 
which is able to cause MLL rearranged leukaemia in concordant twins 
(Greaves, et al 2003), and together with the short latency of infant 
leukaemia, support that MLL translocation is the only event required to 
cause disease. In addition, mouse models of MLL leukaemia in which the 
translocation has been engineered give rise to disease with very short 
latency suggesting that no other event is required (Forster, et al 2003).
However, other mouse models give rise to leukaemia with varying latencies 
and suggest that different MLL-fusion proteins have different capacities to 
induce leukaemia and some may have a greater requirement for secondary 
mutations than others. Such long-latency leukaemias arise in retroviral 
transduction models of MLL-ELL, MLL-CBP, MLL-AFX and MLL- 
FKHRL1 (Lavau, et al 2000a, Lavau, et al 2000b, So and Cleary 2003). 
MLL-ENL, MLL-AF9, MLL-GAS7, MLL-AF10 and MLL-AFlp cause 
leukaemias with shorter latencies in mouse models and may be more 
efficient in their oncogenic action (Cozzio, et al 2003, DiMartino, et al 
2002, Martin, et al 2003, So, et al 2003a, So, et al 2003b).
The MLL fusion may be the primary event that predisposes the cell to 
further genetic aberrations before leukaemia arises. If secondary mutations 
are required, these may become independent of the initial primary event of 
MLL translocation. Conditional MLL-ENL expression in vitro causes 
immortalization in HPC but these cells differentiate when MLL-ENL 
expression is turned off (Horton, et al 2005, Zeisig, et al 2004) suggesting 
that the immortalized phenotype is dependent on the maintenance of 
primary MLL-ENL expression in vitro. Results of inhibiting MLL fusion 
expression in cell lines vary. Maintained expression of the fusion protein
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appears necessary to sustain the phenotype in blasts harbouring MLL-AF9 
which show apoptosis following targeted inhibition of this fusion protein 
(Kawagoe, et al 2001, Pession, et al 2003) and similarly targeted inhibition 
of MLL-ENL in a leukaemic cell line also induced apoptosis (Akao, et al
1998). However, THP-1 cells (from a human monocytic cell line) were 
unable to terminally differentiate following knock down of MLL-AF9 
protein in these cells (Pession, et al 2003), and this may be due to the 
harbouring of many further acquired mutations in such cells which may 
make them independent of MLL-AF9 in regard to their malignant 
behaviour.
1.4.2 The cell of origin of the malignant clone
Acute leukaemia arises from the clonal expansion of myeloblasts or 
lymphoblasts in the blood or bone marrow to form AML or ALL 
respectively (Downing and Shannon 2002). The characteristics of the cell of 
origin, or ‘leukaemic stem cell’ (LSC), in which leukaemia-associated 
translocations arise continue to be investigated. Such a cell might have the 
characteristics of a HSC with the ability to self-renew, or possibly a 
progenitor cell with the ability to proliferate and differentiate but without 
the ability to self-renew (Huntly and Gilliland 2005).
The association of particular lineages of leukaemia with certain MLL fusion 
proteins gives rise to the possibility that the fusion partner determines the 
lineage of the leukaemia in a multipotent haematopoietic progenitor. The 
progenitor cell type may determine its susceptibility to the integration of a 
particular fusion partner, or the cell type may determne its susceptibility to 
being transformed by a particular fusion gene (Daser and Rabbitts 2004).
Evidence for the in utero origin of a number of fusion-associated paediatric 
leukaemias has been established (Greaves 2003). Direct evidence for the 
pre-natal origin of t(4; 11) infant ALL was demonstrated by the presence of
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unique MLL-AF4 genomic fusion sequences present in retrospective 
analysis of neonatal blood spots from individuals who were later diagnosed 
with ALL (Gale, et al 1997) and may suggest the cell type that is targeted in 
these leukaemias. The mechanisms by which these translocations occur in 
utero is unknown, but it is possible that excess LT-HSC which arise during 
highly active foetal haematopoiesis may be more prone to apoptosis but are 
then rescued from cell death (abortive apoptosis). The initiation of DNA 
cleavage in the initial stages of apoptosis may result in transient reversible 
double strand breaks and may additionally mediate recombination events 
resulting in a chromosomal translocation (Khodarev, et al 1999). In this 
way, an occasional cell carrying the fusion gene may survive and 
subsequently expand to form a pre-leukaemic clone if it has a growth 
advantage and a permissive environment (Greaves and Wiemels 2003).
Gene expression analyses of MLL-rearranged leukaemias may give clues as 
to the target cell of origin, and have shown differences in the genes 
expressed depending on the phenotype of the leukaemia. Genes that are 
relatively highly expressed in MLL-rearranged ALL are associated with 
haematopoietic progenitors and developing myeloid cells, while genes 
expressed at lower levels are associated with lymphoid identity (Armstrong, 
et al 2002). This may suggest that the cell of origin is one with both 
lymphoid and myeloid potential, such as the MPP. A number of mouse 
models using primary haematopoietic cells with multilineage potential 
which have been retrovirally transduced with Mil fusion genes have 
resulted in transformation to a self-renewing biphenotypic or myeloid cell 
and the development of leukaemia following transplantation (So, et al 
2003a, Zeisig, et al 2004).
It has been proposed that the LSC arises at the level of the normal HSC 
with its impact being cell-context dependent, and reflecting activation of 
more primitive cell types (Cozzio, et al 2003, Greaves and Wiemels 2003,
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Huntly and Gilliland 2005, Reya, et al 2001). Normal tissue-specific stem 
cells and cancer cells share the ability to self-renew, and it has been 
proposed that newly arising cancer cells result from a deregulation of 
pathways involved in cell division that are normally expressed by stem 
cells. Pathways associated with stem cell renewal and cancer development 
include inhibition of normal apoptosis and over-expression of genes in 
Bcl2, Notch, Sonic hedgehog, Wnt and Polycomb signalling pathways, as 
well as aberrant Hox family transcriptional expression (Domen, et al 1998, 
Taipale and Beachy 2001). In view of this association between deregulated 
self-renewal and malignancy, it is possible that stem cells are the actual 
targets of transformation in cancer. Such a cell would sustain the growth 
and spread of tumours while repopulating the distinct types of cell 
represented within the tumour, and not be subject to the same intrinsic and 
extrinsic controls as normal stem cells (Huntly and Gilliland 2005). 
Alternatively, a stochastic model of tumourigenesis proposes that each 
tumour cell has the potential to self-renew and thus recapitulate the tumour, 
but each has a low probability of entering the cell cycle and encountering a 
permissive environment in which to do this (Reya, et al 2001). The 
phenotype of distinct populations within a tumour, and their functional 
ability to re-capitulate the tumour phenotype will need to be assessed in 
order to differentiate between these models (Huntly and Gilliland 2005).
Stem cells in the haematopoietic system are in a state of constant, activated 
self-renewal and persist for long periods of time and are therefore an 
attractive candidate for the cell of origin in which leukaemic translocations 
arise. Fewer mutations may be required to maintain self-renewal in the 
leukaemic cell and there is temporally a greater opportunity for mutations to 
accumulate in individual haematopoietic stem cells. This is supported by 
evidence that the AML1-ETO fusion transcripts in t(8;21) AML are found in 
a fraction of normal HSC in the marrow, and that cells generating AML in 
non-obese diabetic / severe combined immunodeficient (NOD/SCID) mice
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have a similar immunophenotype to normal HSC in that they are CD34+ 
CD38' (Bonnet and Dick 1997). The LSC in ALL harbouring the breakpoint 
cluster region-Abelson (BCR-ABL) fusion gene has also been demonstrated 
at the level of the HSC (Cox, et al 2004) and distinct patterns of HSC and 
B-cell progenitor involvement have been shown for the different fusion 
products of the t(9;22) translocation (Castor, et al 2005). TEL-AML1 
fusions have been shown to arise in immunophenotypically committed B- 
cell progenitors rather than in the HSC, and in none of the cases involving 
BCR-ABL or TEL-AML1 was there expansion of the leukaemic clone at 
the expense of the normal HSC compartment (Castor, et al 2005).
A role for the more restricted progenitor or differentiated cell as the LSC 
has also been suggested, with activation of oncogenic pathways allowing 
the progenitor to re-establish properties of self-renewal. This model is 
supported by the generation of leukaemia from restricted myeloid 
progenitors overexpressing the B-cell lymphoma 2 (BCL2) protein (Jaiswal, 
et al 2003). A direct role for MLL-ENL in the immortalisation and 
transformation of a myeloid progenitor has been demonstrated (Lavau, et al 
1997). Both HSC as well as restricted progenitors transduced with MLL- 
ENL showed self-renewal properties by forming colonies in serial 
methylcellulose re-platings and growth in liquid culture, and generated 
AML in vivo. However, transformation by MLL-ENL of HSC appeared to 
be more efficient than of CMP as assessed by limiting dilution analysis 
(Cozzio, et al 2003). Similar assays demonstrated expansion of foetal liver 
myeloid progenitor cells by MLL-AF9 (Johnson, et al 2003), and 
purification and analysis of granulocyte/macrophage progenitors from 
patients with chronic myeloid leukaemia in blast crisis has also 
demonstrated self-renewal properties in these cells (Jamieson, et al 2004).
Recently it has been proposed that the leukaemic stem cell may arise from 
overexpression in committed progenitors of genes which normally control
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cell cycle regulation in normal haematopoietic stem cells. MLL-AF9 was 
introduced into committed granulocyte macrophage progenitor cells to 
confer a self-renewal capacity on these cells through re-activation of only a 
subset of normal HSC regulatory genes, that resulted in the emergence of 
leukaemic stem cells that initiated disease (Krivtsov, et al 2006).
Evidence supports both a multipotential as well as more restricted cell of 
origin as the target for MLL translocations, and further studies are required 
to identify whether the LSC in these cases is characteristic for all resulting 
leukaemias, or whether it may vary with the fusion gene or leukaemia 
phenotype.
1.5 MLL-translocations in acute leukaemia
1.5.1 Structure of MLL fusion genes
MLL gene rearrangements include deletions, duplications, inversions and 
reciprocal translocations at 1 lq23, and these are implicated in 
approximately 5-10% of all AML, ALL, biphenotypic leukaemia and 
myelodysplastic syndrome (MDS) in children and adults. The exon-intron 
structure of the MLL gene reveals a number of recombination-prone 
sequences within the breakpoint cluster region (BCR) of the gene spanning 
exons 5-11. Following a reciprocal translocation, the N terminal region of 
MLL is retained with the AT hooks, nuclear localization signals and 
transcriptional repression domains, while the C-terminal region with 
transactivation and SET domains are replaced by the C- terminal region of 
one of over 40 fusion partners (Ayton and Cleary 2001, Collins and 
Rabbitts 2002, Eguchi, et al 2003). The MLL fusion protein also lacks the 
Taspase 1 proteolytic cleavage site and the FYRN domain required for 
interaction with the p i80 C-terminal MLL fragment. The most frequently
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found fusion genes are MLL-AF9 [t(9;l 1)], MLL-AF4 [(t(4;l 1)] and MLL- 
ENL [t( 11; 19)] (Pui, ef a/2003).
1.5.2 Structure and function of MLL partner proteins
Fusion partner genes associated with MLL leukaemias are shown in Table 
2. Most of the fusion partner proteins do not share homology or common 
functional domains and can be broadly divided into nuclear transcriptional 
regulators and cytoplasmic signalling molecules (Eguchi, et al 2003). 
However, some common gene families do exist and group together some 
genes with structural and functional similarity. Such groups include 
AF4/AF5q3I/LAF4, ENL/AF9 and AF10/AF17 (Nakamura, et al 1993, 
Nilson, et al 1997, Taki, et al 1999). The most common fusion partners 
found in paediatric leukaemias are AF4, AF9 and ENL and all proteins have 
regions rich in serine and proline, possess nuclear localisation signals and 
are able to activate transcription (Djabali, et al 1992, Iida, et al 1993, 
Nakamura, et al 1993, Prasad, et al 1995, Rubnitz, et al 1994). AF9 and 
ENL share homology in both their amino and carboxy terminal regions. 
These domains are homologous to domains found in the yeast ANC1 
protein that associates with the SWI/SNF complex involved in chromatin 
remodeling through the SNF5 protein (Cairns, et al 1996, Welch and 
Drubin 1994), and ENL has also been identified as a component of a novel 
human SWI/SNF complex (Nie, et al 2003). Similarly the MLL fusion 
partner AF10 binds to GAS41 which interacts with the SWI/SNF complex 
via INI1 (Debemardi, et al 2002) and AF10 may further be involved in 
chromatin re-modelling through its interaction with the H3-K79 histone 
methyltransferase hDOTIL (Okada, et al 2005). AF4 and AF9 have been 
demonstrated to co-localise in novel nuclear foci (Erfurth, et al 2004) and 
the MLL-AF4 fusion protein is also shown to recruit AF9 to these nuclear 
bodies. ENL has been shown to interact with AF4 among other partners as 
part of a YEATS supercomplex that interconnects them all to bind to H3 in 
order to allow productive transcription and is further evidence that these
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partners function to influence chromatin remodelling (Zeisig, et al 2005). 
Thus AF4, AF9 and ENL may all be able to directly or indirectly recruit the 
SWI/SNF chromatin remodelling complex, and the normal interaction of 
these proteins with each other and with the complex may be disrupted as a 
result of their involvement in the formation of a fusion protein.
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Table 2 Fusion partner genes involved in MLL-associated leukaemias 
Gene d r o n e w n e
Nuclear partner
AF9
AF10
ELL
ENL
AFX
LAF4
AF3p21
FKHRL1
CBP
P300
AF17
LARG
GAS7
4q21 
9p22 
J 0pl2 
19pl3.1
19pl33
Xql3
3p21
6q21
16pl3
17q21
Cvtoplasmie
VmfBBL-
AF6 6q27
Septin 6 
ABI1 10pll.2
llq233
17pl3
Transcriptional activator
Transcriptional factor
RNA polymerase II transcription 
elongation factor 
Transcriptional activator 
Forkhead transcriptional factor 
Transcriptional activator 
Not known
Fodcbead transcriptional factor
Transcriptional coactivator, histone 
acetylase
Transcriptional coactivator, histone 
acetylase
Transcriptional factor, upregulated by 
B-catenin
Maintenance of cell-cell junctions 
and cell polarity 
Septin family
Regulation of endocytosis, cell 
motility
Activation of Rho GTPases
Actin assembly/crosslinking of actin
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filaments
EEN 19pl3.3 Regulation of endocytosis
FBP17 9q34 Not known
GMPS 3q25 Guanosine monophosphate synthetase
GRAF 5q31 Negative regulator of RhoA
AF9q34 9q34 Ras GTPase-activating protein
GPHN 14q24 Gly and GAB A receptors assembly
CBL 1 lq23.3 Negative regulator of receptor
tyrosine kinases 
LASPI 17q21 Not known
Apart from nuclear fusion partners, a number of partner genes encode 
cytoplasmic proteins possessing a number of domains required for protein- 
protein interactions, but lacking in any transactivation domains. Mechanisms 
by which such proteins contribute transcriptional activity to the fusion 
protein are outlined below.
1.5.3 Mechanisms of transcriptional deregulation by MLL-fusion 
genes
Models have been proposed relating to the normal function of MLL in the 
presence of MLL fusion genes and are illustrated in Figure 1.5 (Ernst, et al 
2002). A simple gain-of-function model proposes that normal MLL function 
is altered to cause overexpression of an MLL target gene involved in cell 
survival or proliferation. A second model proposes that in addition to gain- 
of-function of one MLL allele, the second allele becomes haploinsufficient 
with resulting underexpression of a gene normally expressed to negatively 
regulate survival or proliferation. Finally a dominant-negative model 
proposes that the MLL fusion gene simply intereferes with the normal 
expression by MLL of a gene which negatively regulates cell survival and 
proliferation.
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Figure 1.5 Models of how leukaemogenic fusion proteins may confer 
gain-of-function, gain-of-function and haploinsufficiency or dominant- 
negative properties on the WT MLL  allele.
Model 1 shows a simple gain-of-function model where the fusion protein acts 
to cause overexpression of the cell survival/proliferation gene X. Model 2 
shows how haploinsufficiency caused by the fusion protein results in 
underexpression of gene Y, as well as overexpression of another 
proliferation/survival gene Z. Model 3 shows how gene Y is underexpressed 
as a result of inhibition of MLL function by the fusion protein. Reproduced 
from (Ernst, et al 2002).
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The transcriptional activity of the MLL fusion protein is likely to be 
significantly different to that of wild-type MLL as a result of loss of the MLL 
SET domain, loss of the Taspase proteolytic cleavage site and loss of the 
PHD domain and the oncogenic potential of the fusion protein may result 
from this loss-of-function of the normal MLL protein. However, the 
contribution of the C-terminal domains of the fusion partners may also be 
responsible for altered transcription of the MLL target genes, or of a different 
set of target genes, and leukaemia may arise through a gain-of-function of the 
fusion protein.
The MLL fusion protein may act in a dominant negative manner by 
inhibiting the normal function of WT MLL protein such that normal targets 
of MLL are underexpressed. Evidence to support a dominant-negative effect 
of the MLL fusion protein to inhibit normal MLL function includes the 
ability of a truncated MLL protein to inhibit the GCSF-mediated 
differentiation of 32Dcl3 cells, while full length MLL cannot (Joh, et al 
1996). In addition, fusion of a truncated Mil gene to the bacterial LacZ gene 
was sufficient to cause long-latency leukaemias in chimaeric mice following 
homologous recombination in ES cells (Dobson, et al 2000) suggesting that 
either truncation or gene fusion itself was able to cause leukaemia in vivo. In 
addition, the ability of the fusion protein to act as a dominant negative 
inhibitor of the normal function of the partner protein is implied by the 
suppression of the normal apoptotic function of wild-type forkhead protein 
FKHRL1 by the fusion of MLL to the forkhead transcription factor AFX (So 
and Cleary 2002). A similar dominant negative inhibition by the fusion 
protein may suppress the anti-proliferative functions of the wild-type fusion 
partners GAS7, ABI1, AF6 and AFlp (So and Cleary 2002).
However, there is also evidence in favour of a gain of function conferred to 
MLL by the fusion partner. Simple truncation of MLL is not sufficient to 
immortalize HPC, which neither occurs if the partner protein ENL is simply
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overexpressed (Lavau, et al 1997). Loss of one Mil allele does not result in 
leukaemia as shown by knock-in mice which possess only one functional 
copy of Mil and express a portion of MLL found in fusion proteins fused to a 
short MYC tag polypeptide (Dobson, et al 1999). If MLL fusions acted by 
inhibiting endogenous Mil function then Mil-Aft knock in mice would be 
expected to show defects similar to those seen in M il''' or M il+/' mice but 
these abnormalities are not detected (Corral, et al 1996, Dobson, et al 1999). 
Multiple studies using retroviral insertion of Mil fusion genes into HPC to 
generate transformed cells also show the development of leukaemia without 
disrupting the endogenous Mil gene (Lavau, et al 1997, So and Cleary 2002). 
These studies imply that MLL fusions act dominantly over the endogenous 
MLL protein in a gain of function manner.
In vivo models show that the partner protein appears to confer intrinsic 
transactivation activity or provides a dimerization potential to the MLL 
fusion protein resulting in its acquisition of a transformation potential. Both 
the AT hooks and DNA methyltransferase domains of MLL, as well as the 
transcriptional activation domain of ENL are required for MLL-ENL 
mediated transformation (Slany, et al 1998). The transactivation region of 
ENL containing two helical structures is also highly conserved with the AF9 
fusion partner. Both the DNA methyltransferase domain of MLL and the 
transcriptional activation domain of ENL are also required for transactivation 
of the Hoxa.7 promoter by MLL-ENL (Schreiner, et al 1999) and therefore, 
the domains required for transformation are also those required for 
transcriptional activation. The methyltransferase domain of MLL which 
normally represses transcription, is interestingly seen to contribute a 
transactivation potential when fused to a partner protein. Furthermore, the 
ability of a transactivation domain in the nuclear MLL fusion partner to 
confer leukaemic potential is further supported by evidence showing that 
both MLL-ENL as well as an artificial MLL fusion protein, formed by fusion 
of the activation domain of VP 16 to MLL, causes transactivation of the Sv40
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promoter and Hoxa7 (Zeisig, et al 2003a). Two other activation domains 
were less potent than either fusion in transactivating these promoters. In 
addition, only MLL-ENL and MLL-VP16 were able to immortalize HPC 
(Zeisig, et al 2003a). However, MLL-VP16 transactivated these promoters 
less efficiently than MLL-ENL and this was reflected in the phenotype of the 
MLL-VP16 immortalized HPC which did not proliferate as greatly as those 
of MLL-ENL suggesting a correlation between the degree of transactivation 
of target genes and the severity of the phenotype (Zeisig, et al 2003a). Thus 
the transactivation domains of the nuclear fusion partner proteins appear 
instrumental in conferring a leukaemogenic potential to the fusion proteins in 
a gain of function manner.
Cytoplasmic fusion partners such as AFlp, GAS7 and SEPTIN6 do not have 
any intrinsic transactivation capacity but possess coiled coil domains which 
are able to facilitate oligomerization (Ono, et al 2005, So, et al 2003b). The 
fusion of LacZ protein to MLL also confers a transforming capacity which 
may be due to the oligomerization of LacZ protein, rather than leukaemia 
occurring as a result of MLL truncation alone as was originally thought 
(Dobson, et al 2000). The latency of these leukaemias was very long, 
compared to that in mice expressing the MLL-AF9 transgene, suggesting that 
the mechanisms of leukaemogenesis in each case may be different. The 
normal B-galactosidase protein exists in tetrameric form and it was thought 
that MLL-LacZ fusion may therefore also exist as a tetramer (Dobson, et al 
2000).
When fused to MLL both AFlp and GAS7 confer transcriptional activation 
activity to the MLL fusion protein such that it was able to transactivate the 
Hoxa7 promoter (So, et al 2003b). Again it appears that truncated MLL with 
its transrepression domain is converted into a transactivator following fusion 
to a partner protein. Interestingly, both the cytoplasmic partner fusion MLL- 
GAS7 and the nuclear partner fusion MLL-ENL transactivated a similar
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subset of Hox genes to cause immortalization of HPC (So, et al 2003b). Such 
target genes may represent a critical subset required for leukaemogenesis in 
the context of an MLL fusion protein.
A possible mechanism by which MLL target genes are deregulated may 
involve Menin, the tumour suppressor protein product of the MEN1 gene. 
This is essential for embryonic development, and mutation leads to multiple 
endocrine neoplasms (Biondi, et al 2004). The mechanisms by which Menin 
acts as a tumour suppressor are unclear, but it is a co-factor to MLL within a 
histone methyltransferase complex including ASH2, RBBP5, and WDR5, 
and appears to directly regulate expression of the cyclin-dependent kinase 
inhibitors p27Kipl and pl8Ink4c (Milne, et al 2005a). Furthermore, Menin’s 
function as a tumour suppressor gene may be related to its regulation by 
histone methyltransferase activity of Hoxc6 and Hoxc8 as differentiation- 
regulating genes (Hughes, et al 2004), and it appears critical for the 
maintenance of Hox gene expression by MLL in normal development 
(Yokoyama, et al 2004). The role of Menin as a co-factor for MLL in 
regulating normal Hox gene expression may allow insight into the 
mechanism by which the MLL fusion proteins cause leukaemia by 
abberantly expressing Hox genes. This is supported by the finding that MLL 
fusion proteins retain the ability to stably associate with Menin, and cause 
aberrant expression of Hox genes in MLL fusion transformed leukaemic 
blasts, which is then reversed on targeted deletion of Menin, with reversal of 
the differentiation arrest (Yokoyama, et al 2005). Menin, MLL and RBBP5 
localise to the promoters of thousands of human genes but do not always 
bind together, suggesting that Menin is a general regulator of transcription 
(Scacheri, et al 2006).
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1.6 Potential targets of MLL-fusion genes in acute 
leukaemia
1.6.1 The role of Hox genes in MLL-fusion leukaemia
The possibility that Hox genes may be a target of MLL fusion proteins is 
suggested by their role in the transcriptional control of normal 
haematopoiesis under MLL regulation as described above. The implication 
of HOX  genes in causing human leukaemia is suggested by the 
overexpression of certain HOX genes in both AML and ALL, and by the 
finding of HOX proteins as fusion partners of leukaemogeneic proteins.
HOXA and HOXB genes co-express in AML associated with standard or high 
risk (Drabkin, et al 2002), and HOXA9 expression was identified through 
micoarray analysis of ALL and AML as associated with poor prognosis in 
human AML (Golub, et al 1999).
HOXA9 has also been identified as a fusion partner of the nucleoporin gene 
NUP98 in the AML patients with t(7;l 1) translocation, and retroviral gene 
transfer of this fusion results in a myeloproliferative disorder (Kroon, et al 
2001). Acceleration of myeloproliferative syndrome (MPS) to AML was 
observed following co-expression of the fusion with Meisl further supporting 
the Hoxa9 and Meisl interaction in leukaemogenesis (Kroon, et al 2001). A 
number of other HOX genes have been identified as fusion partners of 
NUP98 in patient AML including HOXA11, HOXA13, HOXC11, HOXC13 
and HOXD13 (Pineault, et al 2004). HOX partner proteins HOXA 10 and 
HOXB3 are not found in human disease but are still leukaemogenic in mouse 
models when fused to NUP98 (Pineault, et al 2004) suggesting a common 
mechanism for oncogenic potential shared by most Hox genes when 
aberrantly expressed. However, Hoxb4 has previously been shown to fail in 
its ability to cause leukaemia in retroviral transduction/transplantation 
models (Sauvageau, et al 1995, Thorsteinsdottir, et al 1999) and neither is
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the NUP98-HOXB4 able to generate leukaemia in comparison to other 
NUP98-HOX fusion proteins. There therefore appears to be a definite 
leukaemogenic potential in certain, but not all, Hox genes, and the 
differences between the two groups may be critical to an understanding of 
leukaemia mediated by aberrant Hox gene expression.
The Hox gene transcriptional co-factor Meisl does not contain a 
homeodomain but appears to co-operate with Hoxa7, Hoxa9, HoxalO,
Hoxb3, Hoxb4 or Hoxb6 to induce leukaemia in mouse models (Kroon, et al 
1998, Thorsteinsdottir, et al 2001, Thorsteinsdottir, et al 1997). 
Overexpression of Hoxa.9 and Meisl in HPCs results in immortalization of a 
myeloid lineage HPC (Calvo, et al 2000) and Meisl may increase the 
proliferative or self-renewal capacity of cells which have undergone a 
differentiation block as a result of Hoxa9 expression (Pineault, et al 2005). 
This may explain the dramatically shorter latency of leukaemias which 
develop when Meisl is also overexpressed with Hoxa.9 in HPC in comparison 
to Hoxa9 expression alone, though the phenotype of the resulting leukaemia 
is unchanged by Meisl overexpression (Thorsteinsdottir, et al 2001). Hoxa9 
and Meisl co-expression also protected myeloid and lymphoid cell lines 
from apoptosis (Wermuth and Buchberg 2005) and this may also be another 
mechanism by which these genes co-operate to promote leukaemogenesis.
Studies of gene expression profiles of patient samples harbouring MLL 
rearrangements have identified HOX genes as fundamental to a unique 
signature that differentiates these leukaemias from those lacking MLL 
translocations (Armstrong, et al 2002). Lymphoblastic leukaemia with an 
MLL rearrangement exhibits increased expression of a number of HOXA 
genes HOXA4, HOXA5, HOXA9, HOXA 10, HOXC8 and the HOX  interacting 
gene MEIS1, but not HOXA7 when compared to other ALL (Armstrong, et al 
2002, Tsutsumi, et al 2003, Yeoh, et al 2002). In MLL-rearranged AML 
patient samples, HOX  genes were also overexpressed compared to non MLL-
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rearranged disease and HOXA4, HOXA5, H0XA9, HOXA 10, MEIS1 and 
PBX3 were particularly highly expressed (Debemardi, et al 2003, Ross, et al 
2003). However, co-expression of HOXA9 and MEIS1 is seen in a number of 
myeloid leukaemia cell lines regardless of MLL status (Lawrence, et al 1999) 
By including three T cell lineage MZZ-rearranged ALL in a gene expression 
profiling study some key differences between B cell and T cell lineage MLL- 
rearranged ALL were identified in terms of overexpression of HOXA9, 
HOXAIO, HOXC6, MEIS1 and PBX3 (Ferrando, et al 2003).
In vitro studies using cell lines which inducibly express the fusion protein are 
more likely to examine targets involved in the initiation of leukaemia as 
these cells will not harbour multiple genetic aberrations that may have been 
acquired. Inducible expression of MLL-AF9 in 32Dcl3 cells demonstrated 
over-expression of Hoxa7, Hoxb7 and Hoxc9 genes, although 
characterisation of the phenotype of the cells was not described in this study 
(Joh, et al 1999). Expression of MLL-AF9 in a leukaemic cell line was 
associated with maintained levels of Hoxa7 and HoxalO, and down 
regulation of these genes followed down-regulation of the fusion protein with 
resultant apoptosis (Kawagoe, et al 2001). Inducible expression of MLL- 
ENL in an oestrogen-regulated conditional model showed down-regulation 
of Fit3, Meisl, Hoxa9 and Lmo2 when MLL-ENL expression was turned off 
in the absence of tamoxifen (Zeisig, et al 2004). These cells, which were 
immortalized in the presence of MLL-ENL showed subsequent 
differentiation. In order to differentiate the gene expression profile resulting 
directly from loss of MLL-ENL expression from that resulting from cell 
differentiation alone, a Tetracycline-regulatable model of MLL-ENL 
expression showed that multiple Hoxa genes were down-regulated when 
MLL-ENL was turned off in the presence of doxycycline but maintained in 
differentiating cells which continued to express MLL-ENL (Horton, et al 
2005). These results show that MLL-ENL directly maintains expression of a
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subset of Hox genes to sustain the immortalized phenotype and contribute to 
leukaemogenesis.
The role of Hox genes and their co-factors in MLL-fusion dependent 
immortalisation of bone marrow progenitor cells using knock out, retroviral 
transduction/ transplantation and inter-chromosomal recombination models 
suggests that overexpression of Hoxb8, Hoxa9, Hoxa 10 or Hoxb3, but not 
Hoxb4, will eventually result in AML after several months of latency. Hoxa9 
was of interest as the first Hox gene to be disrupted by a recurrent 
chromosomal translocation in some human leukaemias (Nakamura, et al 
1996b) and it was initially described as essential for induction of MLL 
fusion-associated myeloid leukaemia in vivo in a bone marrow 
transduction/transplantation model (Ayton and Cleary 2003). In this study, 
Hoxa9 and Hoxa7 were thought to be specifically required for efficient 
immortalisation of primary bone marrow cells by MLL-ENL. In the absence 
of MLL-ENL, expression of these Hox genes was lost, and in a conditional 
MLL-ENL expression system Hoxa9 and Hoxa7 deficient progenitors failed 
to immortalise efficiently (Ayton and Cleary 2003). Meisl was initially 
identified as a gene adjacent to a common retroviral integration site found in 
murine myeloid leukaemias, and is frequently co-overexpressed with Hoxa7 
and Hoxa9 in these leukaemias (Nakamura, et al 1996a) and combined action 
of these proteins may more effectively regulate a critical set of target genes. 
However, further studies in which leukaemia occurred following 
transplantation of Hoxa9 deficient progenitors into an Mll-Af9 knock-in 
mouse suggested that the phenotype and malignant potential of the 
transformed cell is rather defined by the expression pattern of several Hox 
genes (Kumar, et al 2004). Furthermore, leukaemic transformation occurred 
in the absence of either Hoxa9 or Hoxa7 in a retroviral transduction model 
(So, et al 2004).
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In summary, MLL fusions do not appear to regulate any particular Hox gene 
but rather a Hox combinatorial code appears important in the immortalisation 
of cells by MLL fusions. In addition, the Hox genes are known to require 
MLL for their maintenance rather than initiation of expression, suggesting 
that alteration of their expression levels by MLL fusions may not be the 
initiating event in MLL fusion-mediated leukaemogenesis.
1.6.2 The role of other candidate targets of MLL-fusion proteins
Microarray studies have highlighted wild-type FLT3 overexpression as a 
distinguishing feature of MZZ-rearranged ALL compared to MLL-non­
rearranged ALL and AML (Armstrong, et al 2002). FLT3 is a receptor 
tyrosine kinase expressed by immature haematopoietic cells and, together 
with its ligand, is important for the normal development of stem cells and the 
immune system. Mutations of FLT3 have been detected in about 30% of 
adult patients with AML and a small number of patients with ALL or MDS, 
and tend to confer a poor prognosis. Activating mutations are found in 
approximately 25% of paediatric AML patients, but interestingly, FLT3 point 
mutations have been found to be particularly common in infant and 
childhood MLL-rearranged leukaemas, with 5 point mutations being found in 
30 patients (17%) (Armstrong, et al 2003). Such mutations were found in 8 
(18.2%) of 44 infants with ALL with MZX-rearranged leukaemia (Taketani, 
et al 2004). The possible cooperation of FLT3 mutations and MLL fusion 
proteins was suggested by induction of an acute myeloid leukemia with short 
latency when HPC were transduced with both genes only, with subsequent 
upregulation of Hoxa7 and Hoxa9 (Ono, et al 2005).
A number of ALL-cell lines harbouring gene rearrangements have been 
shown to express MEIS1, HOXA9 and FLT3 (Quentmeier, et al 2004). 
Microairay analysis of AML cells with and without MLL mutations has
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highlighted overexpression of BEX1 (brain expressed X-linked 1) in MLL- 
rearranged cell lines (Quentmeier, et al 2005).
1.7 Down-regulation of gene expression by shRNA
In order to validate candidate target genes of MLL fusion proteins, the effect 
of down-regulating their expression by RNA interference can be 
examined.The process of RNA interference (RNAi) uses double stranded 
RNA to induce sequence-specific post-transcriptional gene silencing as part 
of an evolutionarily conserved mechanism present throughout a range of 
organisms. This process relates to a normal defence against viruses and the 
mobilisation of transposable genetic elements (Leung and Whittaker 2005). 
As part of this defence, the natural process in mammals is associated with the 
induction of interferon (IFN) leading to non-specific translational shutdown 
and apoptosis (Gil and Esteban 2000). In mammalian cells the biological 
pathway has been harnessed to knock down the expression of specific genes 
either by introducing synthetic double stranded small interfering RNAs 
(siRNAs) of 21-23 base pairs, or by the delivery of plasmid or viral vectors 
that express double stranded short hairpin RNAs (shRNAs) that are 
subsequently processed into siRNAs. The shRNAs connect sense and anti­
sense strands by a loop and are expressed as single molecules, and rapidly 
form a hairpin structure with a stem and loop before being cleaved to 
produce siRNAs. The non-specific cellular activity of the stress response is 
circumvented by these smaller molecules entering the RNAi pathway further 
downstream. The effectiveness of siRNA silencing is sequence-specific and 
thus rules for siRNA design have been developed. The short double stranded 
RNAs are processed in the cytoplasm by an RNase Ill-like protein known as 
a Dicer which cleaves them into small RNA duplexes of 19-25 base pairs, 
with characteristic 3’-dinucleotide overhangs. These are then incorporated 
into a multiprotein complex known as the RNA induced silencing complex 
(RISC), whereupon an ATP-dependent helicase unwinds the duplex,
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allowing one of the two strands to independently recognise the mRNA. Site- 
specific cleavage of the message in the region of the siRNA-mRNA duplex 
then follows. A schematic overview of the mechanism of shRNA-mediated 
silencing of gene expression is shown in Figure 1.6A.
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Figure 1.6 Overview of mechanism of inhibition of gene expression by 
shRNA.
A shows a schematic diagram of the mechanism of shRNA interference with 
gene expression.
B shows the structure of microRNA (miR-30) in the pSM2 retroviral vector. 
The miR-30 was modified to express a shRNA of interest (miR-shRNA). 
Reproduced from (Stegmeier, et al 2005).
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Amplification of the siRNAs occurs by the RNA-dependent RNA 
polymerases which are lacking in mammalian cells, and their co-transfection 
with siRNA duplexes results in transient gene silencing whose persistence 
depends on the proliferative status of the cells (Leung and Whittaker 2005). 
Thus, vector-based systems containing RNA polymerase III promoters have 
been developed and appear to allow the introduction, and the more stable and 
effective expression, of siRNA in target cells, as well as more potent 
induction of RNAi than siRNA, and these can also express shRNAs. The 
human U6 snRNA promoter is the best studied polymerase III promoter and 
is frequently used in RNAi expression vectors. However, a system of shRNA 
expression from polymerase (pol) II, (rather than polymerase III), promoters 
when embedded in a microRNA (miRNA) context has been shown to display 
very efficient knock-down of gene expression (Stegmeier, et al 2005).
The structure of miRNA in the pSM2 vector, and its modification to express 
a shRNA of interest is shown in Figure 1.6B. Pol III promoters are 
constitutively expressed in all cell types whereas tissue-specific expression of 
the shRNA under control of the cell type specific pol II promoter may be 
more desirable, and constitutive expression of all genes may be toxic to the 
transduced cells. Thus, the ability to regulate the timing and levels of 
expression of shRNA may allow more effective downregulation of target 
genes. A method of expressing microRNA (miR) 30-based shRNAs from pol 
II promoters has been described (Stegmeier, et al 2005). Retroviral, lentiviral 
or adenoviral vector systems allow greater ease and efficacy of infection, and 
more stable expression of shRNA constructs than plasmids. Lentiviral 
vectors are derived from human immunodeficiency virus (HIV)-l and can 
infect both dividing and non-dividing post-mitotic cells and successful 
lentiviral delivery of shRNAs to eukaryotic cells in vitro has been reported 
by several groups (An, et al 2003, Tiscomia, et al 2003).
In relation to the use of haematopoietic cells, delivery by lentiviral vectors 
incorporating the spleen focus forming virus (SFFV) long terminal repeat
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(LTR) sequences, together with the Woodchuck hepatitis virus 
posttranscriptional regulatory element (WRE) has been shown to produce 
highly efficient long-term expression of a transgene (Demaison, et al 2002). 
Such a vector was used in this study to drive the expression of microRNA 
expression of shRNA against a gene of interest and a green fluorescent 
protein (GFP) reporter.
1.8 Aims
The aims of the project are outlined below:
• to identify candidate target genes of MLL-ENL and MLL-AF9 in the 
32Dcl3 mouse myeloid progenitor cell line, in order to identify genes 
which may be useful targets for biological therapy following further 
analysis
• to determine the phenotypic and functional characteristics of 32Dcl3 
cells expressing these MLL fusion proteins
• to determine whether the mechanism by which MLL fusion proteins 
function confer the leukaemic phenotype on haematopoietic 
progenitor cells is according to a gain-of-function or dominant- 
negative model
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2 M ateria ls and M eth od s
Chemicals were purchased from VWR, Poole, Dorset, UK unless otherwise 
stated. Tissue culture reagents were purchased from Invitrogen, Paisley, UK 
unless otherwise stated. Restriction enzymes were purchased from Promega, 
Madison, Wisconsin, USA. Primer/probe sets for Q-PCR were purchased 
from Applied Biosystems, Foster City, USA. All recombinant cytokines were 
purchased from Peprotech EC, London, UK.
Table 3 Buffers and Solutions 
Buffer Components
Erythrocyte lysis 17 mM Tris (pH 7.2); 0.144 M NH4CI 
buffer
Stain buffer (flow PBS; 0.5% BSA; 0jOS% sodium azide 
cytometry)
RIPA lysis buffer 150 mM NaCl; 1% Triton X-100; 0.5% sodium
deoxycholate; 0.1% SDS; 50 mM Tris (pH 8.0); 5 mM 
EDTA
NP40 lysis buffer I50mMNaCl; 0.5% NP40; 50 mMTm (pH 8.0)
5 x protein sample 500 mM DTT; 10% SDS; 312.5 mM Tris (pH 6.8); 
buffer 0.05% Bromophenol Blue; 25% Glycerol
2 x protein sample 200mMDithiothreitol(DTT), 80%SDS, 10% 
buffer glycerol[Sigroal, 4% bromophenol blue, 200 mM Tris
pH6.8
1 x running buffer 0.192 M glycine; 25 mM Tris; 0.1% SDS
1 x transfer buffer 9.5 mM CAPS (pH 11.0)
1 x stripping buffer 62.5 mM Tris (pH 6.8); 1% SDS; 50 mM 2- 
mercaptoethanol
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TNES TE (pH 8.0); 0.1 mM NaCl; 1% SDS
Denaturing 1.5 M NaCl; 0.5 M NaOH
solution
Neutralising 1M Tris (pH 7.4); 1.5 M NaCl
solution
5 x probe labelling 0.5 M Na2HP04; 0.5 M NaH2P 0 4; 0.5% 2-ME; 1 mM
buffer of dATP, dGTP and dTTP
Pre-hybridisation 5 xSSQ 0.5% SDS; 0.1 g/ml dextran sulphate; 5 x
solution Denhardt’s solution
TE (pH 8.0) 10 mM Tris (pH 8.0); 1 mM EDTA (pH 8.0)
Luria-Bertani (LB) 1% tryptone, 0.5% yeast extract, 1.0% NaCl (pH 7.0) 
Drotn
LB agar LB broth medium plus 15g/l agar
TAE buffer 40 mM Tris-acetate, 1 mM EDTA at pH 8.3
Electrophoresis 25 mM tris-Hcl (pH 8.3), 192 mM glycine, 0.1% SDS 
buffer
TBS 20mM T^HCl (pH 7.5), 150 mMNaCI
TBS-T 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1 %
Tween 20 [Sigma]
10 x SSC 3M NaCl, 0.3 M sodium citrate (pH 7.0) [National
Diagnostics]
HotSHOT Alkaline 25 mM NaOH, 0.2mM EDTA 
Lysis reagent
HotSHOT 40 mM Tris-Hcl (pH 5.0)
Neutralisation
buffer
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2.1 Culture of 32Dcl3 cell lines
Cells were maintained at 37°C with 5% C 02 in a humidified atmosphere. 
32Dcl3 cells
32Dcl3 cells were obtained from the American Type Culture Collection 
(ATCC) and maintained in liquid culture in Iscove’s Modified Dulbecco’s 
Media (Sigma, Poole, UK) containing 10% fetal calf serum (FCS) 
(Globepharm, Surrey, UK), 10% conditioned interleukin-3 (IL-3) media 
derived from cultured WEHI-3B cells, 1% penicillin/streptomycin (100 
units/ml penicillin, lOOug/ml streptomycin), and 1% (2mM) L-glutamine.
32DTeton cells
Tetracycline-inducible 32Dcl3 clones were maintained in the above media 
and were additionally selected and maintained in media containing genetecin 
at 2.5mg/ml.
32DMAF9 and 32DMENL cells
Tetracycline-inducible 32Dcl3 clones containing the MLL fusion genes were 
additionally selected and maintained in media containing genetecin 
2.5mg/ml.and hygromycin 1.2mg/ml.
WEHI-3B cells
WEHI-3B is a leukaemic cell line containing activating retroviral 
integrations adjacent to the Hoxb8 and 11-3 genes. These cells were 
maintained in DMEM medium containing 10% FCS, lOOunits/ml penicillin, 
lOOug/ml streptomycin and 2mM L-glutamine. WEHI-3B cells grew as a 
mixture of suspension and adherent cells and conditioned medium from these 
cells was used as a source of IL-3. To split the cells, the suspension cells 
were harvested, spun down and resuspended in fresh medium. To obtain 
conditioned medium, the cells were grown for 3 to 4 days until confluent, the
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suspension cells removed by centrifugation and the conditioned medium 
filter sterilised using a 0.22um filter (Millipore, Watford, UK) and stored at 
-20°C in 50ml aliquots.
2.2 Plasmid constructs
All of the MLL fusion plasmid constructs used in the study were made and 
sequenced by Dr. Dale Moulding and Dr. Inusha de Silva of the Molecular 
Haematology and Cancer Biology (MHCB) unit. A diagram of the plasmid 
constructs is shown in Figure 2.1. The pTRE-MLL-ENL, pTRE-MLL-AF9 
and pTRE-MLL-AF4 constructs were all deleted for amino acids 1-26 of 
MLL. The pTet-tTS-Hygr construct was made by digestion of pTRE- Hygr 
with Xhol to release the neomycin resistance cassette, and ligation of this 
into the Xhol site of pTet-tTS.
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Figure 2.1 A diagram of plasmid constructs used in this study.
PSV40: simian virus 40 promoter, Hygr: hygromycin resistance gene, 
PCMV; CMV promoter , Neor: neomycin resistance gene, TRE: tetracycline 
response element, tTS: tetracycline suppressor. MYC: myeloblastosis 
oncogene protein c-MYC tag, HA: haemagluttinin tag.
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2.3 Electroporation of cells with plasmid DNA
To generate tetracycline-inducible 32Dcl3 cells (32DTeton) cells, 5 x 106 
32Dcl3 cells were electroporated in 250ul of IMDM containing 20ug of 
pTet-On at 260V/950uF using the Gene Pulser ® II electroporation system 
(BioRad, Hemel Hempstead, UK). The cells were allowed to recover for 24 
hours at 37°C/5% C02 prior to selection in medium containing 2.5mg/ml 
genetecin for 2 weeks. Single cell clones were isolated, expanded and 
maintained in the same medium. Transient transfection of a luciferase 
reporter gene was used to screen for inducible expression after cells were 
cultured in the presence or absence of doxycycline 2ug/ml for 24 hours.
To generate 32DTeton which expressed the MLL fusion genes, 15 x 106 
32DTeton cells were further electroporated in 750ul of IMDM containing 
60ug of pTRE-MLL-AF9 and ptTS-HygR in varying ratios, or 60ug of 
pTRE-MLL-ENL and ptTS-HygR in varying ratios, or 60ug ptTSHygR 
alone. The cells were allowed to recover for 24 hours at 37°C/5% C02 prior 
to selection in medium containing 2.5mg/ml genetecin and 1.2mg/ml 
hygromycin for 2 weeks. Single cell clones were isolated, expanded and 
maintained in the same medium. Western blotting was used to screen for 
inducible protein expression after cells were cultured in the presence or 
absence of doxycycline 2ug/ml for 24 hours.
2.4 Isolation of single cell clones
Single cell clones were generated from tetracycline-inducible mixed 
populations of cells after FACS sorting. Mixed populations of inducible cells 
were centrifuged and resuspended at 0.5 x 105/ml in IMDM medium 
containing 10% FCS and 10% WEHI-3B conditioned medium. The 
Autoclone® sorting option on the EPICS® ALTRA™ FACS sorter 
(Beckham Coulter, High Wycombe, UK) was used to dispense a single live
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cell into each well of a 96-well round-bottomed plate containing lOOul of 
complete medium with appropriate antibiotics for selection. Cells were 
subsequently propagated and expanded.
2.5 Luciferase reporter constructs and assays
Luciferase assays were performed using the Dual Luciferase Assay system 
(Promega) according to the manufacturer’s recommended procedures. 5 x 106 
cells 32DTeton clones were electroporated in 250ul IMDM containing 18ug 
of the firefly luciferase reporter construct and 2ug of pRL-CMV at 
260V/950uF. Cells were allowed to recover for 24 hours prior to culturing 
with or without 2ug/ml doxycycline for 24 hours. Luciferase activity was 
then measured using the Lumat LB 9507, Perthold Technologies, Austria.
2.6 Preparation of cellular extracts for SDS-PAGE
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
for protein resolution was performed according to standard protocols.
1 x 106 cells were harvested and washed twice in cold PBS. Cells were lysed 
in either 2 x Lysis Buffer at 60ul per 1 x 106 cells, or NP40 lysis buffer 
containing protease inhibitors (Roche). Cell lysates containing 0.25 x 106 
cells were resolved by electrophoresis in 7% SDS-PAGE gels using Mini 
Protean III apparatus (BioRad) according to manufacturer’s instructions.
Gels were electrophoresed in SDS-PAGE electrophoresis buffer at 150V.
2.7 Protein transfer to PVDF
Protein transfer to polyvinylidene fluoride membrane (PVDF)
Proteins in SDS-PAGE gels were transferred on to PVDF membrane 
(Millipore) in protein transfer buffer using a BioRad Mini Trans-Blot
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Electrophoretic Transfer system according to the manufacturer’s instructions. 
Gels were transferred for 1 hour at 100V at 4°C.
2.8 Western analysis for protein expression
All antibodies were diluted in 5% milk powder in TBS-T. Working dilutions 
of antibodies used for Western blotting analysis are given in Table 4. 
Membranes were incubated for 16 hours at 4°C with gentle agitation in 10% 
milk powder in TBS-T. Membranes were subsequently incubated with 
primary antibody for 2 hours at room temperature with gentle agitation. 
Membranes were washed in TBS-T for lx 20 minute wash and 2 x 1 0  minute 
washes. Membranes were then incubated for 1 hour with the relevant 
secondary antibody. Membranes were then washed in TBS-T for 3 x 15 
minute washes. Proteins were visualised by ECL Plus™ reagent (Amersham 
Biosciences, Little Chafont, U.K). Equal protein loading was checked either 
by staining the membranes with Ponceau S (Sigma-Aldrich) or examining 
the expression by Western blot of an appropriate control protein.
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Table 4 Antibodies used for Western blotting
Antibody Clone Supplier Working
dilution
Mouse anti-Myc 9E10 Roche 1:400
Mouse anti-Myc 9B11 Cell signalling technologies 1:1000
Anti-HSP 90 N/A Cell Signalling technologies 1:2000
polyclonal
Ratanti-HA 3F10 Roche 1:500
Mouse anti-MLL N4.4 Dr. M.L Cleary, Stanford. 1:3
Rat anti-tubulin YL1/2 Serotec 1:1000
Sheep anti-mouse N/A Amersham Biosciences 1:2000
HRP
Goat anti-rabbit HRP WA Amersham Biosciences 1:2000
Sheep anti-rat HRP N/A Serotec 1:2000
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2.9 Isolation of genomic DNA from cells
10 x 106 cells were washed in PBS and lysed overnight in TNES (400 ul per 
10 x 106 cells) containing 0.5mg/ml proteinase K (Roche) at 37°C. Genomic 
DNA was extracted using Phenol-Chloroform-Isoamylalcohol (25:24:1) 
(Sigma-Aldrich). 0.5ml Phenol-Chloroform-Isoamylalcohol (25:24:1) was 
added to the 400ul lysate and shaken vigorously for 1 minute. The phases 
were separated by centrifugation at 16 000 x g for 5 minutes and the 
supernatant transferred to a separate tube containing 2 x volume of ethanol: 
3M NaOAc (25:1). Large precipitates of genomic DNA were lifted from 
solution using an inoculation loop and carefully washed in 70% ethanol. The 
DNA was re-dissolved in TE (pH 8.0).
2.10 Southern blotting analysis
Southern blot analysis of DNA was performed according to standard 
procedures. A hybridisation robe was prepared by digesting pTRE-MLL-AF4 
with Hind III. This released a 2.1 kb cDNA fragment which contained the N- 
terminal MLL sequence. This fragment was isolated and gel purified for use 
in probing the membrane. The probe (lOOng) was denatured at 94 °C for 10 
minutes and then labelled with [32P] a-dCTP using random primer labelling. 
The components of the labelling reaction were 5 x labelling buffer (0.25 M 
sodium phosphate buffer, 0.5% 2-ME and 1 mM of dATP, dGTP and dTTP), 
lOOng hexanucleotide primers (Sigma-Aldrich), 0.4 mg/ml BSA, 20 mM 
MgC12, 5 units Klenow (Promega), lOOng denatured probe and 1.11 MBq 
32P dCTP. The labelling reaction was carried out at 37 °C for 2 hours and 
then stopped by the addition of 0.1% SDS in TE. The probe was purified 
using Sephadex G50 columns equilibrated with 0.1 M EDTA. The probe was 
eluted from the column by centrifugation at 390 x g for 3 minutes into 1 M 
NaOH to denature the probe. The probe was then neutralised by the addition 
of 2 M Tris (pH 8.5).
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Prior to hybridisation, the membrane was blocked by incubation with pre­
hybridisation solution containing 0.5mg/ml salmon sperm DNA (Sigma- 
Aldrich) for 2 hours at 65 °C. The probe was then added and allowed to 
hybridise to the membrane overnight at 65°C. The membrane was then 
washed twice in 2 x SSC, 0.1% SDS at 55 °C and bands were visualised 
using a Typhoon phosphorimager (Amersham Biosciences).
2.11 IL-3 withdrawal experiments
32DMENL cells were seeded to a density of 4 x 105/ml in fresh medium at 
12 hours prior to the IL-3 withdrawal experiments. Cells were pelleted and 
washed twice in IL-3 depleted medium (IMDM containing 10% FCS, 2mM 
L-glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin), and 
resuspended in IL-3 depleted medium at a density of 4 x 105/ml. prior to 
staining with propidium iodide, 0.5 x 106 cells were fixed in ethanol at 
appropriate time points. The cells were washed in PBS and resuspended in 
200ul PBS then added drop-wise to tubes containing 2ml of 70% ethanol at - 
20°C and left on ice for 1 hour. Cells were then centrifuged at 200 x g for 5 
minutes at 4°C, resuspended in 800ul PBS and incubated with 50ul RnaseA 
(1 mg/ml stock) and incubated at room temperature for 20 minutes. Finally 
cells were stained with 50ul of propidium iodide (50ug/ml stock) and left 10 
minutes before flowcytometric analysis using EPICS ® XL ™ flow 
cytometer and EXPO ™32 software (Beckman Coulter).
2.12 Cytospin analysis of cellular morphology
Approximately 5 x 104 cells were washed in PBS and resuspended in lOOul 
PBS. Cells were centrifuged onto slides at 500rpm for 5 minutes at low 
deceleration using a cytospin 3 machine (Shandon). The slides were then 
fixed and stained with May-Grunwald-Giemsa (MGG) using a Shandon
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variation 24-4 automated staining machine in the Haematology Department 
at Great Ormond Street Hospital.
2.13 G-CSF induction of cellular differentiation
Cells were plated out at a density of 2xl05/ml in fresh medium. After 12 
hours cells were re-adjusted to 2xl05/ml and differentiation was induced by 
adding 1ml of cells to 1ml of IL-3 depleted medium containing G-CSF, 
(IMDM containing 10% FCS, 2 mM L-glutamine, 100 U/ml penicillin and 
100 ug/ml streptomycin and lOng /ml of G-CSF, i.e O.lug or lOul of a 
lOug/ml solution). At 24 hour intervals, 10% of media was removed (200ul) 
and replaced with 200ul of fresh media containing G-CSF. Wright stained 
cytospin preparations were prepared at intervals and analysed for cellular 
morphology.
2.14 Flow cytometry
Cells were washed in PBS, 0.5% BSA and 0.05% sodium azide and pre­
incubated with unlabelled anti-Fcy III/II receptor mAb (2.4G2) for 15-30 
minutes prior to staining with the primary antibody. Each subsequent stain 
was performed for 30 minutes, following which the cells were washed with 
PBS, 0.05% sodium azide. Cells were stained with specific conjugated 
monoclonal antibodies and isotype control antibodies. Antibodies used for 
flow cytometry are shown in Table 5. Flow cytometry was performed using a 
Beckman Coulter Epics XL analyzer or a Cyan ADP analyser and data 
analysed using EXP03 software or Summit 4.1 software (DakoCytomation) 
respectively.
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Table 5 Antibodies used for flow cytometry
Antibody Clone Isotype Supplier Working
dilution
Anti- Fey III/II 2.4G2 IgG2b K BD Pharmingen 1:100
Anti-cKitPE ■ 2B8 IgO^* BDPharmingen m o o .
Anti-cKit FITC 2B8 IgG2b K BD Pharmingen 1:100
Anti-Mac 1 PE M l/70 IgG2bK BD Pharmingen 1:100
Anti-Mac 1 FITC Ml/70 IgG2b K eBioscience 1:100
Anti-Grl PE RB6-8CS IgG^ K BDPharntingen 1:200
Anti-Grl APC RB6-8CS IgG2b K eBioscience 1:100
Anti-Terll9PE T ed 19 IgGabic BD Pharmingen 1:100
Anti-F4/80 PE F4/80 IgG2a K Caltag 1:100
Anti-B220 PE RA3-6B2 IgG** BD Pharmingen 1:100
Anti-CD41-PE PEG30 IgG2a K Research
Diagnostic
1:200
Aati-CDtil-FITC 2C9.G3 eBioscience 1:200
Anti-IgG2A PE G155-178 IgG2a K BD Pharmingen 1:100
Anti-IgG2BPE mo*u IgG^ K BD Pharmingen 1:100
Streptavidin PE N/A N/A BD Pharmingen 1:250
Macl is a member of the integrin subfamily comprising an alpha subunit 
(CD1 lb) and beta-2 subunit (CD 18), and the two covalently associate to 
form Mac-1 which binds to CD54 (ICAM-1), C3b and fibrinogen. Macl is 
expressed on myeloid cells, natural killer (NK), activated T cells and a B cell 
subset, and upregulation of Macl is particularly seen with leucocyte 
activation.
Integrin CD41 (a2b), and integrin CD61 (beta 3) associate to form the 
heterodimeric integrin a2b-beta3 (CD41/CD61) which is a fibronectin
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expressed in platelets. However, CD41 has also been implicated as a target of 
the SCL/TAL1 transcription factor to define the divergence of 
haematopoietic cells from endothelial cells at the earliest stages of 
haematopoietic development in the mouse embryo (Mikkola, et al 2003a). 
Thus CD41 characterises early murine haematopoietic progenitors and there 
is subsequent down regulation by the foetal liver stage.
The F4/80 antibody recognizes a member of a family of genes including 
human epidermal growth factor (.EGF) module-containing mucin-like 
hormone receptor 1 and human CD97 (Hume, et al 2002). The function of 
F4/80 is not clear but F4/80 antigen is present on the cell surface of a family 
of cells that includes all well-defined members of the mouse monocyte- 
phagocyte system (MPS). F4/80 protein expression is positively correlated 
with macrophage maturation and the antigen has often been used as a ‘pan- 
macrophage’ marker.
The cell surface receptor Grl (CD97) is a member of the G protein coupled 
receptor family and acts as a receptor potentially involved in both adhesion 
and signalling processes early after leucocyte activation, binding to Decay 
Accelerating Factor, a member of the CCP superfamily. It is expressed by the 
myeloid lineage in a developmentally regulated manner in the bone marrow. 
The expression of Grl on bone marrow granulocytes as well as on peripheral 
neutrophils is a good marker for these populations. Grl is known to be 
upregulated upon neutrophil differentiation of 32Dcl3 cells (Bigas, et al 
1998).
2.15 MTS assay
Cells were seeded at a density of between 103 and 104 cells per well of a flat 
bottomed 96-well plate. After a specific period of culture, CellTiter 96® 
Aqueous One Solution reagent (Promega) was added to each well according
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to manufactuer’s instructions. The plates were wrapped in foil and returned 
to culture for 4 hours. After this time the cell viability was measured by 
reading the absorbance at 490nm using a 550 BioRad plate-reader.
2.16 Isolation of total RNA
TRIzol®Reagent (Invitrogen) was used to lyse cells and extract total RNA. 
Cells were harvested in conditions avoiding RNAse contamination and lysed 
in 1ml of TRIzol® per 107 cells and either stored at -80°C for later 
extraction, or left for 10 minutes at room temperature prior to immediate 
extraction. 0.2ml of chloroform per 1ml TRIzol® was added to each sample, 
vigorously mixed and centrifuged at 12 000 x g for 15 minutes at 4 °C. The 
upper layer was carefully transferred to a fresh tube without disturbing the 
DNA interface and 0.5ml of isopropanol per 1ml TRIzol® added. RNA was 
precipitated at room temperature for 10 minutes, and then pelleted at 12 000 
x g for 10 minutes at 4°C. The RNA pellets were washed in 1ml of 70% 
ethanol and centrifuged at 7500 x g for 5 minutes at 4°C. The pellets were air 
dried before being dissolved in diethyl pyrocarbonate (DEPC)-treated water 
(Invitrogen) and stored at -80°C until used.
2.17 RT-PCR for cDNA synthesis
cDNA was synthesised from total RNA for further quantification of 
transcripts using quantitative PCR (Q-PCR). Reactions were carried out in 
40ul reaction volumes. RNA was initially denatured in a 20ul reaction 
volume containing lOug total RNA, 2ul DNAse enzyme, 2ul DNAse enzyme 
buffer, and DEPC-treated water to a total volume of 18ul and was incubated 
at room temperature for 15 minutes. A further 2ul of 25mM EDTA was 
added to terminate the reaction, then incubated at 65 °C for 5 minutes then 
placed on ice. To this was added 20ul of RT reaction containing 8ul first 
Strand buffer (x 5), 4ul DTT, 2ul random hexamers (0.32ug/ul) (Sigma-
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Aldrich), 2ul deoxynucleotide triphosphate (dNTP) (lOmM for each dNTP), 
2ul RNase Out and 2ul MMLV-Reverse transcriptase (Invitrogen). The 
cDNA synthesis reaction was carried out in a PCR machine. 1 cycle was 
performed which consisted of 37 °C for 2 hours then 70 °C for 15 minutes. 
cDNA diluted with DEPC-treated water to obtain a concentration of 50ng/ul 
and stored at -20 °C.
2.18 Microarray analysis of gene expression
Three 32DMAF9 mixed populations were seeded at 2 x 105/ml in fresh 
medium for 12 hours prior to culturing with or without doxycycline for 24 
hours, and eight 32DMENL clones seeded to 2 x 105/ml in fresh medium 
also. Experiments were carried out in triplicate to compensate for biological 
and experimental variation and performed according to the schema outlined 
in Figure 4.3 and Figure 4.4..
Cell culture conditions, reagents and sample processing were kept identical 
for all samples. Western blotting analysis was used to confirm the inducible 
expression of MLL-AF9, and constitutive expression of MLL-ENL. Samples 
were prepared according to Affymetrix Gene Expression Technical Manual 
using the Microarray cDNA synthesis kit 3315622 (Roche). An overview of 
miroarray technology is shown in Figure 2.2. Total RNA was isolated using 
TRIzol reagent and further purified. The quality and quantity of total RNA 
was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies) 
such that the A260/A280 ratio was at least 1.8, and the Bioanalyser gel 
profile exhibited a 28S band twice the intensity of the 18S ribosomal RNA. 
15ug of total RNA were used to synthesise single stranded cDNA by reverse 
transcription using a T7-01igo(dT) promoter primer in the first-strand 
synthesis reaction. The second strand cDNA synthesis reaction was carried 
out following removal of hybridised RNA using RNAse H, and the double­
stranded cDNA was purified. This was then used as a template for the in
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vitro transcription (IVT) reaction in the presence of T7 RNA polymerase and 
biotinylated UTP and CTP to produce biotin-labelled cRNA from the double 
stranded cDNA. The quality and quantity of cRNA was determined using an 
Agilent 2100 Bioanalyzer. The cRNA was then fragmented in the presence 
of heat and Mg before hybridisation to the test array for assessment of 
target quality and labelling efficiency. The sample was then hybridised to the 
standard Affymetrix GeneChip® Mouse Genome 430 (version 2) array for 
16 hours at 45 °C, washed and stained with streptavidin-phycoerythrin 
(SAPE). The fluorescence was amplified by adding a biotinylated anti- 
streptavidin antibody and more SAPE, and the arrays scanned following 
excitation at 570nm using a GeneChip® Scanner 30000 (Affymetrix).
For MLL-AF9 experiments, one probe array was used for cells grown in the 
absence of doxycycline (control) and one for cells grown in the presence of 
doxycycline. For MLL-ENL experiments, one probe array was used for cells 
lacking expression of MLL-ENL and one probe array used for cells 
expressing MLL-ENL.
Affymetrix Microarray Suite 5.0 software was used to calculate gene 
expression values for each probe array. Data was analysed using GeneSpring
7.2 software. Each array underwent normalisation procedures to allow 
comparison of gene signals across multiple arrays. For MLL-AF9 
experiments, gene expression of the induced sample was normalised to the 
non-induced control sample for each experiment. For MLL-ENL 
experiments, gene expression of the non-expressing sample was normalised 
to the MLL-ENL expressing sample. Data was subsequently filtered to be 
reliably detected in both the control and experimental samples. These genes 
were further filtered by Welch t-test to identify genes which were statistically 
significantly changed by greater than 1.5 fold by the expression of MLL-AF9 
or MLL-ENL. Multiple testing correction on this set of genes was performed 
and using the Benjamini-Hochberg false discovery rate procedure applied.
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Microarray technology was used to analyse the effect of MLL-ENL and 
MLL-AF9 on mRNA transcripts on a genome wide scale. Affymetrix 
GeneChip® Mouse Genome 430 (version 2) microarrays were used 
containing a series of eleven 25-mer probes per transcript paired with eleven 
mismatched probes to control for hybridisation specificity for each transcript, 
and assess performance of the probes. Probe set algorithms using Affymetrix 
Microarray Suite 5.0 software were used to interpret the signals from each 
probe set and generate a single signal per probe set. By comparing the level 
of hybridisation of the perfect match and the corresponding mismatch probes, 
a detection call of present or absent was assigned for each gene.
A detection algorithm was used to generate a detection p  value reflecting the 
confidence of the detection call for each probe set containing multiple probe 
pairs. Subtraction of the mismatch probe value, to account for non-specific 
binding, resulted in a signal value for each gene. This gene signal was then 
normalised to the entire microarray to allow comparison of the signal across 
multiple arrays. This was done by generating a scaling factor required to 
adjust the total average signal of each array to an arbitrary target of 100. The 
scaling factor was applied based on the constitutively expressing house­
keeping genes and ensured that the expression levels in the experimental 
samples were comparable to the control. The scaling factor of each array was 
within 3 standard deviations of the mean, and the signal values for each array 
were then multiplied by the appropriate scaling factor. GeneSpring 7.2 
software (Agilent) was used to perform statistical analysis to determine genes 
which were outliers and so given a low significance. Unequal variance was 
assumed between the experimental and control populations and the Welch t- 
test employed to measure standard deviation and detect genes significantly 
changed with a p  value of less than 0.05. In order to reduce the chance of one 
false positive gene among those found to be significantly changed, a 
Bonferroni multiple testing correction was applied to the data using the 
Benjamini-Hochberg false discovery rate procedure.
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Figure 2.2 Overview of Microarray Technology.
Total RNA from the control and experimental populations is isolated and 
used to synthesise single stranded cDNA by reverse transcription. The 
second strand cDNA synthesis reaction is carried out following removal of 
hybridised RNA and the double-stranded cDNA purified. These are used as a 
template for the in vitro transcription (IVT) reaction in the presence of T7 
RNA polymerase and biotinylated UTP and CTP to produce biotin-labelled 
cRNA from the double stranded cDNA. The cRNA are then fragmented 
before hybridisation to the Affymetrix GeneChip® Mouse Genome 430 array 
for 16 hours at 45°C, washed and stained with streptavidin-phycoerythrin 
(SAPE). The fluorescence is amplified by adding a biotinylated anti- 
streptavidin antibody and more SAPE, and the arrays scanned following 
excitation at 570nm using a GeneChip® Scanner 30000 (Affymetrix).
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2.19 Q-PCR
PCR products were quantified to validate the results of microarray analyses 
and quantify the expression levels of MLL fusion genes. For candidate target 
genes and Gapdh control gene, Assay-on demand primer/probe sets and 
Taqman mastermix containing UNG (Uracil-N-Glycosylase to destroy 
contaminating products from previous Q-PCR reactions) were obtained from 
Applied Biosystems, USA. For each primer/probe set the 5’ reporter of the 
probe was 6-carboxyfluorescein (FAM) and the 3’ quencher was 6-carboxy- 
tetramethylrhodamine (TAMRA). For the MLL-ENL fusion gene, 
primer/probe sets were designed using Primer express software (Applied 
Biosystems). In order to measure MLL-ENL transcript expression by Q-PCR, 
two primers and a probe were designed by Dr. Sarah Horton (MHCB), using 
Primer express software (Applied Biosystems). The primers flanked the 
MLL-ENL breakpoint and the probe was designed such that it spanned the 
breakpoint:
Forward primer: 5’ CAGGGTGGTTTGCTTTCTCTGT 3’
Reverse primer: 5’ GCGATGCCCCAGCTCTAA 3’
Probe: 5’ TGGACGGTGCACTCTACATGCCCACTA 3’
These sequences were submitted to Applied Biosystems who then 
synthesised the primers and probe. The 5’ reporter of the probe was 6- 
carboxyfluorescein (FAM) and the 3’ quencher was 6-carboxy- 
tetramethylrhodamine (TAMRA). The optimum primer and probe 
concentrations were determined by Dr. Sarah Horton (MHCB).
Taqman probes were were based on Fluorescent Resonance Energy Transfer 
(FRET) to generate a fluorescent signal in real time Q-PCR when used in a 5' 
nuclease assay that utilised the 5' to 3' exonuclease activity of Taq DNA 
polymerase. The Taqman mastermix + UNG containing 5’ exonuclease
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activity would release FAM from the probe when the gene of interest was 
correctly transcribed. Once cleaved from the rest of the probe the 5' dye 
molecule was freed from the quenching effect (via FRET) when in close 
proximity to the quenching molecule TAMRA. The amount of fluorescence 
reflected the quantity of gene present and was analysed using Sequence 
Detection System, version 1.2 software. 20ul reactions were set up in 
quadruplicate in a 96-well plate (ABS, USA) using 19ul of Taqman 
mastermix, primer/probe set for the gene of interest and DEPC-treated water, 
and lul (50ng) of sample cDNA. Parallel reactions were set up as internal 
controls using primer/probe sets for Gapdh. The plate of PCR reactions was 
placed in a in a Q-PCR 7000 machine and cycling conditions were 2 minutes 
at 50°C hold (UNG activation), 10 minutes 95 °C hold (UNG denatured), 
then 40 cycles of 15 seconds at 95 °C (denaturing), 1 minute at 60 °C 
(annealing and extension).
Relative quantitation was carried out to compare the gene of interest with 
Gapdh within each cDNA sample. Quantitation was carried out relative to 
Gapdh by subtracting the cycle threshold (Ct) of this gene from the Ct of the 
gene of interest to give the difference in cycle number (ACt) for each sample 
studied.
Equation 1: ACt (sample) =Ct (gene of interest) -  Ct {Gapdh)
The difference between the cycle numbers of the control population 32DtTS 
(ACt Calib) and the experimental 32DMENL samples was calculated as the 
AACt for each sample.
Equation 2: AACt = ACt (experimental sample) -  ACt (Calibration sample)
The fold difference of template for the candidate and reference genes, studied 
in the experimental sample (32DMENL) compared to the calibration sample
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(32DtTS), was the exponent of the base 2 due to the doubling function of 
PCR, and is represented by Equation 3.
Equation 3: 2 'AACt
In a collaboration with the Haematology Department, CCRCB (Queen’s 
University, Belfast), the global Hox gene expression profile of MLL-ENL 
immortalised cells was analysed by Q-PCR. The murine Hox genes were 
cloned and standard curves were generated for 38 of the 39 genes and for the 
Hox co-factors Meisl and Pbxl. These curves were used to convert Q-PCR 
data, which had been normalised to 18S ribosomal RNA expression, into Hox 
gene copy number.
2.20 Lentiviral shRNA constructs
The lentiviral constructs used in this study are shown in Figure 2.3.
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Figure 2.3 A diagram of the lentiviral shRNA constructs used in this 
study.
LTR: long terminal repeat, SFFV: spleen focus forming virus, v|/+: viral 
packaging signal, WRE: Woodchuck hepatitis virus posttranscriptional 
regulatory element, GFP: green gluorescent protein.
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shRNAs against a gene of interest were expressed using microRNA 
(miRNA) expression in pSFFV-GFP lentiviral vectors. Synthetic sense and 
antisense short hairpin oligoribonucleotides were designed using a web- 
based algorithm by Dr. Jasper de Boer and expressed in a lentiviral vector 
using the miR30-shRNA cloning protocol for the generation of pRIME 
(Potent RNA interference using MicroRNA expression) vectors. Briefly,
PCR was used to amplify the 97mer hairpin oligo using the miRNA forward 
and reverse oligos to add Xhol and EcoRl sites to the ends of the hairpin for 
cloning into the miRNA vector. Following PCR amplification, the products 
were purified and both the PCR product (insert) and the vector (miRNA 
vector) digested with Xhol and EcoRl. The digested amplified hairpin inserts 
and miRNA vector were purified. The ligation mix was transformed into a 
strain of E.coli and clones were sequence-verified. Transfection of 293T 
packaging cells to produce concentrated lentivirus expressing miRNA- 
shRNA was carried out by Dr. Jasper de Boer according to standard 
procedures.
Sequences for miRNA expressing shRNAs against human ENL (shENL 
sequences 1 and 2), MLL (shMLL) and HLF (shHLF) genes are shown in 
Table 6.
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Table 6 Sequences for miRNA constructs used
Sequence
TG C  T G T  T G A  CAG T G A  GCG CGC GAG A A G  C T C  A C C  T  
T C  A A C  A T A  GTG A A G  C C A  CAG A T G  T A T  G T T  GAA GG 
T GAG C T T  C T C  G C A  T G C  C T A  C T G  C C T  CGG A
TGC TGT TGA CAG TGA GCG AGC AAA GAC TCC GAG A 
GC Am  ATA GTG AAG CCA C*j8r ATG CTT GOT CT ■
C GGA GTC TTT GCG TGC CTA CTG CCT CGG A
TG C T G T  T G A  C A G  T G A  GCG CGG A G A  T A A  GAT C A A  G 
A A  G A A  A T A  G TG  A A G  C C A  CAG A T G  T A T  T T C  T T C  T T  
G A T C  T T A  T C T  C C A  TG C  C T A  C TG  C C T  CGG A
TGC TGT TGA CAG TGA GCG CGC AAG AAC ATA CTT G 
CC AAG TTA GTG AAG CCA CAG ATG TAA CTT GGC AA 
G TAT GTT CTT GCA TGC CTA CTG CCT CGG A
A series of lentiviral vectors have been developed that provided high 
penetrance regulatable knockdown at single copy (pPRIME), and allow for 
the tracking of shRNA expression with a variety of reporter genes 
(Stegmeier, et al 2005). A system of pPRIME vector delivery of miRNA 
embedded shRNA was used to downregulate the expression of MLL-ENL in 
32DMENL cells. In addition, to enhance the efficiency of expression of the 
shRNA transduction and expression, the pRIME vector was modified to 
express the miRNA from the U3 part of the SFFV strain P LTR sequence 
(SFFV-U3LTR). The GFP was expressed upstream of the WPRE and 
efficiency of lentiviral infection was assessed by flow cytometric analysis of 
GFP.
2.21 Transduction of 32Dcl3 cell lines with lentiviral
shRNA constructs
32Dcl3 cell lines were transduced at a density of 104 cells per well of a 96- 
well flat-bottomed plate. A total of 6 wells were set up for each condition and 
6 x 104 of control and 32DMENL cells were transduced with a total of 600 pi
Oligo
same
shENL
1
shENL
2
shMLL
shHLF
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lentivirus. The viral supernatant was supplemented with 20% FCS, 50 pM 2- 
mercaptoethanol (2-ME) (BDH), 5 pg/ml polybrene, and 10 ng/ml 
interleukin-3 (IL-3). All recombinant murine growth factors were supplied 
by Peprotech EC. The cells were transduced by spinoculation (centrifugation 
at 700 g, 25 °C, 45 minutes) and then returned to culture. Cell culture 
conditions were optimised by the addition of a supplement of lOng/ml IL-3 
to the culture medium after 24 hours. The transduced cell lines were kept in 
culture and expanded within 4 days to allow harvesting of 1 x 105 cells for 
FACS analysis of GFP expression, and 1 x 106 cells for Western analysis of 
MLL-ENL expression.
2.22 Retroviral constructs
Diagrams of all the retroviral constructs are shown in Figure 2.4. All of the 
MLL-fusions were sequenced prior to sub-cloning by Dr. Dale Moulding and 
Dr. Inusha de Silva of the Molecular Haematology and Cancer Biology 
(MHCB) unit and sub-cloning carried out by Dr. Sarah Horton of the 
Molecular Haematology and Cancer Biology (MHCB) unit. Comprehensive 
restriction digests of the constructs were performed by Dr. Sarah Horton and 
DNA sequencing around the cloning sites of the MLL fusion constructs 
confirmed that errors had not been introduced during the sub-cloning 
process. The pMSCV-Neo-MLL-ENLA1'26 construct was made by Dr. Sarah 
Horton (MHCB) and lacked the first 26 amino acids of MLL containing the 
high-afflnity Menin-binding domain. The pMSCV-Neo-MLL-ENL^11'16116111 
construct was made by Dr. Inusha de Silva (MHCB) and retained this 
domain. The pMSCV-Neo-E2A-HLF construct was made by Dr. Jenny 
Yeung (MHCB).
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Figure 2.4 A diagram of fusion gene retroviral constructs used in this 
study.
LTR: long terminal repeat, \|/+: viral packaging signal, PGK: 
phosphoglycerate kinase promoter, Neor: neomycin resistance gene.
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2.23 Culture of LinXE and 293T cell lines
The LinXE ecotropic retrovirus packaging cell line and 293T cell lines were 
cultured in complete medium (Dulbecco’s Modified Eagle’s medium 
(DMEM, Invitrogen) supplemented with 10% foetal calf serum (FCS) and 2 
mM L-glutamine). The LinXE cells were maintained in 7.5 pg/ml 
hygromycin (Cayla) to select for the presence of the gag, pol and env genes.
2.24 Transfection of LinXE cells
LinXE cells were seeded at a density of 0.75 x 106 per 10cm plate 3 days 
prior to transfection. Cells were transfected with 8 pg retroviral plasmid 
DNA using 40 pi Lipofectamine (Invitrogen) in a total volume of 8 ml 
optimum (Invitrogen) according to the manufacturer’s instructions.
2.24.1 Isolation of haematopoietic progenitor cells
HPCs were isolated from mice which were maintained in the animal facilities 
of the National Institute for Medical Research. All experiments were 
performed according to institutional guidelines and Home Office regulations.
Foetal HPC
Ter-119' HPCs were purified from embryonic day 13.5 (E l3.5) foetal liver of 
mice by HPCs were purified by magnetic activated cell sorting (MACS) 
using MACS separation columns (Miltenyi Biotech) and monoclonal 
antibodies specific to Terl 19 .
Adult HPC
Bone marrow was extracted from 4-6 week old mice using standard 
techniques. A single cell suspension was made from the marrow of the femur 
and tibia and the red cells were lysed in 2 ml of erythrocyte lysis buffer for 
10 minutes at room temperature. HPCs were purified by MACS using MACS
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separation columns (Miltenyi Biotech). Lineage depleted cells were isolated 
by MACS using a lineage panel kit which consisted of anti-CD3 (145-2C11), 
anti-Macl (Ml/70), anti-B220 (RA3-6B2), anti-Grl (RB6-8C5), anti-Ter- 
119 (BD Pharmingen).
2.24.2 Culture of HPC
Foetal HPCs were seeded at a density of 2 x 105/ml and adult HPCs were 
seeded at a density of 1 x 106/ml. HPCs were stimulated overnight in 
complete medium supplemented with 50 pM 2-ME (BDH), 100 ng/ml stem 
cell factor (SCF), 10 ng/ml interleukin-6 (IL-6) and 10 ng/ml IL-3. All 
recombinant murine growth factors were supplied by Peprotech EC.
2.25 Transduction of haematopietic progenitor cells with
retroviral constructs
Retroviral supernatant was harvested as described previously. HPCs were 
transduced on two consecutive days. Complete medium was added to the 
LinXE cells after the first virus harvest and fresh virus was collected from 
the same culture the following day. The retroviral supernatant was 
concentrated 10-fold in some experiments. The supernatant was cleared of 
cell debris by 2 rounds of centrifugation at 580g for 5 minutes. Cleared virus 
was then aliquotted into 1.5ml eppendorf tubes and concentrated by 
centrifugation for 1 hour at 16,000g. HPCs were transduced at a density of 
104 cells per well of a 96-well flat-bottomed plate. A total of 6 wells were set 
up for each condition and 6 x 104 HPCs were transduced with a total of 600 
pi virus unless otherwise stated. The viral supernatant was supplemented 
with 20% FCS, 50 pM 2-ME, 5 pg/ml polybrene, 100 ng/ml SCF, 10 ng/ml 
IL-3 and 10 ng/ml IL-6. The cells were transduced by spinoculation 
(centrifugation at 700 g, 25°C, 45 minutes) and then returned to culture. The 
transduction was repeated after 24 hours, 60 pi of medium was removed
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from each well and replaced with 100 pi of fresh viral supernatant and 
growth factors. After culture overnight, the transduced HPCs were used for 
colony forming assays.
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Figure 2.5 Experimental strategy of haematopoietic progenitor cell 
retroviral transduction.
See text for details.
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2.26 Colony forming assays
Approximately 24 hours after the second transduction, the 6 wells of 
transduced cells were pooled, washed in 5 ml Minimal Essential-Alpha 
Media (MEM) (Invitrogen) and resuspended in 100 pi MEM. For the 
myeloid assays the cells were added to 3 ml of methylcellulose (M3434) 
(Stem cell Technologies Inc.), containing IL-3, IL-6 and SCF which was 
supplemented with 10 ng/ml GM-CSF (Peprotech). Selection was employed 
in the first round of methylcellulose plating. 1 mg/ml G418 (Invitrogen) was 
used to select for cells transduced with pMSCV-neo constructs and 1.5 
mg/ml hygromycin (Cayla) was used to select for cells transduced with 
pMSCV constructs. The volume of methylcellulose containing the cells, 
antibiotic and growth factors was made up to 3.3 ml with MEM. The 
components were then mixed thoroughly and 1.1 ml was aliquotted into 
duplicate 35mm plates according to the manufacturer’s instructions. The 
duplicate methylcellulose cultures were placed in 10cm plates and cultured 
for 6-10 days alongside a 35mm plate containing PBS to humidify the 
cultures.
After 6-10 days, colonies containing 50 cells or more were scored. The cells 
were harvested from the methylcellulose by the addition of 1 ml MEM to 
each plate, followed by gentle pipetting to create a single cell suspension.
The cells from duplicate methylcellulose cultures were pooled and washed in 
10 ml MEM containing 2% FCS. The cells were counted and 1 x 104 cells 
were replated into secondary assays under identical conditions but in the 
absence of antibiotic selection. This process was repeated every 7-10 days. 
Colonies were stained with 1 mg/ml p-iodonitrotetrazolium (INT) (Sigma- 
Aldrich) in PBS.
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2.27 PCR for genotyping
DNA samples for genotyping of mice were prepared from unsorted foetal 
liver or BM cells using the hot sodium hydroxide and tris method (see 
HotSHOT genomic DNA preparation, Camper Lab, Biotechniques 2000 29 
(1) 52-54). Briefly 1 x 105 cells were washed in PBS, spun at 4°C at 4000rpm 
for 5 minutes. The cells were lysed in 25ul of HotSHOT alkaline lysis 
reagent at 95°C for 20 minutes, then immediately neutralized with 25ul of 
HotSHOT neutralization buffer. 2ul of DNA was used in a 25ul PCR 
reaction. DNA samples for genotyping of individual colonies grown in 
methylcellulose were prepared by picking individual colonies into lOOul of 
PBS each and washing twice with PBS. 25ul of 0.05M sodium hydroxide 
were added to each sample and boiled for 5 minutes. 2.5ul of 2M Tris pH 7.5 
were added to each sample and spun at 13 000 rpm for 1 minute. 4ul of DNA 
were used in a 25ul PCR reaction.
The DNA was analysed by PCR using three combinations of primers. The 
primers and their binding sites in the different alleles are shown in Figure 
5.6. PCR reactions for genotyping of the Mil gene were carried out using the 
Advantage GC2 PCR kit according to manufacturer instructions (BD- 
Biosciences). The primer combinations are shown in Table 7. Genotyping to 
detect the 5' LoxP site used primers E and F, and primers E and G and the 
programme used was [97°C 3 min, (97°C 30s, 62°C 1 min, 72°C 2 min) x 3 
cycles, (96°C 30s, 62°C 1 min, 72°C 2 min) x 7 cycles, (96°C 30s, 61°C 1 
min, 72°C 2 min) x 10 cycles, (96°C 30s, 60°C 1 min, 72°C 2 min) x 10 
cycles, 72°C 10 min].
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Table 7 Prim er combinations used for genotyping of the Mil allele 
Primer name Primer sequence
E 5’ GCCAGTCAGTCCGAAAGTAC
3’
F 5’ AAGATGTTCAAAGTGCCTGC
, 3* •- .*
G2 5’ GCTCTAGAACTAGTGGATCCC
3’
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3 E xpression  o f  M L L -E N L  in 32D cl3 cells confers  
an altered  phenotype
3.1 Introduction
MLL fusion proteins MLL-ENL and MLL-AF9 were expressed in 32Dcl3 
cells and the phenotype of cells expressing MLL-ENL was studied.
32Dcl3 cells are a murine multipotential (erythroid-neutrophil-mast cell- 
basophil-eosinophil) cell line derived from long term bone marrow cultures 
of Toll-like receptor defective C3H/HeJ mice infected with the Friend 
murine leukaemia virus (Greenberger, et al 1983). This cell line was chosen 
for its characteristics as a non-transformed, immortalised murine myeloid 
precursor cell line which has been previously used to demonstrate pathways 
of haematopoietic differentiation in response to erythropoietin (EPO), 
granulocyte-macrophage colony stimulating factor (GM-CSF) and 
granulocyte colony stimulating factor (G-CSF) (Migliaccio, et al 1989). Of 
the MLL fusion proteins studied, MLL-AF9 is found almost exclusively in 
infant myeloid leukaemias, and MLL-ENL is found equally in myeloid and 
lymphoid infant leukaemias. This myeloid precursor cell line therefore 
appeared to be appropriate for the investigation of target genes of these 
fusion proteins in myeloid leukaemias, as well as for the study of the effects 
of these fusion proteins in terms of their effect on cellular differentiation and 
requirement of IL-3 for survival.
3.2 The tetracycline inducible system
The ideal conditional expression system should allow the ability to switch 
transgene expression on and off, rapidly and reversibly in a chosen cell type. 
The tetracycline transactivator system has been established as a reliable tool 
for regulated transgene expression, and exploits the pathway that controls the 
expression of a tetracycline resistance gene in E. coli (Gossen and Bujard
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1993). 32Dcl3 clones which inducibly expressed a gene of interest were 
generated using the Tet-On gene expression system (Clontech) by which 
gene expression follows the addition of doxycycline, a tetracycline 
derivative.
The Tet repressor protein (TetR) is a regulatory protein which negatively 
regulates the expression of genes of the tetracycline resistance operon in E. 
coli by binding to Tet operator sequences (TetO) in the absence of 
tetracycline. In the presence of tetracycline, dissociation of the TetR 
normally occurs to allow expression of the tetracycline resistance protein 
(TetA). The regulatory protein used in the Tet-On system is the reverse 
tetracycline-controlled transactivator (rtTA) which is a transcriptional 
activator protein which responds to doxycycline. It is based on a ‘reverse’
Tet repressor protein (rTetR) which results from a four amino acid change in 
the TetR that reverses the protein’s response to doxycycline,. The rtTA is 
comprised of the rTetR fused to the C-terminal 127 amino acids of the 
Herpes simplex virus VP 16 activation domain, which converts the rTetR 
from a transcriptional repressor to a transcriptional activator (Gossen and 
Bujard 1992). The rtTA is located upstream of the CMV promoter (P CMV) 
in the pTet-On regulatory plasmid, which also contains a neomycin 
resistance gene.
The second component of the Tet-On system is the response plasmid pTRE 
which expresses a gene of interest under the control of the tetracycline- 
response element (TRE). The TRE consists of seven direct repeats of a 42-bp 
sequence containing the TetO, and is located just upstream of the minimal 
CMV promoter (Pmin CMV). This minimal promoter lacks the strong 
enhancer elements normally associated with the CMV immediate early 
promoter so that little or no background expression of the gene of interest 
should occur in the absence of binding of the rtTA to the TRE. In the Tet-On 
system, binding of rtTA to the TRE occurs only in the presence of
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doxycycline as it causes a conformational change of the rtTA to allow 
binding to the TRE and activation of transcription of the gene of interest. 
Thus, transcription is turned on in response to doxycycline and in a dose- 
dependent manner (Gossen and Bujard 1995).
The control of background constitutive expression can additionally be 
optimised by the co-transfection of the pTet-tTS plasmid which expresses the 
tetracycline-controlled transcriptional silencer (tTS). This is a fusion of the 
Tet repressor protein (TetR) and the KRAB-AB domain of the KID-1 protein 
(Freundlieb, et al 1999, Witzgall, et al 1994), and prevents gene expression 
in the absence of doxycycline by binding to the TetO sequences in the TRE. 
The addition of doxycycline switches the system from one that is actively 
silenced by tTS to one that is induced by rtTA. The activation of doxycycline 
responsive gene transcription in the Tet-On system is illustrated in Figure 
3.1.
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Figure 3.1 Regulation of gene expression by the Tet-On system.
The rtTA is a transcriptional activator protein which responds to 
doxycycline. Binding of rtTA to the TRE occurs only in the presence of 
doxycycline following a conformational change of the rtTA, to allow 
subsequent activation of transcription of a gene of interest. The tTS prevents 
gene expression in the absence of doxycycline by binding to Tet operator 
sequences in the TRE.
rTetR: reverse Tet repressor, VP 16: VP 16 activation domain, rtTA: reverse 
Tetracycline-controlled transactivator, Pqmv' CMV promoter, TRE: 
Tetracycline-response element, PmmcMw‘ minimal CMV promoter, tTS: 
Tetracycline-controlled transcriptional silencer..
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3.3 Characterisation of 32Dcl3 cells
Differentiation of 32Dcl3 cells into neutrophils has been demonstrated in the 
presence of G-CSF and GM-CSF, by both morphological criteria and a well- 
characterised system of cell surface markers (Ingles-Esteve, et al 2001). This 
differentiation is thought to be partly mediated by the Notch gene family 
whose protein products are involved in cell fate decisions in haematopoietic 
progenitors and usually inhibit differentiation (Milner, et al 1996). G-CSF 
has been shown to phosphorylate and inactivate NOTCH2 to allow 
neutrophil differentiation, while GM-CSF appears to mediate differentiation 
through its effect on NOTCH 1 (Ingles-Esteve, et al 2001). 32Dcl3 cells have 
been used previously in one study to demonstrate differentiation arrest by the 
N-terminal MLL retained in the fusion protein MLL-AF9 (Joh, et al 1999). 
The effect of MLL fusion protein expression on differentiation was assayed 
in this study following exposure of 32Dcl3 cells to G-CSF.
A further characteristic of 32Dcl3 cells is their dependence on IL-3 for 
survival. DNA histograms have previously shown 40% of cells in G0/G1 
phase and 40% in S phase when incubated with this growth factor (Shimada, 
et al 1993). These cells undergo significant apoptotic death following IL-3 
withdrawal (Houben, et al 1997). Over-expression of oncogenes such as Bcl2 
has been shown to protect these cells from such apoptosis (Baffy, et al 1993). 
In this study the effects of MLL fusion proteins in conferring IL-3 
independent survival, or increased sensitivity to apoptosis can be readily 
determined following withdrawal of this cytokine.
When maintained in IL-3, 32Dcl3 cells proliferate in suspension as round 
undifferentiated blasts, growing singly or in small clusters with a doubling 
time of less than 24 hours (Shaknovich, et al 1998). The morphology of these 
cells was characterised following examination of Giemsa-Wright stained 
cytospin preparations in which the cells were seen to have a single large,
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relatively round nucleus and scant dark blue cytoplasm containing few 
granules (Figure 3.2B). The cells were incubated with G-CSF to induce 
neutrophil differentiation according to previously described methods (Bigas, 
et al 1998). Evidence of neutrophil differentiation was seen at day six, with 
complete differentiation of the majority of cells by day fourteen in line with 
previous reports (Ingles-Esteve, et al 2001, Miranda, et al 2002) and is 
shown in Figure 3.3A. Criteria for neutrophil differentiation included 
increased cytoplasmic to nuclear ratio, increased cytoplasmic granulation, 
increased intensity of eosin staining and increased nuclear segmentation. 
Figure 3.2A shows the cell surface marker profile of 32Dcl3 cells in which 
they express the macrophage marker F4/80, and do not express the 
granulocyte marker Grl or granulocyte/macrophage marker Macl. These 
results are consistent with an early precursor with capacity for macrophage or 
granulocyte differentiation.
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Figure 3.2 Characterisation of the phenotype of 32Dcl3 cells.
A Expression of cell surface markers Grl, Macl, F4/80, CD61 and CD41 by 
FACS analysis. Isotype control is shown in bold, and sample in blue.
B Cytospin Giemsa-stained preparation of 32Dcl3 cells.
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In line with previous reports, the granulocyte marker Grl and 
granulocyte/macrophage marker Macl are up-regulated following G-CSF 
induced neutrophil differentiation as shown in Figure 3.3B.
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Figure 3.3 G-CSF mediated neutrophils differentiation of 32Dcl3 cells.
A Cytospin Giemsa-stained preparations of 32Dcl3 cells following 
incubation with G-CSF shows wild-type 32Dcl3 cells at day 0 (a), and 
subsequent neutrophil differentiation at day 6 (b), day 8 (c), and day 12 (d). 
B Expression of Grl and Macl cell surface markers at day 12 of 
differentiation. Isotype controls are in black, shaded areas represent samples.
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Confirmation of IL-3 dependence of the 32Dcl3 cells was demonstrated by a 
normal cell cycle profile in the presence of IL-3, with subsequent massive 
apoptotic cell death following the incubation of cells for 24 hours in media 
lacking IL-3 as seen in Figure 3.4.
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Figure 3.4 Cell cycle and apoptotic profile of 32Dcl3 cells.
A Cell cycle profile of 32Dcl3 cells when cultured with IL-3 shows the 
majority of cells in a phase of protein synthesis (Gl), DNA synthesis (S), or 
DNA proof-reading and preparation for mitosis (G2/M).
B Cell cycle profile of 32Dcl3 cells following withdrawal of IL-3 from 
culture media for 24 hours shows the majority of cells having undergone 
apoptosis with associated DNA fragmentation (sub Gl phase)..
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3.4 Generation of tetracycline inducible 32Dcl3 cells
32Dcl3 cells were electroporated with the TetOn plasmid containing the 
transcriptional activator rtTA cassette and neomycin resistance gene. The 
electroporated populations were sorted into single clones in 96-well plates 
using the Autoclone sorting option on the EPICS ALTRA FACS sorter 
(Beckman Coulter, High Wycombe, UK), and each clone further expanded 
under neomycin selection. A large number of clones were then screened 
using the dual luciferase assay to detect inducible expression of a luciferase 
reporter gene in the presence of doxycycline. Clones were electroporated 
with the firefly luciferase reporter gene under control of the TRE (TRE-Luc), 
together with the constitutively expressing renilla luciferase gene under 
control of the CMV promoter as a control for transfection efficiency. Cells 
were incubated with doxycycline for 24 hours. Comparison of firefly 
luciferase activity in the presence and absence of doxycycline indicated the 
fold induction of gene expression as shown in Figure 3.5.
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Figure 3.5 Inducible expression of luciferase reporter by 32Dcl3 
tetracycline-responsive clones.
The degree of luciferase expression in the presence and absence of 
doxycycline is shown for each 32Dcl3 clone. ( ’•'Clones stably transfected 
with luciferase reporter constructs and selected in hygromycin).
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In this way, doxycycline responsive inducible 32Dcl3 clones were generated 
that would express a gene of interest in a regulatable and temporal manner. 
Specific clones were chosen which had the lowest levels of background 
expression in the absence of doxycycline, together with the highest levels of 
gene induction. The two clones chosen were those named 3E and 8D, with 
8D being chosen for its higher level of induction despite a higher level of 
background expression.
Isolating such clones involved an extensive screening process in which large 
numbers of clones were tested, and for this reason individual clones were not 
tested in triplicate. However, the clones 3E and 8D were used repeatedly and 
inducubility was reproducibly seen, for example, as in. Figure 4.1.
3.5 Generation of tetracycline inducible 32Dcl3 cells which
constitutively express MLL-ENL
In order to study the transcriptional targets of MLL-ENL, it was necessary to 
generate 32Dcl3 rtTA clones able to inducibly express this fusion protein.
The 9678bp pTRE-MLL-ENL plasmid (pTREMENL) contained the amino 
acids 27-1444 of human MLL fused to amino acids 1506-2060 of human 
ENL under control of the TRE, with a c-MYC tag at the N terminus and HA 
tag at the C terminus as shown in Figure 2.1. As a result of deletion of the 
first 26 amino acids of MLL, this construct lacked the Menin-binding domain 
of MLL which was subsequently found to reside within this region. The 
pTREMENL was created by replacement of the Sal\-Cla\ fragment of 
pCSARQ2 with the 441 bp Sal\-Cla\ fragment containing the TRE, and 
insertion of c-MYC and HA tags. The pTREMENL plasmid was linearised 
by digestion with the Sea 1 restriction enzyme.
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In order to generate inducible clones expressing MLL-ENL, the 3E 
32DTeton clone was co-transfected with the pTet-tTSHygR and 
pTREMENL. Initially the plasmids were electroporated in molar ratios of 
1:15 pTet-tTSHygR and pTREMENL and this 32DMENL-Popl grown in 
hygromycin selection. 32DMENL-Popl was then tested in the presence and 
absence of doxycycline for expression of MLL-ENL. Cells were incubated 
with doxycycline for 24 hours and Western blot performed using the 9E10 
anti-cMYC antibody.
114
f - M L L - E N L  2 2 0 k D a  
" * ” 2 1 0 k D a
D o x y c y c l i n e
M L L - E N L  2 2 0 k D a  
2 1 0 k D a
D o x y c y c l i n e
contro l 32DMENL clones
M L L - E N L  2 2 0 k D a  
2 1 0 k D a
D o x y c y c l i n e
M L L - E N L  2 2 0 k D a
2 1 0 k D a
D o x y c y c l i n e
control 32DMENL c lones
Figure 3.6 Western analysis showing expression of MLL-ENL.
A and C show expression of MLL-ENL in initial mixed populations 
(32DMENL-Pop)
B and D show MLL-ENL expression in clones (32DMENL)
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Figure 3.6A shows the low level and leaky (showing background expression 
in the absence of doxycycline) expression of MLL-ENL from mixed 
population 32DMENL-Popl. Clones were isolated from this population by 
limiting dilution and two weakly expressing, non-leaky clones were obtained 
(data not shown). In order to obtain clones with greater expression of MLL- 
ENL, further electroporation was carried out at altered ratios of tTSHygR to 
pTREMENL of 1:10 and 1:20 to generate 32DMENL-Pop2 and 32DMENL- 
Pop3 respectively. 32DMENL-Pop2 showed no expression of MLL-ENL 
(data not shown).
Figure 3.6A shows the leaky expression of MLL-ENL in 32DMENL-Pop3 
following incubation with doxycycline for 24 hours, Single cell clones were 
isolated by FACS sorting of single cells into 96-well plates and these were 
propagated and expanded. Intial screening of numerous isolated clones was 
performed following incubation of cells with doxycycline for 24 hours. 
Those whose expression was positive were tested again in the presence and 
absence of doxycycline to confirm any degree of background expression. 
This allowed more rapid screening and isolation of expressing clones. 
Twenty-one clones were isolated which all expressed MLL-ENL in the 
presence of doxycycline, but which were all subsequently confirmed to have 
a high level of constitutive expression.
Possible reasons for the the constitutive expression of MLL-ENL in these 
clones were:
• possible low levels of tetracycline derivatives in the fetal calf serum 
used for cell culture which may be causing transactivation of MLL- 
ENL
• the preferential integration of MLL-ENL into transcriptionally active 
regions of euchromatin
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In order to investigate the first possibility, the clones were washed and 
incubated in Tetracycline-free serum and re-tested for inducible expression 
of MLL-ENL. However, all these clones continued to have high levels of 
constitutive expression and MLL-ENL expression in five of these clones is 
shown in Figure 3.6B.
Further electroporation was carried out in ratios of tTSHygR to pTREMENL 
of 1:5 and 1:15 to generate 32DMENL-Pop4 and 32DMENL-Pop5 
respectively in an effort to again obtain inducible clones. These last two 
populations were further divided into six mini populations each and tested for 
inducible expression of MLL-ENL. This was done in order to increase the 
representation of different clones with a range of genomic integrations that 
would result in variable levels of inducibility. Both 32DMENL-Pop5a and 
32DMENL-Pop5b mini populations showed high level leaky expression as 
shown in Figure 3.6C. Clones were isolated from 32DMENL-Pop5b by 
FACS sorting of single cells. However, Figure 3.6D shows the Western 
analysis in which these 32DMENL clones are seen to have similar levels of 
constitutive expression to that of clones previously generated.
The experiment was therefore modified to make use of the 32DMENL 
constitutive clones generated from 32DMENL-Pop5b. mRNA was isolated 
from eight constitutively expressing clones for gene expression analysis and 
pooled following cDNA synthesis. Comparison was made to a mixed 
population generated by electroporation of the same rtTA clone with pTet- 
tTSHygR only (32DtTS).
The disadvantages of this system compared to a comparison of inducibly 
expressing clones were that:
• clonal variation would need to be considered and could not be 
eliminated, although comparison to a mixed population of control 
cells would limit some error.
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• it would not be possible to study the immediate targets of transcription 
following induction of expression by doxycycline, or the result of 
different levels of expression at different time points, in order to 
compare the degree to which a candidate target was up- or down- 
regulated. The identification of significantly highly changed targets 
following constitutive expression may, however, prove equally useful, 
as these candidate targets would subsequently be analysed more 
rigorously for their role in the leukaemic phenotype.
Such a system of constitutive expression did allow the following advantages:
• the effect of doxycycline itself on changes in gene expression was no 
longer a confounding variable in the microarray and Q-PCR 
experiments.
• the effect of doxycycline itself on cell cycle was no longer a difficult 
variable to control in the study of the effect of MLL-ENL on apoptosis 
following IL-3 withdrawal, and on 32Dcl3 cell differentiation, and 
other possible aspects of phenotype.
Figure 3.7 shows eight chosen clones with variable levels of protein 
expression, and their levels of relative levels of MLL-ENL mRNA transcripts 
analysed by Q-PCR. The fold difference between MLL-ENL and control gene 
(Gapdh) is seen to be large for all clones. The levels of MLL-ENL mRNA do 
not appear to correlate with protein expression for each clone, and this may 
be a result of post-translational modification of gene expression. Total RNA 
was isolated from each clone in the absence of doxycycline and used for 
microarray analysis. The detailed outcome of this microarray analysis will be 
discussed in Chapter 4.
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Figure 3.7 32DMENL clones constitutively express MLL-ENL.
A shows the expression of MLL-ENL protein in nine 32DMENL clones 
labeled as shown
B shows the relative levels of expression of mRNA in each clone by Q-PCR. 
The figure also shows the level of expression in a positive control 
(HPCMENL)
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3.6 Expression of human MLL-ENL increases sensitivity 
to apoptosis induced by IL-3 withdrawal in murine 
32Dcl3 cells
The dependence of 32Dcl3 cells on IL-3 for growth and survival, and the 
high degree of apoptosis following IL-3 withdrawal for 24 hours has been 
shown in Figure 3.4. In order to investigate whether the chimeric 
transcription factor MLL-ENL had a role in altering the dependence of 
32Dcl3 cells on IL-3 for growth and survival, IL-3 was withdrawn from 
culture media from six 32DMENL clones, and the degree of apoptosis 
measured at different time points by flow cytometry of ethanol-fixed cells 
stained with propidium iodide. The results are shown in Figure 3.8.
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Figure 3.8 Sensitivity to apoptosis of 32DMENL clones following 
withdrawal of IL-3 from cell culture medium.
(p<0.01 for all 32DMENL compared to control at 8, 10 and 14 hours, except 
for A6 at 8 hours).
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Compared to the control 32D and 32DtTS cells, the 32DMENL clones 
showed:
• a significantly increased sensitivity to apoptosis following IL-3 
withdrawal, p<0.01 at 8, 10 and 14 hours for all clones except A6 at 8 
hours.
•  an earlier sensitivity to apoptosis after IL-3 withdrawal, which in most 
clones increased over the time course from 8 hours to 14 hours. All 
clones except A10 showed significantly increased sensitivity to 
apoptosis at 8 hours compared to 0 hours (p<0.01), A8, B3 and D ll  
significantly sensitive at 10 hours compared to 8 hours, and all clones 
were significantly sensitive at 14 hours compared to 10 hours 
(p<0.01). There was no such change in apoptotic sensitivity over the 
same time course in the 32D and 32DtTS cells.
There was a variation among the 32DMENL clones in regard to their 
sensitivity to apoptosis which may have been due to their levels of 
expression of MLL-ENL. However, Western analysis showed no correlation 
of protein expression levels with apoptotic sensitivity for individual clones.
MLL-ENL thus appears to confer a phenotype on 32Dcl3 cells of increased 
sensitivity to apoptosis following growth factor withdrawal.
3.7 Expression of human MLL-ENL confers a
macrophage-like phenotype in murine 32Dcl3 cells
Arrest of cell differentiation has been shown to be a mechanism involved in 
leukaemogenesis by a number of oncogenes. A role for MLL-ENL in 
impeding differentiation has been described in a study of the effect of 
retroviral MLL-ENL expression in primary mouse haematopoietic cells 
(Schreiner, et al 1999). The addition of G-CSF reversed the maturation block 
set by MLL-ENL and induced the development of mature granulocytes and
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macrophages accompanied by growth arrest. This study also described the 
need for a further event, in this case cMYC over-expression, before 
differentiation arrest of the myelomonocytic precursor population was seen. 
32Dcl3 cells expressing MLL-AF9 showed an altered Hox gene profile 
following down-regulation of the fusion protein but no morphology was 
described (Joh, et al 1999). Cell lines derived from blasts bearing MLL-AF9 
have also been studied for their capacity to differentiate following down 
regulation of the fusion protein. THP-1 cells did not terminally differentiate 
following knock down of MLL-AF9 protein (Pession, et al 2003), and this 
may be due to the harbouring of many further acquired mutations in such 
cells which may make them independent of MLL-AF9 in regard to their 
malignant behaviour.
The morphology of wild type 32Dcl3 cells and their ability to differentiate 
into neutrophils in the presence of G-CSF has been shown in Figure 3.3. In 
order to investigate the effects of MLL-ENL on the differentiation of 32Dcl3 
cells, the morphology of Giemsa-stained cytospin preparations prior to and 
following incubation with G-CSF was studied and compared to that of wild- 
type 32Dcl3 cells. The results are shown in Figure 3.9. The morphology of 
32DMENL clones at day 0 show two appearances; five of eight clones 
showed increased cytoplasmic vacuolation and cytoplasmic/nuclear ratio. 
Such macrophage-like features persisted and were accentuated following 6 
days of incubation with G-CSF, while features typical of neutrophil 
differentiation were also seen. Three 32DMENL clones had an appearance 
similar to the myeloblast-like morphology of parental cells prior to G-CSF 
incubation and showed neutrophil differentiation at day 6 similar to parental 
cells.
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Figure 3.9 Morphology of 32DMENL clones.
Morphology of Giemsa-stained cytospin preparations following incubation 
with G-CSF shows wild-type 32D cells (a), and subsequent neutrophil 
differentiation at day 6 (b), day 8 (c), and day 12 (d). Morphology of 
32DMENL clones at day 0 shows two appearances; five of eight clones 
showed increased cytoplasmic vacuolation and cytoplasmic/nuclear ratio (e). 
At day 6, features typical of neutrophil differentiation, as well as associated 
gross cytoplasmic vacuolation can be seen (f) The remaining three MLL- 
ENL clones show myeloblast-like morphology (g) and neutrophil 
differentiation at day 6 (h) similar to parental cells.
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FACS analysis using antibodies to cell surface markers also showed a more 
differentiated phenotype in the 32DMENL clones. The surface markers 
studied were all markers of myeloid cell differentiation toward granulocyte, 
macrophage-monocyte or megakaryocyte-erythroid cells.
Figure 3.10 shows up-regulation of Mac 1 expression in seven of eight 
32DMENL clones. Figure 3.11 shows up-regulated CD41 expression in 
seven of eight 32DMENL clones compared to that of parental 32Dcl3 cells, 
suggesting a more differentiated phenotype towards a macrophage or 
megakaryocyte in cells expressing MLL-ENL. Clone B3 showed loss of 
CD41 expression compared to wild-type cells, but lack of an isotype control 
does not allow an accurate assessment of true up-regulation or loss of CD41 
expression in 32DMENL cells. Loss of CD41 expression in the case of clone 
B3 may have been due to staining of an isolated population of wild-type cells 
rather than those expressing MLL-ENL.
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Figure 3.10 Expression of the macrophage cell surface antigen Macl in 
32DMENL clones.
The expression of Macl is shown in eight 32DMENL clones at T=0 (black 
line: 32Dcl3; blue line: sample, note absence of isotype control).
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Figure 3.11 Expression of the megakaryocytic cell surface antigen CD41 
in 32DMENL clones.
The expression of CD41 is shown in eight 32DMENL clones at T=0 (black 
line: 32Dcl3; blue line: sample, note absence of isotype control).
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Three of eight clones survived to day 6 following treatment with G-CSF, and 
cell surface marker profiles were unchanged from day 0 with no up- 
regulation of Grl (data not shown). Comparison was unable to be made with 
the parental 32Dcl3 cells which showed predominant neutrophil morphology 
and up-regulation of Grl by day 14 due to the large amount of cell death 
observed following incubation of 32DMENL cells with G-CSF.
Interestingly, the three clones which survived to day 6 were those that most 
resembled the parental cells at day 0.
It therefore appears that MLL-ENL affects 32Dcl3 phenotype by promoting 
differentiation toward a megakaryocyte-erythroid precursor in view of its up- 
regulation of CD41, and toward a macrophage-monocyte precursor in view 
of the up-regulation of Macl and macrophage features.
3.8 Discussion
3.8.1 The function of MLL-ENL in promoting sensitivity to 
apoptosis following IL-3 withdrawal
Apoptosis is a programmed process resulting in cell destruction without 
eliciting an inflammatory response, and is caused by the activation of 
intracellular cysteine proteases or caspases (Brady 2003). Morphological 
features of apoptosis include plasma membrane blebbing, volume 
contraction, nuclear condensation and endonucleolytic cleavage of DNA 
(Kerr 2002, Kerr, et al 1972). Such a process is required for the development 
and maintenance of normal tissue homeostasis and is tightly interlinked with 
other essential pathways (Danial and Korsmeyer 2004). The process of 
normal cell differentiation into specific lineages, as seen in the 
haematopoietic system, requires the control of death as well as cell division. 
Deregulation of these processes in a HSC or restricted progenitor to block 
apoptosis or senescence, or interference with cell cycle to cause hyper­
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proliferation may contribute to the leukaemic phenotype. Major apoptotic 
pathways in haematopoietic cells that are implicated in oncogenesis are the 
receptor-mediated and mitochondrial-mediated pathways (Brady 2003,
Danial and Korsmeyer 2004, Evan and Vousden 2001, Marsden and Strasser 
2003).
IL-3 is a cytokine growth factor produced by activated T cells, 
monocytes/macrophages and stromal cells, and importantly regulates 
haematopoiesis through its influence on the proliferation, differentiation and 
survival of various haematopoietic cell lineages and early progenitors (de 
Groot, et al 1998). 32Dcl3 cells were shown to be strictly dependent on IL-3 
for growth and survival, and in medium lacking IL-3 these cells undergo 
apoptosis. IL-3 mediated survival of haematopoietic progenitors or 32Dcl3 
cells in vitro appears to be due to the up-regulation of anti-apoptotic proteins 
BCL2, BCL-X and cMYC, and down-regulation of pro-apoptotic proteins 
such as BAD (Leverrier, et al 1997, Low, et al 2001).
32DMENL cells were shown to have a greater sensitivity to apoptosis 
following IL-3 withdrawal from culture medium, and de-regulation of 
apoptosis by MLL-ENL may provide a context for leukaemia to arise. A 
number of in vitro and in vivo findings from studies of leukaemia with MLL 
gene rearrangements point to the importance of the apoptotic process in these 
leukaemias. Maternal exposure to epipodophylotoxins is associated with 
infant MZZ-rearranged leukaemia, while therapy-related short-latency 
leukaemias and infant leukaemias share a similar clustering of MLL genomic 
breakpoints. The proximity of these sites to topoisomerase II consensus 
binding sites has implicated topoisomerase II inhibitors directly in the 
development of MLL rearrangements and subsequent leukaemia (Broeker, et 
al 1996). The analysis of MLL breakpoints of five t(9,l 1) non therapy-related 
childhood AML cases revealed almost identical sequences that were very 
close to an area susceptible to breakage by topoisomerase II inhibitors,
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suggesting that the development of t(9;l 1) AML involves damage-repair 
mechanisms (Langer, et al 2003). Other studies show that the MLL 
breakpoints seen in therapy-related leukaemias cluster in the same region that 
is targeted by nucleases of the effector apoptotic pathway. These nucleases 
are recruited following apoptotic triggers in vitro and may be responsible for 
MLL gene breakage and subsequent formation of fusion genes early in 
leukaemogenesis without direct involvement of topoisomerase II inhibitors 
(Betti, et al 2001). Cells stimulated to undergo apoptosis following 
stimulation by an anti-FAS antibody resulted in the formation of the Mil-Aft 
fusion gene following chromatin cleavage at 1 lq23 at an early stage and 
evasion of apoptotic execution (Vaughan, et al 2005). These mechanisms are 
not necessarily mutually exclusive and both may contribute to the 
development these leukaemias.
While a pro-survival effect of over-expressed oncogenes has often been 
described, a number of oncogenes are pro-apoptotic, this being tissue specific 
and dependent on the presence of other genetic aberrations. Over-expression 
of the cMYC oncogene has been described as conferring a proliferative 
advantage leading to cancer in hepatocytes, skin and haematopoietic cells. 
Subsequent down-regulation of cMYC leads to differentiation or apoptosis, 
but also to a dormant population which are then allowed to acquire further 
mutations which confer a definitive survival advantage that is not dependent 
on the initiating oncogene (Jonkers and Bems 2004). In addition cMYC 
over-expression in pancreatic islet cells results in apoptosis which can only 
be rescued by BCL-Xl , an anti-apoptotic gene. Yet regression of the tumours 
that result are dependent on down regulation of cMYC alone (Pelengaris, et 
al 2002). Thus, potentially oncogenic proliferative signals are coupled to a 
variety of growth-inhibitory processes such as the induction of apoptosis, 
differentiation or senescence, each of which resists subsequent clonal 
expansion and neoplastic tumour evolution. Tumour progression occurs only
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in the very rare instances where these growth-inhibitory mechanisms are 
thwarted by compensatory mutations (Evan and Vousden 2001).
Previous studies of the effect of MLL fusion proteins in blasts harbouring 
MLL-AF9 have shown apoptosis following targeted inhibition of this fusion 
protein (Kawagoe, et al 2001, Pession, et al 2003). Targeted inhibition of 
MLL-ENL in a leukaemic cell line also induced apoptosis (Akao, et al 1998) 
while MLL-AF4 bearing leukaemic cells show resistance to serum- 
deprivation-induced or interferon gamma regulated FAS-mediated apoptosis. 
GADD34 expression correlates with, and enhances, apoptosis after treatment 
with ionizing radiation (Hollander, et al 1997), and both MLL-AF9 and 
MLL-ENL have been shown to abrogate GADD34-induced apoptosis while 
wild-type MLL causes increased apoptosis (Adler, et al 1999). In addition to 
the abrogation of GADD34-mediated apoptosis, MLL fusion proteins have 
been shown to abrogate p53-mediated apoptosis also (Wiederschain, et al 
2005).
The prosurvival effect seen in studies involving leukaemic cell lines derived 
from patients with MLL translocations may be complicated by the numerous 
other acquired mutations likely to be present which may themselves be 
responsible for the survival advantage of the cell rather than it being a direct 
effect of the MLL fusion. In this study, MLL-ENL is expressed alone 
without the confounding effects of possible other accumulated mutations, 
and a pro-apoptotic effect is observed in the context of IL-3 withdrawal. The 
role of the fusion protein in promoting apoptosis may be to confer a selective 
pressure for the cell to acquire a mutation in order to survive, and if a cell is 
able to escape apoptosis by acquiring a survival advantage, it may then go on 
to cause leukaemia.
The pro-apoptotic effect of isolated expression of an MLL fusion protein is 
supported by the finding that graded increased expression of MLL-AF4 in
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U937 cells results in G1 cell cycle arrest, prolonged doubling time as well as 
up-regulation of Macl, thus possibly protecting the cell from etoposide- 
mediated cytotoxicity (Caslini, et al 2004). Studies have also examined the 
effect of MLL-ENL expression on apoptosis and cell survival in other 
contexts of apoptotic stimuli causing DNA damage that result in receptor- 
mediated apoptosis. MLL-ENL function has been shown in murine 
progenitor cells to substantially increase the incidence of chromosomal 
abnormalities in proliferating cells that survive exposure to etoposide, also 
known to be associated with secondary MLL fusion leukaemias. This 
phenotype is also associated with an altered pattern of cell cycle arrest and/or 
apoptosis and the authors suggest that MLL fusion proteins render cells more 
vulnerable to further DNA damage and mutation in the presence of chronic 
exposure to the agent that induced the MLL fusion itself (Eguchi, et al 2006).
Thus apoptosis is a context for further oncogenic mutations that synergise 
with the fusion protein to form a leukaemic clone, and this may be a 
mechanism by which MLL-ENL is involved in leukaemogenesis.
3.8.2 The function of MLL-ENL in promoting differentiation 
towards a macrophage phenotype in 32Dcl3 cells
During G-CSF induced differentiation of 32Dcl3 cells, Hoxa9, Hoxb8, Meisl 
and Meis2 were shown to be down-regulated, while enforced expression of 
Hox or Meis genes inhibited such differentiation (Fujino, et al 2001). 
Disruption of ubiquitin-mediated degradation of Hoxa9 and subsequent 
altered expression levels have also been shown to inhibit G-CSF mediated 
neutrophil differentiation of 32Dcl3 cells (Zhang, et al 2003). Aberrant 
cellular differentiation may therefore result from the expression of MLL 
fusion proteins in which normal expression of the MLL gene is lost and such 
abnormal differentiation may be a result of aberrant Hox gene expression. G- 
CSF induced differentiation of 32Dcl3 cells inducibly expressing MLL-AF9
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was shown to result in aberrant Hox gene expression with up-regulation of 
Hoxa7, Hoxbl and Hoxc9 genes, but characterisation of the phenotype of the 
cells was not described in this study (Joh, et al 1999). Expression of MLL- 
AF9 in a leukaemic cell line was associated with maintained levels of Hoxa7 
and HoxalO, and down regulation of these genes followed down-regulation 
of the fusion protein with resultant apoptosis (Kawagoe, et al 2001), but 
there was no evidence of increased differentiation. Similarly, anti-sense 
mediated down regulation of MLL-AF9 in the same cell line failed to 
promote terminal macrophage differentiation, suggesting that early 
expression of MLL-AF9 may serve to maintain the monocytic phenotype but 
was not responsible for a differentiation block in these cells (Pession, et al 
2003).
Other studies suggest that MLL fusion proteins actually promote 
haematopoietic cell differentiation. Tetracycline-inducible expression of 
MLL-AF9 in monoblastic U937 cells was associated with differentiation of 
these cells into macrophages, with up-regulated expression of Macl and 
CD 14 and eventual cell death, while expression of N-terminal MLL only was 
associated with partial macrophage differentiation thought to be attributable 
to the MLL AT hook-containing region (Caslini, et al 2000). Increased 
differentiation of monoblastic U937 cells with up-regulated Macl was also 
observed in the presence of graded increased conditional expression of MLL- 
AF4 (Caslini, et al 2004).
Studies in which primary cells are transformed by MLL fusions, and results 
of in vivo mouse models are more conclusive that the fusion proteins cause 
arrested haematopoietic differentiation. Primary cells transduced with MLL- 
ENL form an IL-3 myelomonocytic precursor population capable of 
differentiation by G-CSF, but co-operation of MLL-ENL with cMYC 
induces a block in differentiation of these cells (Schreiner, et al 2001). 
Furthermore, retroviral transplantation models of MLL-ENL and MLL-
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GAS7 have shown that these fusion proteins alone transform multipotent 
haematopoietic progenitors, as well as more committed progenitors, with 
resulting impaired differentiation and in vivo leukaemia (Cozzio, et al 2003, 
Lavau, et al 1997, So, et al 2003a, Zeisig, et al 2003b).
In summary, studies investigating the association of expressed MLL fusion 
proteins and differentiation in conditionally expressing cells or leukaemic 
cell lines do not demonstrate a definitive role for these proteins in causing 
maturation arrest. However, arrested differentiation of primary 
haematopoietic cells transduced with MLL fusion proteins suggests that they 
mediate such an effect in these cells. The phenotype seen in leukaemic cell 
lines may be due to the presence of additionally sustained mutations which 
may be responsible for maintaining arrested differentiation rather than it 
being due to the MLL fusion protein, although the latter may have had a role 
at an earlier stage in leukaemogenesis in causing differentiation arrest.
In this study, constitutive expression of MLL-ENL promoted macrophage 
differentiation of 32Dcl3 cells with up-regulation of Macl and the 
megakaryocyte marker CD41, and morphological features in 5 of 8 clones. 
Such a phenotype suggests a role for MLL-ENL in disrupting pathways of 
differentiation in MLL-associated leukaemias, and is in keeping with the 
promotion of macrophage differentiation by MLL-AF9 and MLL-AF4 in 
U937 cells (Caslini, et al 2004, Caslini, et al 2000). However, enhanced 
differentiation is in contrast to a maturation arrest suggested by increased 
Hox gene expression in 32Dcl3 cells expressing MLL-AF9 (Joh, et al 1999). 
This difference may be a result of the different fusion protein studied, or 
rather the constitutive nature of MLL-ENL expression in the cells studied 
currently. It may be that MLL-ENL expression at an initial stage in 32Dcl3 
cells drives cells toward a maturation arrest, but that continued constitutive 
expression results in the activation of downstream events in response to this 
attempt at arrest. It may be these events that are responsible for the mature
134
phenotype rather than the MLL fusion itself which may then no longer have a 
role itself in altered differentiation of the cells. This would mirror the 
situation seen in the U937 cells studied which are have probably sustained 
further mutations or downstream activation of events by the fusion proteins. 
Further incubation of these differentiated cells with G-CSF resulted in 
observed accelerated cell death which would follow terminal differentiation.
The finding that CD41 is up-regulated by MLL-ENL may be related to the 
identification of Gatal as a candidate target of MLL-ENL following 
microarray analysis (see Chapter 4). GATA1 is a transcription factor that 
promotes erythroid and megakaryoblastic differentiation of primary 
haematopoietic cells, and also has a role in myeloid differentiation. Up- 
regulated Gatal may aberrantly promote megakaryocyte differentiation in 
32Dcl3 cells. The effect of attempted megakaryocyte differentiation with 
thrombopoietin, or of erythroid differentiation with erythropoietin in 
32DMENL cells compared to control may support the role of MLL-ENL 
mediated up-regulation of Gatal in promoting aberrant differentiation. In 
addition, a direct association was recently found between MLL and GATA3 
indicating an important role of MLL in regulating GATA family 
transcription factors and in maintaining memory Th2 cell function as part of 
immune regulation (Yamashita, et al 2006). However, subsequent validation 
of Gatal showed this gene to be undetected by Q-PCR in primary cells 
transduced with MLL-ENL, making its role less interesting than other genes 
that were regulated in these cells by the fusion protein, and the association of 
MLL-ENL with erythroblastic or megakaryocytic leukaemia in humans is 
also not reported. Therefore, these experiments were deferred in favour of 
others that had begun to suggest insights into the role of MLL-ENL in 
leukaemogenesis.
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4 Iden tification  o f  p oten tia l targets o f  the
tran scr ip tion a l fusion  proteins M L L -E N L  and  
M L L -A F 9
4.1 Introduction
The aim of the project was to identify targets of MLL-ENL and MLL-AF9 in 
order to understand the mechanism of leukaemogenesis arising from 
expression of these fusion proteins. As a result, novel genes amenable to 
molecular targeted therapy may be found. MLL-ENL and MLL-AF9 are 
likely to regulate the expression of a different subset of genes to those 
regulated by MLL or each partner gene alone. In order to examine targets of 
these fusion proteins, expression clones expressing MLL-ENL and MLL- 
AF9 were first generated, as well as control expression clones. Gene 
expression analysis using microarray technology was then used to identify 
subsets of genes regulated by the fusion proteins.
4.2 Generation of tetracycline 32Dcl3 cells which 
inducibly express MLL-AF9 and analysis of gene 
expression
4.2.1 Generation of MLL-AF9 expression clones
The 8047bp pTRE-MLL-AF9 plasmid (pTREMAF9) contained the amino 
acids 27-1362 of human MLL fused to amino acids 478-568 of human AF9 
under control of the TRE, with a cMYC tag at the N terminus and HA tag at 
the C terminus as shown in Figure 2.1. The pTREMAF9 plasmid was created 
by replacement of the Sall-Clal fragment of pCSHRXAF9 with the 441 bp 
Sall-Cla\ fragment containing the TRE, and insertion of cMYC and HA
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tags. The pTREMAF9 plasmid was linearised by digestion with the Seal 
restriction enzyme.
A hygromycin resistance gene under control of the SV40 promoter was 
digested from the pTRE2Hyg plasmid by restriction enzyme digestion with 
Xhol, and ligated to the pTet-tTS plasmid at the Xhol site to create pTet- 
tTsHygR as shown in Figure 2.1. This plasmid was created in order to 
eliminate any background expression of the fusion protein that may be toxic 
to the cells, and which may have caused previous reported failures to 
generate stable cell lines expressing these proteins (Ayton and Cleary 2001).
In order to generate inducible clones expressing MLL-AF9, the 3E and 8D 
32DTet-On clones were co-transfected with the pTet-tTSHygR and 
pTREMAF9. Initially the plasmids were electroporated in molar ratios of 
1:10 tTSHygR: pTREMAF9 and the mixed populations kept as one and not 
divided. The two mixed populations 32DMAF9-Popl and 32DMAF9-Pop2 
were grown in hygromycin selection. These populations were then tested in 
the presence and in the absence of 24 hours of doxycycline for expression of 
MLL-AF9 by Western blot using the anti-c-MYC antibody 9E10.
Both 32DMAF9-Popl and 32DMAF9-Pop2 showed expression of MLL-AF9 
with a significant degree of background expression in the absence of 
doxycycline. Figure 4.1 A shows expression in 32DMAF9-Popl as a 
representative example. Single cell clones were isolated from these 
populations by a process of limiting dilution, the clones expanded and a large 
number screened for expression of MLL-AF9. Only one clone showed 
expression of MLL-AF9, and did so very weakly (data not shown).
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Figure 4.1 Expression of MLL-AF9 in inducible populations.
Western analysis showing
A MLL-AF9 expression in a mixed population 32DMAF9-Popl; 
B MLL-AF9 expression in a 32DMAF9 clone;
C MLL-AF9 expression in 32DMAF9 mini populations.
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Further electroporations of pTet-tTSHygR and pTREMAF9, again in molar 
ratios of 1:10, generated 32DMAF9-Pop3 and 32DMAF9-Pop4 mixed 
populations. Inducible but leaky expression of both populations was seen 
(data not shown). Single cell clones were generated from these populations 
after FACS sorting to dispense a single live cell into each well of a 96-well 
round-bottomed plate containing lOOul complete medium. Cells were 
subsequently propagated and expanded. Following extensive screening, again 
only one clone, 32MAF9 clone 1, was isolated which showed a high but 
leaky level of expression of MLL-AF9 shown in Figure 4. IB.
In view of the difficulty thus far in generating inducible MLL-AF9 clones, 
the electroporation strategy was modified to vary the ratios of pTet-tTSHygR 
and pTREMAF9. Electroporation in a ratio of pTet-tTSHygR to pTREMAF9 
of 1:5 and 1:15 generated 32DMAF9-Pop5 and 32DMAF9-Pop6. Twenty- 
four hours following electroporation, just prior to adding hygromycin 
selection, 32DMAF9-Pop5 was further split into six mini populations 
32DMAF9-Pop5a to 5f. This was done in order to increase the representation 
of different clones with a range of genomic integrations that would result in 
variable levels of inducibility. 32DMAF9-Pop6 was not further split in order 
to see the effect of changing one variable only, i.e that of the ratio of pTet- 
tTSHygR to pTREMAF9 from 1:10 to 1:15. The mini populations and 
32DMAF9-Pop6 were expanded and tested in the presence and absence of 24 
hours of doxycycline by Western blot using an anti-cMYC antibody 9B11 
that had greater affinity for the cMYC epitope. One mini population, 
32DMAF9-Pop5a, showed a high level of induction of MLL-AF9 with no 
expression in the absence of doxycycline, shown in Figure 4.1C. However, 
generation of single cell clones by FACS sorting into 96 well plates, 
expansion, and extensive screening of these did not result in any expression 
of MLL-AF9.
139
The isolation of single cell clones expressing MLL-AF9 appeared to be 
highly problematic so the aim was modified to generate inducible mini 
populations instead, and to use the isolated mRNA for gene expression 
analysis. In view of previous generation of a mixed population following 
electroporation in the ratio of 1:5 tTSHygR to pTREMAF9, 32DMAF9-Pop7 
was generated in the same way. This population was split into mini 
populations 32DMAF9-Pop7a to 7f prior to hygromycin selection and 
expanded. These were tested in the presence and absence of 24 hours of 
doxycycline by Western blot. Mini population 7f was found to be highly 
inducible with no background expression as shown in Figure 4.1C, while the 
remaining five mini populations all showed leaky expression of MLL-AF9. 
Equal loading of protein was demonstrated by Ponceau staining of the 
membrane and confirmed for all populations tested (data not shown). The 
mRNA isolated from 32DMAF9-Pop7f in the presence and absence of 
doxycycline was used for microarray analysis.
Following a further electroporation two additional mini populations, 
32DMAF9-Pop8a and 2DMAF9-Pop9a, were generated in the same way. 
Figure 4.1C shows that 8a had a low level background expression with a high 
level of induction, while 9a showed a low level of induction with no 
background expression. mRNA was isolated from both these populations 
also in the presence and absence of doxycycline and used for microarray 
analysis.
4.2.2 Expression of MLL-AF9 protein in murine 32Dcl3 cells is lost 
following maintenance of cells in culture
There appeared to be a problem in maintaining expression of the MLL-AF9 
protein. Some of the mixed and mini populations initially expressed the 
protein and then failed to do so after a period of time in culture. Examples 
included 32DMAF9-Pop5a which was maintained in culture for ten days 
after which the initially high expression was not at all detectable and all
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single cell clones were negative (data not shown). This population showed 
leaky expression when a lysate frozen at the time of initial expression was 
thawed and tested (data not shown). Mini populations 7d and 7e were two of 
five strongly expressing and leaky populations that subsequently expressed 
much more weakly, and did not express at all on further testing as seen in 
Figure 4.2A. This was very problematic as regards generation of inducible 
single cell clones for microarray analysis or functional studies.
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Figure 4.2 Investigation of lost expression in MLL-AF9 populations.
A shows a Western analysis of MLL-AF9 expression in 32DMAF9 mini­
populations at initial testing, and after 14 days in culture.
B shows Southern analysis to determine the presence of MLL-AF9 transgene 
at the time of absent protein expression.
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Possible explanations included:
• silencing of the MLL-AF9 transgene by epigenetic mechanisms
• selective loss of the cells expressing the MLL-AF9 protein due to 
cytotoxicity to the cell
• loss of the transfected DNA during replication due to adverse selective 
pressure following prolonged cell culture (unlikely).
In order to investigate these possibilities, Southern analysis was carried out 
to examine the presence of transgene DNA in relation to protein expression. 
Genomic DNA was digested from the following samples:
• 32Dcl3 cells without the MLL-AF9 transgene (negative control)
• mini populations 7d and 7e which initially expressed the transgene 
and then did so more weakly.
• mini population 7f which strongly expressed the transgene and still 
continued to do so
• TonBaf3 cells expressing the transgene (positive control)
• haematopoietic progenitor cells inducibly expressing the MLL-ENL 
transgene (positive control)
Genomic DNA from these samples was digested with Xho 1 and EcoRl to 
release a 4.2kb fragment of MLL-AF9 detectable by a probe derived from N- 
terminal MLL as shown schematically in Figure 2.1 and Figure 4.2. The 
hybridisation probe was prepared by Hindlll digestion of the pTRE-MLL- 
AF4 vector expressing MLL-AF4 under the TRE (Figure 2.1). This released 
a 2.1 kb fragment of MLL which was gel purified and radioactively labelled 
with 32P and used as a hybridisation probe for the MLL-AF9 transgene. 
Southern analysis for the presence of the MLL-AF9 transgene, together with 
simultaneous Western analysis for the expression of the protein is shown in 
Figure 4.2. Following initial generation of the 32DMAF9 populations, high 
background expression of MLL-AF9 is seen in 32DMAF9-Pop7d and 7e,
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and inducible expression seen by 7f. A repeat Western after the cells had 
been for 14 days in culture shows no protein expression of 7d and 7e, while 
inducible expression of 7f remains (Figure 4.2A). Corresponding Southern 
analysis shown in Figure 4.2B demonstrates that the presence of the 
transgene correlates with protein expression, while absence of the transgene 
correlates with absent protein expression. It therefore appeared that cells 
containing the MLL-AF9 transgene were being lost due to cytotoxicity to the 
cell as this seemed to occur in cells showing leaky expression, and the 
selective pressure of a high concentration of hygromycin may additionally be 
contributing to such cell death. The cells remained neomycin resistant so it 
was unlikely that the rtTA transactivator gene was being lost.
In order to further investigate if cells with leaky expression of MLL-AF9 
could survive more easily in the absence of the selective pressure of 
hygromycin, two leaky mini populations 32DMAF9-Pop5e and 5f were 
grown in the presence and absence of hygromycin. However, Western 
analysis did not reveal a difference in the expression of MLL-AF9 in the 
presence or absence of hygromycin by population 5e and 5f (data not 
shown), which also showed high background expression.
It appears likely that cells with leaky expression of MLL-AF9 are selected 
against within a mixed population of cells both expressing and not expressing 
the transgene. This resulted in loss of cells expressing the transgene over a 
period of time and led to modifications of the microarray experiment as 
described.
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4.2.3 Experimental strategy for MLL-AF9 microarray 
experiments
The experimental strategy for MLL-AF9 experiments is shown in Figure 4.3. 
Three 32DMAF9 mixed populations inducibly expressing MLL-AF9 were 
cultured with doxycycline to induce gene expression, and three reference 
32DTTSHyg mixed populations were also cultured in the presence and 
absence of doxycycline to allow exclusion of targets of doxycycline only. 
Total RNA was extracted and processed and analysed by microarray in 
comparison to cells cultured in the absence of doxycycline. The three 
inducible populations were grouped as replicates so that pair-wise 
comparisons of the samples treated with and without doxycycline could be 
made to identify differentially expressed genes.
An overview of microarray technology is shown in Figure 2.2 and samples 
were prepared according to the method outlined in Chapter 2. An overview 
of the strategy for MLL-AF9 microarray experiments is shown in Figure 4.3.
145
3 x 32D MLL AF9 
mixed populations 
DOX
Triplicate
experiments
3 x 32D MLLAF9 
mixed populations  
NO DOX
Scan chips Scan chips
Generation of 
P robes
Generation of 
P robes
Hybridisation to 
chips
Hybridisation to 
ch ips
RNA RNA
Data analysis
MLL AF9 targets by comparison of data from all chips
Figure 4.3 Experimental strategy for MLL-AF9 microarray 
experiments.
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4.2.4 Differential gene expression in 32Dcl3 cells expressing MLL- 
AF9
Gene expression values for each probe set were calculated using Affymetrix 
Microarry Suite 5.0 software, and the signal normalised to each array to 
allow comparison across arrays. The image intensity of each array was 
subject to a scaling factor of 100 based on the signal of control genes.
The gene expression level of the doxycycline-induced 32DMAF9 sample 
was compared to the non-induced 32DMAF9 sample for each experiment to 
allow comparison of gene expression levels between the induced and non­
induced samples. Data was subsequently filtered to identify genes that were 
reliably detected in both the induced and non-induced samples, and were not 
the targets of doxycycline treatment alone. The data was further subjected to 
statistical analysis by applying the Welch t-test to determine genes 
significantly changed with a p value of 0.05. Of genes reliably detected in 
both induced and non-induced samples, only 327 genes were significantly 
changed with fold changes varying between 3.3 and 0.07.
In order for potentially relevant genes to be detected, the level of significance 
was relaxed. 665 genes passed the Welch t-test at a significance level where 
p  was less than 0.1, and fold change between induced and non-induced 
samples ranged from 6.6 to 0.16. From this list, genes were identified as 
candidate targets according to the following criteria:
• fold change of >1.4 between induced and non-induced sample
• a potential role in normal or malignant haematopoiesis
4.2.5 Genes up-regulated by MLL-AF9
Of the 665 genes, 8 were identified which were up-regulated and fulfilled the 
above criteria, and their fold changes varied between 1.4 and 6.7. These
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genes are shown in Table 8.421 genes were up-regulated by >1.4 fold but of 
these all except the 8 genes shown had no known function, or their function 
did not suggest a potential role in haematopoiesis, and were therefore 
excluded as potential candidate genes.
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Table 8 Genes up-regulated and down-regulated by MLL-AF9
Probe set ID Fold
change
Gene
symbol
Notes
1425618_at 6.7 Dhx9 RNA helicase, regulation of transcription, DNA-dependent, spermatogenesis
1442604_at 2.7 Ercc6 Pyrimidine dimer repair, excision repair cross-complementing rodent repair deficiency, 
complementation group 6
1446499_at 1.8 Fadd FAS (TNFRSF6)-associated via death domain, regulation of apoptosis, signal transduction
1443792_at 1.8 Pip5k2b phosphatidylinositol metabolism
1419607_at 1.7 Tnf tumor necrosis factor, cell proliferation cytokine and chemokine mediated signaling 
pathway, induction of apoptosis via death domain receptors, inflammatory response
1426329_s_at 1.6 Baalc brain and acute leukemia, cytoplasmic. Predicts poor survival in AML normal cytogenetics, 
expressed BM CD34+, downregulated with differentiation
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1452844_at 1.4 Pou6fl POU domain, class 6, transcription factor 1, regulation of transcription
1443943_at 1.4 Plagl pleiomorphic adenoma gene 1, Plagl and Plag2 cooperating oncogenes with 
CBFbeta-SMMHC in AML inv (16), mouse model
1455853_at 0.6 Cdk4 positive regulation of cell proliferation
1457929_at 0.4 Mdm2 cell growth and maintenance, protein catabolism, protein ubiquitination, traversing start 
control point of mitotic cell cycle
1453928_at 0.2 Gli3 brain /CNS development, negative regulation of transcription
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4.2.6 Genes down-regulated by MLL-AF9
Of the 665 genes, 3 genes were identified which were down-regulated and 
fulfilled the above criteria of having a known function of potential relevance 
to haematopoiesis, and their fold changes varied between 0.2 and 0.6. These 
genes are shown in Table 8.
4.2.7 Expression of previously identified targets of MLL-AF9
A comparison of genes identified in the current study was made with those 
highlighted in published studies. The caveats to such comparisons will be 
discussed in the following section regarding MLL-ENL candidate genes, but 
no genes in the current study were identified by other studies. In addition, it 
was noted that there was a very low level of expression of all genes turned on 
by MLL-AF9 only, as well as those whose expression may have been altered 
by MLL-AF9 as well as doxycycline, ie both significant and non-significant 
genes. In addition there were poor degrees of fold change for all the genes. 
Reasons for this may have included:
• the time point of induction of MLL-AF9 expression was too early at 
24 hours. However, Western blotting had shown high levels of protein 
expression at this time point.
• the quality of material was poor. This was unlikely as the material 
underwent various quality control tests before hybridisation to the 
microarrays.
• the 32Dcl3 myeloid progenitor cell did not represent an appropriate 
stage of myeloid differentiation. No previous studies using this cell 
line for microarray screening have been perfomed, but MLL-AF9 has 
been expressed in this cell line and Hox gene analysis carried out by 
Q-PCR (Joh, et al 1999).
While candidate genes have been chosen according to the criteria described, 
Q-PCR analysis will be required to assess their validity, and further study of
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the biological significance of valid candidate genes carried out. In order to 
allow completion of work into the mechanism of leukaemogenesis by MLL- 
ENL, further work related to targets of MLL-AF9 will be continued by 
another member of the group.
4.3 Analysis of gene expression in 32Dcl3 cells expressing 
MLL-ENL
4.3.1 Experimental strategy for MLL-ENL microarray 
experiments
The generation of MLL-ENL expression clones has been described in 
Chapter 3. The experimental strategy for MLL-ENL microarray experiments 
is shown in Figure 2.2. Eight 32DMENL clones constitutively expressing 
MLL-ENL, and one reference 32DTtsHyg mixed population were harvested 
and total RNA extracted. The clones were not incubated with doxycycline as 
they constitutively expressed MLL-ENL as described in Chapter 3. The 
cDNAs from each of the eight 32DMENL clones were combined prior to the 
generation of cRNA which underwent further processing and hybridisation to 
microarrays, and compared to that of the reference mixed population. The 
experiment was performed in triplicate, and the three experimental samples 
grouped as replicates to allow comparison with the control samples. As gene 
expression could not be analysed following abolition of MLL-ENL 
expression, this method would not allow discrimination of primary or 
secondary targets of the fusion protein. However, candidate targets were 
subsequently analysed in HPC where MLL-ENL expression was inducible 
and tightly controlled.
Samples were prepared according to the method outlined in Chapter 2 and an 
overview of the experimental strategy for MLL-ENL experiments is shown 
in Figure 4.4.
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The gene expression level of the pooled 32DMENL constitutive sample was 
compared to the reference sample for each experiment to allow comparison 
of gene expression levels between the expressing and non-expressing 
samples. The data was further subjected to statistical analysis by applying the 
Welch t-test to determine genes significantly changed by 1.5 fold with a p  
value of less than 0.05. Of genes reliably detected in both experimental and 
control samples, 1300 genes passed this test. Bonferroni multiple testing 
correction was applied to the data using the Benjamini-Hochberg false 
discovery rate procedure. 77 genes passed this procedure. A list of such 
genes with known function down-regulated and up-regulated by MLL-ENL 
following classification according to their biological role is shown in Table 
10 and Table 11 in the Appendix.
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4.3.2 Genes down-regulated by MLL-ENL
Genes were identified according to the criteria above that were down- 
regulated in the presence of a high level of constitutive expression of MLL- 
ENL. These genes may be of great interest and biological significance and 
will require further validation by another member of the group. Validation of 
genes up-regulated by MLL-ENL were given priority in view of the putative 
role of fusion proteins to transactivate their target genes, and the opportunity 
arose to focus on some identified genes that showed highly significant and 
high levels of expression seen in the presence of high levels of MLL-ENL 
expression, these genes also appearing to be of high biological significance.
4.3.3 Genes up-regulated by MLL-ENL
The Benjamini-Hochberg test is extremely rigorous, and absence of up- 
regulation of a gene in one of the eight clones may result in that gene not 
passing this test. Some of these genes may, however, be biologically valid 
and significant but may result in being excluded due to clonal variation.
As described, data was first analysed to identify genes that were significantly 
only up-regulated by MLL-ENL. This would allow identification of 
candidate target genes whose over-expression may be related to the 
phenotype observed in 32DMENL cells, and up-regulation of these genes 
may also be present in primary cells transduced with MLL-ENL. Down- 
regulation of these candidate targets in 32DMENL cells, and primary cells 
transduced with MLL-ENL would be strong evidence to support their role as 
a direct target of MLL-ENL and their potentially significant role in 
leukaemogenesis that would require further analysis.
Therefore, criteria were used to identify candidate targets from both the list 
of 77 highly significantly changed genes, as well as from the list of 1300 
genes which passed the Welch t-test. These criteria were:
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• genes known to have a role in normal or malignant haematopoiesis
• genes up-regulated in the experimental sample by a fold change of 
greater or equal to 10.
Genes significantly up-regulated by MLL-ENL and chosen as candidate 
targets according to the above criteria are shown in Table 9. Two of these 
genes, (ApoJ  and HTm4), passed the Benjamini-Hochberg false discovery 
rate procedure.
Table 9 Candidate target genes up-regulated by MLL-ENL
Probe set ID P-value Fold change Gene symbol
1454849_at 0.0004 154.8 ApoJ
1421441_at 0.0064 103.5 Agpt
1420572_at 0.0004 82.9 HTm4
1450297_at 0.0054 71.7 11-6
1449232_at 0.0062 70.5 G atal
1417714_at 0.0031 63.8 Hba-al
1415960_at 0.0028 18.7 Mpo
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4.3.4 Expression of previously identified targets of MLL-ENL
A number of studies have described gene expression profiles of patient 
samples of ALL, AML and MLL-rearranged leukaemias or leukaemic cell 
lines harbouring MLL translocations, and one study to date investigates the 
profile of primary haematopoietic cells transformed by MLL-ENL (Zeisig, et 
al 2004). These studies are discussed in Chapter 1.
These previously published gene expression analyses were reviewed to see if 
any of the currently identified targets were also duplicated in these studies. 
This would possibly allow an insight into the role of such candidate targets 
depending on the context of the experiments in which such genes were 
found. The context is important to consider as many of these studies analyse 
human leukaemic blasts at the time of diagnosis, or leukaemic cell lines 
which have undergone multiple mutations associated with tumour initiation 
and progression. The cells currently studied are at an early stage of 
differentiation and express the MLL fusion gene alone with no other 
secondary mutations, and retain IL-3 dependence suggesting that they might 
be at an early stage in the leukaemia process. In addition the primary 
haematopoietic cells transformed by MLL-ENL and analysed by microarray 
(Zeisig, et al 2004) are not strictly comparable to the myeloid precursor cells 
constitutively expressing full-length MLL-ENL used here.
Only two genes highlighted by the above published studies were found in 
this current study. These were 11-6 and Mpo, both of which were chosen as 
candidate genes according to criteria described. 11-6 was up-regulated when 
MLL-ENL expression was silenced in a conditional model (Zeisig, et al 
2004). Mpo was up-regulated in MLL-AML patient blasts (Debemardi, et al 
2003). None of the Hox genes highlighted in the above studies were detected 
in the current study but the caveats of comparisons between this and previous 
studies have been outlined. A possible reason for the failure to detect Hox
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gene changes in the current system using microarrays is that they may be 
already down-regulated in these 32DMENL cells which partially show 
macrophage features. The ability to perform an extensive Q-PCR profile of 
Hox genes (in collaboration with the Haematology Department, CCRCB, 
Queen’s University, Belfast) has revealed a low level of expression of a 
number of Hox genes in 32Dcl3 cells (data not shown). Up-regulation of 
Hoxa7, Hoxbl and Hoxc9 in 32Dcl3 cells incubated with G-CSF has been 
shown to be inhibited by MLL-AF9 expression (Joh, et al 1999), and in this 
study Q-PCR was used to determine alterations in Hox gene expression in 
HPC expressing MLL-ENL where Hox genes could be measured in a control 
population. These experiments will be discussed in Chapter 5.
4.4 Potential target genes of MLL-ENL are validated by 
Q-PCR
Real time Q-PCR reliably detects and measures products generated during 
each cycle of the PCR which are directly proportional to the amount of 
template prior to the start of the PCR process (Ginzinger 2002). Levels of 
mRNA of the candidate target genes were measured using cDNA derived by 
reverse transcription of total RNA from the eight 32DMENL clones which 
had previously been pooled for microarray experiments. Target signals were 
compared to those in a 32DtTS reference sample, and so the level to which 
each target gene was up-regulated in each clone could be measured to 
validate that the candidate gene was changed.
Relative quantitation was carried out to compare the gene of interest with a 
control gene (Gapdh) within each cDNA sample.
All candidate target genes except Hbal and Mpo were found to be expressed 
at higher levels in the 32DMENL clones compared to control as shown in 
Figure 4.5. The fold difference in expression of the candidate genes varied
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with the gene studied, so that Gatal and Apo J, were maximally expressed 8- 
12000 fold compared to control, whereas 11-6 and HTm4 were up-regulated 
100-120 fold. There also appeared to be variation between clones in regard to 
expression levels. Fold change of each of the target genes did not appear to 
correlate with fold changes in MLL-ENL expression measured by Q-PCR for 
each clone.
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Figure 4.5 Q PCR showing relative quantitation of mRNA for each 
candidate target gene in each 32DMENL clone.
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4.4.1 MLL-ENL is down-regulated following lentiviral delivery of 
shRNA
Technical difficulties resulting in problems in achieving stable expression of 
shRNAs against genes of interest prompted the use of a microRNA system 
whose expression was driven by a polymerase II. A system of pPRIME- 
SFFV vector delivery of miRNA embedded shRNA was used to down- 
regulate the expression of MLL-ENL in 32DMENL cells. In addition, to 
enhance the efficiency of expression of the shRNA transduction and 
expression, the pRIME vector was modified to express the miRNA from the 
U3 part of the SFFV strain LTR sequence (SFFV-U3LTR). The GFP was 
expressed upstream of the WPRE and efficiency of lentiviral infection was 
assessed by flow cytometric analysis of GFP.
Experiments involving RNA interference of gene expression were carried out 
in collaboration with Dr. Jasper de Boer.
32DMENL cells were infected with pRIME-SFFV vectors expressing two 
different miR-shRNAs against human ENL (referred to as shENL 1 and 
shENL 2), miR-shRNA against MLL (shMLL), and against E2A-HLF control 
(shHLF). The lentiviral constructs used to down-regulate MLL-ENL by 
shRNA are shown schematically in Figure 2.3.
The expression of these miRNAs were under the control of the SFFV- 
U3LTR. The miR-shRNAs were cloned into the lentivirus and the lentiviral 
construct was co-transfected into a 293T producer cell line with psPAX2 
containing the packaging protein and pMD2G containing the envelope 
protein required for lentiviral function, and which were on separate 
individual plasmids to reduce the chance of recombination into the retrovirus. 
The viral supernatant was concentrated by ultrafiltration, and centrifugation- 
mediated transduction of 32DMENL cells carried out with the addition of
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polycationic polybrene to increase transduction efficiency, and recombinant 
IL-3 to optimize cell growth. Sustained high expression of each miRNA 
construct was measured by flow cytometry of GFP at days 1, 7 and 14, and 
cells were sorted by FACS for GFP expression at 14 days. Figure 4.6A 
shows the levels of stable GFP expression at 14 days of cell culture reflecting 
stable expression of the miRNA constructs over time. Figure 4.6B shows a 
high level of GFP expression in FACS sorted cells reflected a high level of 
infection with the pRIME-SFFV vectors. Thus, in the absence of an inducible 
system of expression of the MLL-fusion genes, RNA interference was a way 
in which expression of specific genes could be down-regulated and 
downstream targets of the MLL fusions examined in a similar way to 
inhibiting expression in an inducible system.
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Figure 4.6 Expression of GFP in 32DMENL cells infected with pSFFV- 
GFP-miR-shRNA constructs.
Panel A shows expression of GFP over 14 days reflecting stable expression 
of the miRNA constructs shENL 1, shENL 2, shMLL and shHLF labelled. 
Panel B shows high expression of GFP in cells infected with each of the 
constructs and then sorted for GFP expression and expanded for 24 hours.
165
32MENL cells sorted for GFP expression were harvested for protein and 
Western analysis of the level of down-regulation of MLL-ENL by shRNA 
against hENL carried out. Sorted cells were also harvested for RNA and 
cDNA was used to carry out Q-PCR analysis of the down-regulation of 
MLL-ENL by the shRNA constructs. The results of these experiments are 
shown in Figure 4.7. Figure 4.7A shows the down regulation of MLL-ENL 
protein in cells expressing MLL-ENL infected with the miRNA constructs 
shENL 1 and shENL 2. In Figure 4.7B Q-PCR analysis demonstrates the less 
dramatic level of down-regulation of MLL-ENL mRNA in cells infected with 
shMLL.
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Figure 4.7 Expression of MLL-ENL following infection with shRNA 
against human ENL.
A shows Western analysis of MLL-ENL protein in cells expressing MLL- 
ENL infected with shENl 1 and shENL 2. Parental 32D cells uninfected and 
infected with shENL 1 are shown. B shows Q-PCR demonstrating the level 
of expression of MLL-ENL mRNA in these cells.
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In the absence of an inducible system of MLL-ENL expression in 32DMENL 
cells, such levels of knock-down of MLL-ENL protein by shENL 1 and 2 
then made it possible to examine the effect of this on the candidate target 
genes Gatal and HTm4 to determine if either was a direct downstream target 
of MLL-ENL in 32DMENL cells. cDNA of cells in which MLL-ENL was 
down-regulated as shown in Figure 4.7 was analysed by Q-PCR for 
expression of Gatal and HTm4. The results are shown in Figure 4.8. This 
figure demonstrates that down-regulation of MLL-ENL by miRNA does not 
result in down-regulation of potential candidate target genes Gatal and 
HTm4.
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Figure 4.8 Q-PCR of Gatal and HTm4 in 32DMENL cells following 
knock-down of MLL-ENL.
A shows Gatal and B shows HTm4 mRNA levels in 32DMENL cells in 
which there is down-regulation of MLL-ENL by shENL 1 and shENL 2 as 
seen in Figure 4.7.
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The figure shows that neither Gatal nor HTm4 are down-regulated in the 
presence of the achieved levels of MLL-ENL knock-down.
The results may be interpreted in the following ways:
• saturation of GATA1/MLL-ENL or HTm4/MLL-ENL binding sites 
by the MLL-ENL still resulted due to insufficient levels of down- 
regulation of the fusion protein
• MLL-ENL binds to GATA1 or HTm4 to initiate its expression, but 
that continued or maintained levels of either protein are not dependent 
on MLL-ENL and are not affected by down-regulation of the fusion 
protein
• neither Gatal nor HTm4 is a direct target of MLL-ENL
• HTm4 may require the high-affinity menin-binding domain of MLL to 
more tightly regulate its expression in the presence of MLL fusion 
proteins. This behaviour would be similar to that of other cell cycle 
regulator genes. As HTm4 regulates HSC cycling, its expression may 
be more clearly regulated in these cells compared to 32Dcl3.
In order to determine whether HTm4 was target of MLL-ENL, its expression 
was studied in a more appropriate cell type, under tightly controlled levels of 
MLL-ENL expression, and in the presence of MLL-ENL expressing the 
high-affinity Menin-binding domain. Q-PCR analysis of HTm4 expression 
was determined in immortalized HPC expressing full-length MLL-ENL 
(HPCMENLfull‘length) whose expression was proven in the laboratory to be 
regulated in a tetracycline-inducible manner so that it was silenced in the 
presence of doxycycline.
HTm4 is down-regulated in immortalized primary HPC when full length 
MLL-ENL containing the Menin-binding domain is turned off. A system of 
tightly regulated, tetracycline-inducible expression of MLL-ENL in HPC has 
been generated in our laboratory (Horton, et al 2005). These HPC were
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infected with pMSCV-neo-MLL-ENLAI '26 (HPCMENL*1'26). These HPC 
were dependent on continued MLL-ENL expression for their sustained 
proliferation and inhibition of differentiation. The high-affinity Menin- 
binding domain is required by MLL, and possibly MLL fusion proteins, to 
effectively regulate expression of its target genes (Milne, et al 2005a). The 
MLL-ENL construct expressed in the HPCMENL A1'26 and in 32DMENL 
cells lacked the first 26 amino-acids of MLL, which contained this Menin- 
binding domain. Therefore, HPC have also been generated that are 
conditional for the expression of full-length MLL-ENL (HPCMENL6*11'16"8*) 
and these cells also have a similar requirement for MLL-ENL-dependent 
proliferation. Control HPC that were not tetracycline-responsive and which 
constitutively expressed full-length MLL-ENL (HPCconst6*11'16"8*) were also 
generated (Horton et al., manuscript in preparation).
cDNA was derived from both HPCMENLA1'26 cell lines, and HPCMENL6*11' 
Iength cell lines, as well as HPCconst6*11'16"8*, in the presence and absence of 
doxycycline. Q-PCR analysis for HTm4 was carried out to determine if 
HTm4 was regulated by MLL-ENL in HPCMENL6*11'16"8111 containing the 
Menin-binding domain. The results in Figure 4.9 show that HTm4 is down- 
regulated in HPC in the absence of MLL-ENL (when doxycycline is present) 
in HPCMENLA1'26 which contains only the low-affinity Menin-binding 
domain. However, this regulation is seen more greatly in HPCMENLfull'length 
where HTm4 is down-regulated in two HPCMENL6*11'16"8* cell lines when 
MLL-ENL is turned off in the presence of doxycycline. Hoxa9 is known to 
be down-regulated in the absence of MLL-ENL serving as a positive control. 
Thus HTm4 is a candidate target gene of MLL-ENL in HPC, and its 
regulation by MLL-ENL is likely to require the high-affinity menin binding 
domain of the MLL portion of the fusion.
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Figure 4.9 HTm4 is regulated in primary cells immortalised with full- 
length MLL-ENL containing the Menin-binding domain.
This figure shows Q-PCR analysis of A HTm4 mRNA levels in primary cells 
transduced with inducible HPCMENLA1'26 lacking the Menin-binding 
domain, and B HTm4 mRNA levels in HPCMENLfilll‘length containing the 
Menin-binding domain, when MLL-ENL expression is turned off in the 
presence of doxycycline (+) and turned on in the absence of doxycycline (-) 
C shows Gatal expression in HPCMENLfull'length in the presence and absence 
of doxycycline.
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4.5 Discussion
4.5.1 The prospective role of new validated targets of MLL-ENL in 
leukaemogenesis
The candidate targets identified by microarray analysis are known to have a 
role in normal and malignant haematopoiesis and their further analysis in 
32Dcl3 cells and in primary haematopoietic cells may identify them as 
contributing toward the leukaemic phenotype. A brief description of each 
candidate gene is described below.
Htm4
This is a novel protein, expressed in human haematopoietic cells and bone 
marrow, and acts as a regulator of the haematopoietic cell cycle by binding 
directly to KAP to modulate the level of phosphorylation of CDK2 (Donato, 
et al 2002). HTm4 binds via its C-terminal region to the complex formed 
between KAP and CDK2 to stimulate phosphatase activity and modulate 
KAP activity within the KAP-CDK2 complex. It belongs to the MS4 
(membrane spanning 4) protein group with a distinctive four-transmembrane 
structure, and is also expressed in developing and adult murine 
haematopoietic and central nervous systems (Kutok, et al 2005). Of interest 
is the finding that HTm4 has a role in mediating HSC quiescence by 
modulating G1 to S cell cycle transition, and is tightly regulated during 
normal haematopoietic stem cell differentiation, and its exogenous 
expression in U937 cells leads to G0/G1 arrest. Aberrant expression of this 
gene in the presence of an oncogene may therefore result in abnormal 
regulation of cell cycle in cells that may then develop a leukaemogenic 
potential.
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Gatal
Critical in multilineage homeostasis, GATA1 binds sites in the promoters 
and enhancers of erythroid-specific genes and is essential for erythroid and 
megakaryocyte (MegE) development (Friedman 2002). Ectopic GATA1 
prevents normal lymphoid and granulocyte/macrophage differentiation, re­
directing them toward MegE commitment (Iwasaki, et al 2003). Ectopic 
GATA1 in 416B (a myeloid cell line capable of megakaryocyte and 
granulocyte differentiation) induces megakaryocyte development (Visvader, 
et al 1995), and this may be relevant to the finding that the megakaryocyte 
marker CD41 is up-regulated in 32DMENL cells where GATA1 is highly 
expressed. In addition, GATA1 induces apoptosis in proB and 
myelomonocytic cells which is not abrogated by BCL2 and this is again 
considered in relation to the profile of apoptotic sensitivity seen in 
32DMENL cells in the current study.
Angl
Angiopoietin is a growth factor involved in angiogenesis. Angiopoietin-1 
(ANG1) and angiopoietin-2 (ANG2) are ligands for the endothelial cell- 
specific receptor tyrosine kinase TIE2, a transcription factor in early 
haematopoiesis (Davis, et al 1996). The interaction between haematopoietic 
cells and endothelial cells is important in normal haematopoiesis as well as 
leukaemogenesis. The cell cycle status of the HSC is dynamically controlled 
by the microenvironment, and the interaction of TIE2 and its ligand ANG1 
leads to tight adhesion of HSC to stromal cells, resulting in maintenance of 
long-term repopulating activity of HSC (Arai, et al 2004, Hirao, et al 2004). 
Thus, the TIE2/ANG1 signalling pathway plays a critical role in the 
maintenance of HSC in a quiescent state in the BM niche, and its 
deregulation may cause aberrant proliferation or survival of primary cells.
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11-6
Interleukin-6 (IL-6) is a lineage-specific transcription factor which stimulates 
granulopoiesis via receptor signaling (Liu, et al 1997). The transcription 
factor C/EBPa is required for myeloid differentiation, and C/EBPa''' mice 
show loss of IL-6 receptor and lack of IL-6 responsive colony forming units. 
Previously such mice have been shown to lack the G-CSF receptor. The 
addition of soluble IL-6 receptor and IL-6 rescues these mice in their ability 
to form granulocytes. Thus IL-6 and G-CSF, and possibly other cytokine 
receptors, are important for the block in granulocyte differentiation observed 
in vivo in C/EBPa-deficient mice (Zhang, et al 1998). Deregulation of IL-6 
may result in aberrant myeloid differentiation, and may be implicated in the 
macrophage phenotype seen in 32DMENL cells.
A poJ
APO J is a complex heterodimeric glycoprotein up-regulated during 
tumorigenesis, as well as during cell injury or death. Secreted APO J is anti- 
apoptotic in the presence of increased b-Myb but over-expression sensitises 
malignant cell lines to cytotoxic-induced apoptosis (Trougakos, et al 2005). 
Increased apoptosis is also seen in neuroblastoma cells over-expressing 
secreted APO J and co-cultured with an APO J- blocking antibody (You, et 
al 2003). In stress situations, the nuclear protein is pro-papoptotic and cell 
specific (Trougakos, et al 2005). Thus, APO J may have a role in the 
phenotype of increased apoptotic sensitivity seen in 32DMENL cells.
Mpo
Myeloperoxidase (MPO) is a lysosomal haemoprotein located in the 
azurophilic granules of polymorphonuclear (PMN) leukocytes and 
monocytes. MPO is located in the nucleus as well as in the cytoplasm. 
Intranuclear MPO may help to protect DNA against damage resulting from 
oxygen radicals produced during myeloid cell maturation and function 
(Borregaard and Cowland 1997). MPO gene was translocated to
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chromosome 15 in all cases of acute promyelocytic leukemia (subtype M3), 
MPO may be pivotal in the pathogenesis of APL (Weil, et al 1988).
Hbal
The alpha and beta loci determine the structure of the two types of 
polypeptide chains in the tetrameric adult haemoglobin, HbA, alpha-2/beta-2. 
Haemoglobin alpha locus-1 (HBA1) encodes the alpha polypeptide chain.
This gene was highlighted in a gene expression analysis of FL5.12 pro B 
cells where apoptosis was induced either following cytotoxic treatment or 
following IL-3 withdrawal (Brachat, et al 2000). Over-expression of HBA 1 
was found to be pro-apoptotic after IL-3 withdrawal, similar to BAX over­
expression and associated with increased caspase activity. This gene was 
therefore further validated in view of the increased apoptotic sensitivity of 
32DMENL cells following IL-3 withdrawal.
4.5.2 The role of Menin in the expression of target genes of MLL 
fusion proteins
The role of Menin in its association with MLL as part of a histone 
methyltransferase complex to regulate Hox gene expression has been 
described in Chapter 1 together with its implication in the aberrant regulation 
of Hox genes by MLL-fusion proteins. In addition, Menin is a known 
regulator of the CDKI genes p27Kipl and pl8Ink4c (Milne, et al 2005a) and 
the association of Menin with MLL fusion proteins may similarly result in 
de-regulation of such CDKI. The expression of p27Kipl is increased 
following inducible MLL-AF4 in a lymphoid leukaemia cell line, and these 
cells show slower growth without increased apoptosis compared to control 
(Xia, et al 2005). In this study ChIP assays suggested that p27Kiplwas a 
direct target of MLL-AF4 as well as of WT MLL and increased expression 
by MLL-AF4 may be responsible for the observed reduction in lymphoid cell 
cycling (Xia, et al 2005). Suppression of cell proliferation among HSC 
harbouring MLL fusion genes may have implications for increased
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chemotherapy resistance in these poor prognosis infant leukaemias with a 
high relapse rate. Alterations of the tumour suppressors pl5Ink4a and 
pl6Ink4b have also been associated with MLL fusions in both myeloid and 
lymphoid leukaemia cells lines (Ohnishi, et al 1997) (Maloney, et al 1997).
4.5.3 A model of HTm4 as a target gene of MLL-ENL whose 
activation by the fusion protein is mediated by Menin
In this study, HTm4 has been identified as a potential target of MLL-ENL, 
being significantly up-regulated by microarray analysis in the presence of 
constitutive over-expression of MLL-ENL in 32Dcl3 cells. HTm4 has been 
previously identified as a novel human haematopoietic cell cycle regulator of 
Gl/S phase cell cycle transition, and is tightly regulated during HSC 
differentiation to maintain their quiescent state (Donato, et al 2002). This 
study has demonstrated that HTm4 is up-regulated following Q-PCR analysis 
in seven of eight 32D clones constitutively expressing MLL-ENL, and up to 
160-fold in these cells. However, following down-regulation of MLL-ENL 
by shRNA against human ENL in a single 32DMENL clone, no down- 
regulation of HTm4 was observed.
Reasons for the initial high expression but failed down-regulation of HTm4 
are:
• the levels of shRNA inhibition of MLL-ENL are not great enough to 
prevent the maintenance of HTm4 expression if HTm4 binding sites 
are already saturated by remaining levels of MLL-ENL protein.
• MLL-ENL may be responsible for the initiation but not the 
maintenance of HTm4 expression. As 32D cells are more 
differentiated, they may not have the same requirement for HTm4 as 
HPC in order to maintain a quiescent state (Donato, et al 2002).
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The subsequent down-regulation of HTm4 in a tightly regulated system of 
MLL-ENL expression supports the first possible explanation to be more 
likely.
The results of HTm4 expression in HPC transduced with truncated and full- 
length MLL-ENL constructs suggest a role for Menin in mediating 
transcription of HTm4 by MLL-ENL in primary cells.
The pTRE-MLL-ENL and pMSCV-neo-MLL-ENLA1'26 constructs used 
lacked the first 26 amino acids which may contain domains that are 
necessary for direct and specific binding of MLL-ENL to its targets. One 
such domain is the Menin binding domain, and the high affinity domain is 
contained in first 35 amino acids of MLL which is therefore absent in the 
truncated construct. The low affinity domain is present in this construct at 
amino acids 640-1251. (Yokoyama, et al 2005). The pTRE-MLL-ENL was 
used in the transfection of 32Dcl3 cells. It may be that different cells may 
have different requirements for Menin in the regulation of the target gene by 
MLL-ENL. Thus a truncated MLL-ENL construct may be sufficient to 
induce expression of HTm4 via its low affinity domain in 32DMENL and 
HPCMENLa1‘26, but a specific requirement of Menin may exist to allow 
greater specific binding and regulation of HTm4 as seen in HPCMENLfu11'
length
In order to test the cell specificity of HTm4 regulation, the expression was 
examined in HPC expressing MLL-ENL where there was tight inducible 
regulation of the fusion gene. MLL-ENL expression is abrogated in the 
presence of doxycycline in HPCMENL cells via the Tetoff system. In 
HPCMENLA1'26, compared to 32DMENL cells, HTm4 expression was 
regulated by MLL-ENL. This is possibly due to the specific requirement of 
HTm4 for cell cycle regulation in this cell type compared to 32D cells.
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Furthermore, HTm4 was regulated to an even greater extent in HPCMENLfu11' 
length expressing the full length fusion protein including the Menin binding 
domain, with HTm4 being down-regulated when MLL-ENL was turned off. 
These results suggest a specific requirement for Menin in these cells in order 
to more effectively regulate HTm4 by MLL-ENL. MLL-ENL may function 
to induce cell cycle inhibition of HPC via its up-regulation of HTm4 in order 
to inhibit cell proliferation. Either this could be a mechanism by which HPC 
harbouring MLL fusions evade chemotherapy, allowing them to emerge later 
to cause relapse of disease, or it allows an environment where a HSC 
harbouring an MLL fusion is more able to acquire another mutation in order 
to escape such proliferation inhibition, and such a cell would be a candidate 
for initiation of leukaemogenesis.
The possibility that a normal HPC may progress to a leukaemic stem cell has 
been suggested by a study where MLL-AF9 immortalises a committed 
progenitor to create a leukaemic stem cell as a result of re-activation of a 
subset of genes normally only expressed in HSC (Krivtsov, et al 2006). In 
this respect HTm4 is a candidate gene that may be involved in such a 
pathway leading to a cancer stem cell, and makes it potentially a valuable 
target in the eradication of the generation of stem cells which initiate and 
maintain leukaemia, such a strategy being more likely to achieve effective 
cure rather than the reduction in tumour burden alone. HTm4 is known to 
regulate normal HSC quiescence (Donato, et al 2002), is found to be highly 
expressed in a granulocyte macrophage progenitor cell in this study, and its 
regulation in HPC over-expressing MLL-ENL in this study correlates with 
the presence of the high-affinity Menin-binding domain known to associate 
with MLL fusion proteins to regulate other CDKI and Hox gene targets 
(Milne, et al 2005a) (Yokoyama, et al 2005).
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4.5.4 Further work
Analysis of the candidate target genes identified by microarray analysis for 
any role in deregulating the proliferation, survival and differentiation of 
primary haematopoietic cells would identify them as contributors to the 
leukaemic phenotypedue to MLL-ENL expression. HTm4 will be studied 
further as it has been shown to be down regulated following shRNA 
inhibition of MLL-ENL.
The ability of HTm4 to immortalise and transform myeloid and lymphoid 
progenitor cells, either alone or in co-operation with other potential 
oncogenes, will be assessed using colony-forming assays in methylcellulose 
where the number of colonies formed during successive rounds of re-plating 
reflects the self-renewal and proliferative capacity of the HPC (Lavau, et al 
1997). HTm4 will be introduced into HPC derived from murine bone marrow 
or foetal liver by retroviral transduction. This work will continue in the 
laboratory by another member of the group, and will identify any functional 
role that HTm4 might have in leukaemogenesis.
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5 M L L -E N L  acts in  a gain-of-function  m an n er to  
im m ortalize M U  deleted  haem atopoietic  
progen itor cells
Very different human pathological conditions arise from either gain- or loss- 
of-function mutations of the same gene. For example, gain-of-function 
mutations in the RET gene results in growth factor independent signalling of 
the RET protein leading to the syndrome of multiple endocrine neoplasia 
type 2, where familial medullary thyroid carcinoma develops as part of one 
of the disease subtypes. However, a non-functional protein results from a 
loss-of-function mutation of the RET gene leading to abnormal development 
of enteric nerves to cause Hirschprung’s disease (Lesueur, et al 2006,
Sijmons, et al 1998). In relation to human leukaemia, a loss-of-function 
mutation of the CREB binding protein (CBP) gene results in a characteristic 
syndrome of cardiac anomaly, broad thumbs, big toes and typical facies 
(Rubinstein-Taybi syndrome). However, fusion proteins formed following 
translocation of the CBP gene on chromosome 16 to form MOZ-CBP 
[t(8; 16)] and MLL-CBP [t( 11; 16)] are associated with AML, either de novo 
or following previous anticancer treatment in the case of MLL-CBP (Taki, et 
al 1997). Such fusion proteins are thought to contribute to haematological 
malignancy through a gain-of-function mechanism, perhaps accompanied by 
the inactivation of the un-rearranged CBP gene (Taki, et al 1997).
Models have been proposed relating to the normal function of MLL in the 
presence of MLL fusion genes (see (Ernst, et al 2002) for review). A simple 
gain-of-function model proposes that normal MLL function is altered to 
cause over-expression of an MLL target gene involved in cell survival or 
proliferation. A second model proposes that in addition to gain-of-function of 
one MLL allele, the second allele becomes haploinsufficient with resulting
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under-expression of a gene normally expressed to negatively regulate 
survival or proliferation. Finally a dominant-negative model proposes that 
the Mil fusion gene simply interferes with the normal expression by MLL of 
a gene which negatively regulates cell survival and proliferation.
A model of gain-of-function mediated transformation is thought to occur in 
the case of leukaemia associated with MLL fusion genes, although there is no 
conclusive experimental proof that this is the case. As described in Chapter 
1.5, leukaemia develops in MII-AJ9 knock-in mice where one copy of Mil is 
replaced by Mll-A/9. However, knock out of one copy of Mil does not result 
in leukaemia, which would have been expected if disease was due to Mil 
loss-of-function (Corral, et al 1996). Also in support of a gain-of-function 
mechanism, a number of studies have shown that retroviral insertion of Mil 
fusion genes into HPC transforms cells, and gives rise to leukaemia without 
disrupting the endogenous Mil gene (So and Cleary 2002);(Lavau, et al 
1997)). On the other hand, loss of one copy of Mil in a knock-in model where 
Mil is fused to a short cMYC tag polypeptide does not lead to leukaemia 
(Corral, et al 1996). Furthermore, Mll-A/9 knock-in mice do not show defects 
similar to those seen in Mil knockout or heterozygote mice (Corral, et al 
1996);(Dobson, et al 1999); (Dobson, et al 2000) as would be expected if 
there was Mil loss-of-function in these knock-in mice. These studies imply 
that MLL fusions act dominantly over endogenous MLL in a gain-of- 
function manner, rather than by MLL fusions inhibiting endogenous MLL 
function. The PHD domain of MLL is lost in the fusion protein and binding 
of Cyp33 to this domain normally represses MLL target genes. Therefore, 
loss of the PHD domain may change the balance of MLL function towards 
transactivation in the fusion protein (Fair, et al 2001).
However, a possible role for wild-type (WT) Mil in contributing to 
transformation is suggested by studies which show high degrees of Mil gene 
amplification by fluorescent in situ hybridization (FISH) in MDS and
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leukaemia (Papenhausen, et al 2005). In addition, studies show that WT 
MLL is bound to the promoters of Hoxa9 and Meisl in the presence of the 
fusion proteins MLL-ENL-ER and dimerised MLL-FKBP, suggesting that 
WT MLL may be recruited by these fusion proteins to contribute to 
transformation, or that MLL may simply bind to target loci (Milne, et al 
2005b).
In order to determine the dependence of transformation on WT MLL, the 
MLL fusion protein MLL-ENL was expressed in Mir1' HPC. The ability of 
MLL-ENL to immortalise such Mil knockout (KO) HPC would provide 
substantial evidence for a gain-of-function mechanism of MLL-ENL leading 
to leukaemia.
Previous Mil knockout embryos have demonstrated abnormalities in 
haematopoiesis with reduced cellularity and colony forming capacity in Mil 
knockout yolk sac and foetal liver HPC (Hess, et al 1997, Yagi, et al 1998)). 
Knockout HPC from the AGM of Mil deficient mice were also unable to 
reconstitute the bone marrow of irradiated mice compared to WT controls 
(Ernst, et al 2004a). However, because homozygous deletion of Mil results in 
embryonic lethality, a knockout mouse model was generated in our 
laboratory in which deletion of exons 9 and 10 of both alleles was achieved 
in a conditional manner (McMahon, et al 2007 manuscript submitted). These 
embryos died at E12.5-16.5, and analysis of E12.5-E14.5 foetal liver cells 
showed defects in the haematopoietic stem and progenitor pools, including 
reductions in LT-HSC and ST-HSC number. In the conditional model, LoxP 
sites were inserted flanking exons 9 and 10 of the Mil allele (floxed allele), 
and these sites were subject to recombination in the presence of the enzyme 
Cre recombinase. The breeding of mice carrying a floxed Mil allele to mice 
carrying the Vav-Cre transgene resulted in a further conditional knockout 
(cKO) model in which Mil was deleted in cells of the haematopoietic system 
only, as the Vav promoter was only expressed in haematopoietic cells, and
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this allowed the effects of Mil deletion on post-natal haematopoiesis to be 
studied (McMahon, et al 2007 manuscript submitted). Although normal 
numbers of cells appeared in the bone marrow, spleen and thymus, 
haematopoietic function was compromised with reduced numbers of pre-B 
and myeloid colonies seen in culture, and bone marrow cells were unable to 
compete with WT cells in competitive reconstitution assays. HPC from 
knockout foetal livers and from conditional knockout adult bone marrow 
were utilized to examine the effect of MLL-ENL on HPC lacking both Mil 
alleles.
5.1 MLL-ENL immortalizes murine M lf/+ foetal liver and
adult bone marrow haematopoietic progenitor cells
Previous models of MLL fusion leukaemia, in which HPC enriched in stem 
cells were transduced with retrovirally-delivered Mil fusion gene constructs, 
have been described in Chapter 1. In these studies both WT alleles of Mil are 
present in the transduced HPC.
In this study, HPC were isolated from E l3.5 foetal liver or adult bone 
marrow and HPC enriched for stem cells by depleting Terl 19+ foetal liver 
cells or Lin+ BM cells. These HPC were then transduced with the pMSCV- 
neo-MLL-ENLful,'length construct shown in Figure 2.4. The results of colony 
forming assays are shown in Figure 5.1 and Figure 5.2 and demonstrate that 
MLL-ENL immortalizes M ltl+ HPC. Figure 5.1 A shows that large numbers 
of dense colonies continued to plate into the eighteenth round, and were 
macroscopically typical of myeloid colony forming units (CFU), 
demonstrating a high capacity for renewal of the haematopoietic progenitors. 
Figure 5. IB shows cytospin analysis of the cells showed blast-like 
morphology, and immunophenotype of M acl+G rl+c-Kitlow, suggesting cells 
at an immature stage of myeloid differentiation (data not shown).
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Figure 5.1 Colony and cell number following expression of MLL-ENL in 
wild type adult murine haematopoietic cells
A shows the number of colonies formed, and number of cells per 104 cells 
plated following serial re-platings of Lineage depleted adult murine HPC 
transduced with pMSCV-neo- MLL-ENLfu"'len8lh.
B shows the typical colony and cellular morphology of WT adult HPC 
immortalised by pMSCV-neo- MLL-ENLfull‘length. Cells were visualised by 
cytospin preparation followed by May-Grunwald-Giemsa staining (original 
magnification x 400).
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Figure 5.2 Colony and cell number following expression of MLL-ENL in 
wild type foetal murine haematopoietic cells.
A shows the number of colonies formed, and number of cells, per 104 cells 
plated following serial re-platings of Ter-119 depleted E l3.5 foetal murine 
HPC transduced with pMSCV-neo- MLL-ENLfu"'len8th.
B shows the typical colony and cellular morphology of WT foetal HPC 
immortalised by pMSCV-neo- MLL-ENLfulWength.
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5.2 Generation of a knockout and conditional knockout 
M il mouse and characterization o iM l t1’ and MIT1' 
HPC
A conditional knockout Mil mouse model was generated in the laboratory 
using an ES cell targeting strategy (McMahon, et al 2007 manuscript 
submitted). In this model, LoxP sites flanked exons 9 and 10 which encode 
the first PHD finger of Mil, and these exons are deleted in the presence of 
Cre recombinase. Two lines of PC3 ES cells that had been successfully 
targeted were injected into blastocysts. The chimeras which arose were bred 
onto C57BI/6 background to give rise to Mil conditional {M lfox/Jlox) and 
constitutive knockout (M lfox/') lines. Expression of Cre recombinase was 
under the control of the protamine promoter in male spermatocytes, and 
recombination resulted in a deleted Mil allele and a floxed Mil allele. The 
floxed Mil allele was fully functional and mice either homozygous or 
heterozygous for this allele were bom live with no abnormalities. MirA mice 
homozygous for the deleted allele {Mil KO), died between E12.5 and E16.5. 
No MLL protein could be detected by immunoblotting of protein lysates 
made from KO fetal liver cells (Figure 5.3C).
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Figure 5.3 Diagram of the targeted Mil allele in a conditional mouse cell 
line.
A shows the targeted Mil allele following homologous recombination in ES 
cells, and the floxed and deleted allele created by recombination of the loxP 
sites. Red triangles denote LoxP sites. Kp = Kpnl. Also shown are the 
position of the probe used in Southern Blots and the sizes seen from each 
allele (Figure courtesy of K. McMahon).
B shows the genotyping by PCR of MITA (KO) embryos. WT allele = 730 bp, 
Deleted allele = 250bp. (PCR performed by K. McMahon).
C demonstrates the absence of MLL protein in MIT1' foetal liver by Western 
blot. Lysates made from foetal liver from Mll+/+, Mll+/' and MITA embryos 
were run alongside K562 lysates as a positive control. MLL N-terminal 
(MLL-N) and MLL C-terminal (MLL-C) antibodies were used to detect the 
presence of MLL. An antibody against HSP-90 was used as a loading 
control. (Western analysis performed by S. Hiew).
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In order to study the effect of the loss of Mil expression in adult 
haematopoiesis, a further conditional knockout (cKO) model was developed 
in which Mil was deleted only in haematopoietic cells. This was established 
by breeding Mllflox/floxmicQ to Mll+/' mice carrying the Vav Cre transgene in 
which Cre recombinase expression was under the control of the Vav 
promoter, expressed only in haematopoietic cells. This gave rise to 
Mil ~/JIox VavCre mice (Mil cKO), in which Mil expression was absent due to 
recombination of the floxed allele in the presence of Cre recombinase.
Characterisation of fetal liver haematopoiesis in Mil KO embryos showed 
that there was a significant reduction in the number of haematopoietic 
progenitors in the KO fetal livers compared to Mll+/' (heterozygote, Het), 
livers (McMahon, et al 2007 manuscript submitted). The different HSC 
populations in the fetal liver cells were analysed by flow cytometry and a 
significant reduction in both LT-HSC and ST-HSC compartments were seen 
in the KO fetal livers compared to the Het. Further competitive repopulation 
assays confirmed that KO fetal liver cells were unable to give rise to either 
short term or long term reconstitution when compared with Mil WT fetal 
liver cells. Thus, whilst HSC are present in KO fetal livers they were not able 
to function as self-renewing stem cells when in competition with WT HSC.
Characterisation of the effect of Mil deletion on adult haematpoiesis using 
the cKO model described above showed no difference in any of the major 
blood cell populations between Mil cKO and M lfox/' (floxed heterozygote, 
FloxHet) controls. This suggested that Mil is not required either to establish 
normal steady-state haematopoiesis postnatally or for the differentiation of 
mature haematopoietic cells (McMahon, et al 2007 manuscript submitted).
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5.3 Retroviral constitutive expression of MLL-ENL and 
E2A-HLF causes only a transient enhancement of self­
renewal in foetal haematopoietic cells
Foetal liver Terl 19" HPC were isolated from E l3.5 M/^embryos and Mll+/' 
littermate controls. The genotype of embryos was confirmed by PCR analysis 
of DNA extracted from unsorted foetal liver (data not shown). The efficiency 
of Terl 19” isolation by MACS is shown in Figure 5.4A. These cells were 
then retrovirally transduced with pMSCV-neo- MLL-ENLfu,,'length (MLL- 
ENL), pMSCV-neo (neomycin) and, as a positive control, the known 
immortalizing oncogene E2A-HLF. The Mil gene status has no known 
relation to the immortalizing potential of E2A-HLF and so could not act to 
dominantly inhibit MLL function itself. Following spinfection, the cells were 
transferred to methylcellulose medium M3434 containing recombinant 
cytokines IL-3, IL-6, SCF and erythropoietin to promote the growth of 
myeloid lineage cells, and to which GM-CSF was also added. Cells that were 
resistant to neomycin were assessed for immortalization following serial 
plating in methylcellulose.
Figure 5.4 shows that M ltf' cells embryos did not undergo immortalization by 
either MLL-ENL, or E2A-HLF, whereas both oncogenes did immortalize 
Mll+/~ HPC. The M ltf' cells formed small, dysmorphic colonies that were not 
typical of myeloid CFU, up to the fourth round of plating. Mll+/' colonies, 
however, formed typical myeloid CFU and continued to plate beyond the 
fifth round with high colony and cell numbers.
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Figure 5.4 Retroviral constitutive expression of MLL-ENL and E2A- 
HLF causes only a transient enhancement of self-renewal in foetal 
hamatopoietic cells.
M l t  (KO) and M il*'' (Het) foetal liver (FL) HPC were isolated for Terl 19" 
cells and transduced with MLL-ENL, E2A-HLF or neomycin expression 
constructs, and underwent serial re-plating in methylcellulose.
A shows a representative histogram of the typical efficiency of isolation of a 
Terl 19“ population by MACS from foetal liver cells. The genotype of M f7' 
and M /+/‘ embryos was confirmed by PCR of DNA extracted from unsorted 
foetal liver cells (data not shown).
B shows the number of colonies and cells per 104 cells plated following serial 
re-platings from one representative experiment.
C Typical morphology of MIT ’and M lt'~ MLL-ENL and E2A-HLF colonies 
at the third and fifth round of re-plating (original magnification x40).
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5.4 Retroviral constitutive expression of MLL-ENL in
j^lj-zflo^avCre ck q  adult haematopoietic cells results in 
immortalization and confirms that MLL-ENL acts in a 
gain-of-function manner
MLL expression in the haematopoietic system of Mil cKO mice was 
abolished following the recombination of the floxed allele in the presence of 
Cre recombinase driven by the Vav promoter as a result of expression of the 
Vav Cre transgene. Adult BM HPC were isolated from M ir^ox VavCre (cKO) 
mice and MlT,flox (FloxHet) littermate controls. The genotypes of the mice 
were confirmed by PCR of DNA extracted from unsorted BM (data not 
shown). The population was enriched for stem cells by sorting the BM HPC 
for a Lin" population and the typical efficiency of this isolation is shown in 
Figure 5.5A. These cells were then retrovirally transduced with constructs 
expressing MLL-ENL, neomycin only and E2A-HLF. Following spinfection, 
the cells were transferred to methylcellulose medium M3434 with added 
GM-CSF. Cells that were resistant to neomycin were assessed as regards 
immortalization following serial plating in methylcellulose. Figure 5.5 shows 
that both the Mil '^ox VavCre and MIT/flox HPC were immortalized by both MLL- 
ENL and E2A-HLF, consistent with the result that MLL-ENL is able to 
immortalize HPC in the absence of WT MLL. Both fusion proteins formed 
colonies that were large, with a dense centre and lighter halo appearance, 
containing high cell numbers, and reflecting the capacity of the cells for self­
renewal. Cytospin preparations revealed the cells to have blast-like 
morphology. These cells actively proliferated in liquid culture containing 
cytokines (11-6, IL-3 and SCF) that supported the growth of myeloid lineage 
cells (data not shown). The appearance of the immortalised colonies and cells 
was the same for those derived from cells with an Mll'/flox VavCre or MIT^0X 
genotype.
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Figure 5.5 MLL is not required for the initiation of immortalisation by 
MLL-ENL.
M ir/flox VavCre and MlT/flox BM HPC transduced with the constitutive MLL- 
ENL, E2A-HLF, and neomycin expression construct were examined for their 
ability to form immortalised colonies following serial re-plating in 
methylcellulose.
A The genotype of M V /flox VavCre and Mll/flox embryos was confirmed by PCR 
of DNA extracted from unsorted foetal liver cells (data not shown). These 
cells were then sorted by MACS for a Lin" population. This figure shows a 
representative histogram of the typical efficiency of the isolation.
B The number of colonies formed per 104 cells plated following serial re­
platings from one representative experiment is shown.
C INT stains of the third round methylcellulose cultures.
D Typical morphology of Mir/flox VavCre and Mir/JJox MLL-ENL and E2A-HLF 
colonies (original magnification, x 40).
E Typical morphology of the cells from these colonies (original 
magnification, x 400). Cells were visualised by cytospin preparation 
followed by May-Grunwald-Giemsa staining.
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Individual colonies were picked from the Mil '/flox VavCre and MlT/flox 
methylcellulose plates infected with MLL-ENL and E2A-HLF. These cells 
were examined to ensure that both Mil alleles were absent in cells 
immortalized by MLL-ENL, and that these cells did not contain non­
recombined Mil which could have accounted for the results seen. Colonies 
were picked from each of the triplicate experiments. DNA was extracted 
from each colony. PCR reactions were then carried out using primers E and F 
to amplify the Floxed allele (F), and using E and G to amplify the deleted 
allele (D), using the PCR strategy described in Chapter 2. The position of the 
primers and the size of their predicted products are shown in Figure 5.6A.
Figure 5.6B shows the results of triplicate experiments in which a series of 
individual colonies immortalized with MLL-ENL or E2A-HLF were 
genotyped. Panel a) shows three individual MLL-ENL immortalized colonies 
from each experiment in which only a floxed allele is present, with the 
presence of a PCR band resulting from the deleted allele confirming a MIT 
/Flox genotype. At least seven individual colonies from each experiment were 
picked and all revealed the same genotype (data not shown). Panel b) shows 
seven different MLL-ENL immortalised colonies from each experiment in 
which both Mil alleles are deleted (Mir/floxVavCre) as confirmed by the 
presence of the band resulting from the deleted allele only, and absence of 
the Floxed band. Panel c) shows three different colonies from each 
experiment also with a Mil '/flox VavCre genotype and immortalized by E2A- 
HLF.
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Figure 5.6 MLL-ENL immortalises adult HPC lacking both Mil loci.
The figure shows the HPC genotype by PCR of DNA extracted from 
individual colonies immortalised by MLL-ENL from three replicate 
experiments i, ii and iii.
A shows the targeted Mil allele following homologous recombination in ES 
cells, and the floxed and deleted allele created by recombination at the loxP 
sites. Black triangles denote the loxP sites. Kp=Kpnl. The primers used to 
amplify the wild-type allele (primers E and F), and the deleted allele (primers 
E and G) are also shown. (Figure courtesy of K. McMahon).
B Colonies whose genotype is Mir^ox (panel a), and Mir/Jlox VavCre (panel b) 
are all immortalised by MLL-ENL. WT= wild-type Mil band, D= deleted 
band. Colonies with Mil deleted genotype and immortalised by E2A-HLF are 
shown in panel c.
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Although the MLL-ENL immortalized Mil '/flox VavCre and M lt,flox colonies 
appeared the same morphologically in that they formed dense colonies with a 
surrounding halo, and were composed of myeloblast-like cells, it was 
possible that they comprised cells at different stages of differentiation. This 
could suggest that there was a requirement for MLL in order to confer the 
capacity for HSC renewal in the presence of MLL-ENL. The 
immunophenotype of the different colonies was therefore determined. Figure 
5.7 A shows one representative experiment in which the levels of Mac 1 and 
Grl expression are similar in both the Mil '^ox VavCre and M ir^ox cells 
following immortalization with MLL-ENL, confirming their similar stage of 
myeloid differentiation. Figure 5.7B shows that the levels of c-Kit 
expression are also similar.
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Figure 5.7 ^f//-^0Jf,/avCre an(j M lt/flox colonies immortalised with MLL- 
ENL express similar levels of G rl and Macl, and have similar levels of 
c-Kit expression.
This figure shows the immunophenotype of colonies immortalised with 
MLL-ENL from knockout and control colonies.
A shows the levels of double positive Macl and Grl expression in Mll'/flox 
VavCre and Mir/flox colonies immortalised with MLL-ENL. A representative 
experiment of three is shown, together with a plot showing the mean and SD 
of triplicate experiments.
B Levels of expression of the stem cell marker c-kit are shown in Mil flox 
VavCre and Mir/flox colonies immortalised with MLL-ENL. The shaded area 
represents unstained cells, and the bold line represents the sample. A 
representative experiment of three is shown, together with a plot showing the 
mean and SD of triplicate experiments
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These experiments confirm that MLL-ENL acts in a gain-of-function manner 
to confer the same characteristics of stem cell renewal, morphology and 
immunophenotypic stage on HPC despite the absence of WT MLL. MLL is 
therefore not required for the initiation of leukaemogenesis by MLL-ENL.
5.5 The Hox gene profile of M lli'ox/- VmCre and M lt/flox HPC 
immortalized by MLL-ENL
Studies that suggest that Hox genes have a role in rescuing the differentiation 
ability but not the proliferate capacity of Mil deficient haematopoietic cells 
have been described in Chapter 1. In addition, a number of studies suggest 
that MLL fusion proteins are likely to activate a combination of specific Hox 
genes, rather than specific ones, which may act together to promote 
leukaemogenesis. This pattern may be superimposed on Mll+/+ cells or act 
independently of Mil status. Examination of the Hox profile of cells 
immortalized by MLL-ENL in the absence of MLL could therefore reveal a 
specific pattern of Hox gene expression determined by MLL-ENL. 
cDNA was extracted from uninfected Mll~/flox VavCre haematopoietic cells and 
from M ir/Jlox VavCre colonies immortalized by MLL-ENL, as well as from 
uninfected MlT/fiox cells and MlT,flox colonies immortalized by MLL-ENL. Q- 
PCR analysis of Hoxa, Hoxb and Hoxc genes was conducted in collaboration 
with the Haematology Department, CCRCB (Queen’s University, Belfast). 
Figure 5.8 shows the genotype of cells from which cDNA was examined and 
the Hoxa profile of immortalized MLL-ENL M ir,flm VavCre and MLL-ENL 
Mir/M  cells.
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Figure 5.8 The Hox gene profile of MLL-ENL compared to
MLL-ENL Mir/f,"x HPC.
A shows the genotype of cells from which cDNA was extracted and analysed 
by Q-PCR for the profile of Hox genes. Colonies were harvested from 
methylcellulose plates (MLL-ENL M r m  and MLL-ENL 
from three independent experiments (1, 2 and 3), and the genotypes of the 
cells harvested from each plate confirm that the genotype of the cells 
harvested are M lt/flox VavCre and Mir^ oxin each of the triplicate experiments 
according to the presence of the Floxed (F) and Deleted (D) bands.
B shows the results of Q-PCR analysis of the Hoxa profiles of MLL-ENL 
M ir/flox VavCre and MLL-ENL MlT/floxcolonies from experiments 1, 2 and 3.
The graphs show the number of copies of each Hoxa gene per 0.2ul cDNA 
(25ug of total RNA) for each immortalised cell type.
All the MLL-ENL M ll/flox samples containing a wild-type Mil allele 
expressed all the Hoxa genes except Hoxal3. In particular Hoxa6, Hoxa?, 
Hoxa9, Hoxa 10, and Hoxa 11 are over-expressed in all MENL M lf0^ ' cells. 
MENL M ir/flox VavCre cells lacked both wild-type Mil alleles and in contrast to 
Mir/Jlox cells, MENL Mil '/Jlox VavCre 1,2 and 3 show minimal expression of 
Hoxa genes. This expression level remained low in the case of Hoxa6 to 
Hoxa 11 genes, whereas it was raised in MENL M lt/flox cells compared to the 
remaining Hoxa genes.
The results show that the Hoxa code of gene over-expression, which is 
present in MIT^0* HPC immortalised by MLL-ENL, is not imposed by MLL- 
ENL on HPC lacking Mil. However, these HPC still undergo immortalisation 
in the absence of this Hoxa code of over-expression.
5.6 Discussion
Leukaemic blasts derived from infants who develop M/-fusion leukaemia, 
and from older children and adults who do so as a result of previous 
cytotoxic therapy, demonstrate the presence of one WT Mil allele. It would 
be conceivable that the fusion gene disrupts WT Mil, and previous studies 
suggests that MLL may be recruited by the fusion protein during the 
leukaemogenesis process (Milne, et al 2005b). This study sought to establish 
whether MLL was required, or redundant, to the process of initiation of 
leukaemogenesis by Mil fusion genes.
The inability of either MLL-ENL or E2A-HLF oncogenes to immortalize 
M lf' foetal liver HPC initially suggested that both Mil alleles are 
fundamentally required for self-renewal of HPC. It appeared that self­
renewal capacity could not be conferred upon MIFA cells by a fusion 
oncogene alone, even when that oncogene had no known requirement for WT 
Mil for its oncogenic function, as is the case with E2A-HLF. However,
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subsequent results using adult HPC from a conditional knockout model 
demonstrate that both fusion genes cause enhanced self-renewal capacity of 
HPC in which WT Mil is absent. This confirms that a typical Mil fusion gene 
such as MLL-ENL acts in a gain-of-function manner to initiate 
leukaemogenesis, rather than doing so by disrupting the WT MLL gene.
Further characterization of HPC derived from these M lf' foetal liver and 
from M ir/Jlox VavCre bone marrow models demonstrated differences in their 
contribution to the HPC pool (McMahon, et al 2007 manuscript submitted) 
and may explain why foetal MIT ' HPC failed to immortalize. Foetal livers 
lacking Mil were shown to have a significant reduction in the proportion of 
LT-HSC and ST-HSC as analysed by cell surface markers, and these M lt ~ 
cells were unable to reconstitute bone marrow in competitive repopulation 
assays suggesting that whilst HSC are present in M il1'foetal livers they are 
not able to function as self-renewing stem cells when in competition with 
normal HSC.
It is therefore possible that the numbers of Mil'' HSC with self-renewal 
capacity among the population of isolated Terl 19" cells was extremely small 
compared to that of the Mll+/' HPC, and had a significantly smaller chance of 
being targeted by the transduced fusion-gene expression constructs. Also, the 
MirA HSC may have lost their capacity to proliferate and die in culture with 
cytokines rather than proliferate. These reasons may have resulted in the 
failure of immortalization of the M lt ~ cells by the fusion genes.
The domains of common fusion proteins that may be responsible for 
transcriptional de-regulation have been described in Chapter 1. The common 
fusion partners AF4, AF9 and ENL have been shown to have transactivation 
properties determined by reporter assays, and may confer these on the fusion 
protein to cause aberrant transcription of target genes. In addition, a number 
of fusion partners including ENL have been shown to be directly or
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indirectly involved in chromatin remodeling. ENL is homologue of the yeast 
SWI/SNF subunit, ANC1/TGF3, and is found to be a component of two 
human SWI/SNF chromatin remodeling complexes (Nie, et al 2003). The 
partner protein appears to assist in accessing chromatin to activate 
transcription of target genes of MLL-ENL such as the Hoxa7 promoter. Such 
mechanisms, in isolation or combined, allow the fusion protein to 
transactivate its target genes in the absence of WT MLL to cause leukaemia.
The importance of Hoxa genes as target genes critical to the initiation of 
immortalization by MLL fusion proteins was investigated by analysis of 
HPC immortalized by MLL-ENL but lacking either wild-type Mil allele. The 
results presented show for the first time that the Hoxa code of gene over­
expression, which is present in M lt/flox HPC immortalised by MLL-ENL, is 
not superimposed by MLL-ENL on HPC lacking Mil. Critically, these HPC 
still undergo immortalisation in the absence of this Hoxa code of over­
expression.
The expression of a Hox combinatorial code has been described by a number 
of studies to be important in the maintenance of the MLL-fusion mediated 
immortalized phenotype in vitro and in vivo, with no specific Hox gene 
described as critical to this phenotype (Horton, et al 2005, Kumar, et al 2004, 
So, et al 2004, Zeisig, et al 2004). The Hoxa genes, particularly Hoxa7 and 
Hoxa9 have been repeatedly implicated as part of this code. However, all 
published studies to date use HPC in which at least one wild-type Mil allele 
is present. The Hoxa expression profile of these cells may therefore be a 
result of gain-of-function properties conferred upon MLL by the fusion 
protein, and may contribute the the maintenance of the immortalized 
phenotype. However, such altered Hox gene expression is not necessarily 
contributory or essential to the initiation of immortalization by MLL-ENL. 
MLL is known to be involved in the maintenance, and not the initiation of 
Hox gene expression, and so aberrant MLL function may maintain aberrant
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Hox gene expression and so contribute to maintaining the immortalized 
phenotype. However, the critical genes involved in the initiation of the 
leukaemic process may be targets of the MLL fusion protein that are distinct 
from those of normally-functioning MLL, and there may be no initial 
requirement for genes altered by aberrant MLL function. The data presented 
here show for the first time that neither wild-type MLL, nor Hoxa gene over­
expression is required for the initiation of HPC immortalization by MLL- 
ENL.
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6 C onclusions
6.1 A model of leukaemogenesis by gain-of-function of 
MLL-ENL in primary HSC resulting in aberrant 
regulation of HTm4 mediated by binding of the target 
gene via the Menin-binding domain of the fusion 
protein
I suggest here a model to bring together my observations that MLL-ENL 
immortalizes HPC in a gain-of-function manner, and that HTm4 appears to 
be a target gene of MLL-ENL. MLL-ENL is shown to immortalize HPC 
without a requirement for WT MLL, showing that alteration of the function 
of a remaining Mil allele by the fusion protein does not contribute to the 
initiation of immortalization by MLL-ENL. In addition, MLL-ENL does not 
itself cause aberrant expression of a subset of Hoxa genes in the absence of 
wild-type MLL in immortalized HPC, and these genes are therefore unlikely 
to be responsible for the initiation of immortalization by MLL-ENL. It is 
likely, therefore, that MLL-ENL acts in a gain-of-function manner to activate 
targets distinct from those altered by aberrant MLL function in order to 
initiate leukaemogenesis. The immortalized phenotype may however be 
subsequently maintained by aberrant expression of Hox genes in the presence 
of altered expression of a remaining Mil gene, as reflected in the results of 
this and other studies.
The domains of MLL that are replaced by the partner protein to form the 
fusion protein include the SET domain which, together with other members 
of the supercomplex, normally contributes to H3-K4 methyltransferase 
activity to maintain expression of MLL target genes. Transactivation of a set 
of target genes by the fusion protein uses other mechanisms of
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transactivation as described above, such as chromatin remodeling. In 
comparison to the stability and activity of MLL as part of a chromatin 
remodeling complex, the MLL fusion protein will not be processed by 
Taspase 1, and hence will have an altered relationship to the components of a 
chromatin remodeling complex that will also have different activity to that 
containing WT MLL. Such a relationship involves the retained ability of the 
fusion protein to interact with Menin, as opposed to other members of the 
MLL/HCF complex (Yokoyama, et al 2004). The activation of Hox targets of 
MLL fusions and CDKI targets of MLL-AF4 have been shown to rely on 
such Menin-binding (Milne, et al 2005a). Presented here is a model which 
postulates that MLL-ENL maintains its ability to interact with Menin as part 
of a chromatin remodeling complex that contributes to the activation of a 
novel target gene. This novel target, HTm4, has been shown to be a highly 
significantly up-regulated target of MLL-ENL in 32D cells following 
microarray analysis and has subsequently been validated as a target of MLL- 
ENL in 32Dcl3 cells. Validation of HTm4 demonstrates that it is regulated 
with greatest efficiency in the presence of the Menin binding domain of 
MLL-ENL. Expression of HTm4 in HSC is involved in keeping HSC 
quiescent, and its abnormal activation by MLL-ENL may result in increased 
cell cycle arrest of cells that may then evade death by chemotherapeutic 
agents, or acquire further mutations that allow escape from normal cell cycle 
control and the initiation of a malignant clone.
This model is outlined schematically below.
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MLL fusion confers 
gain-of-function on WT 
MLL to increase Hox 
target expression
Menin
HTm4++
Maintenance of 
malignant clone
Hox + +
Gain of function 
of MLL fusion 
protein causes 
overexpression 
of HTm4
Inhibition of 
CDK2 leads to 
increased cell 
cycle arrest
F o rm a tio n  of
m a l ig n a n t
c lo n e
Escape from cell cycle 
arrest as a result of further 
acquired mutation
restin g
Figure 6.1 A model of leukaemogenesis in which gain-of-function of 
MLL-ENL in primary HSC results in aberrant regulation of HTm4, 
which is mediated by binding of the target gene via the Menin-binding 
domain of the fusion protein.
See text for details.
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The data presented in this project support a model of leukaemogenesis in 
which MLL fusion proteins function in a gain-of-function manner, and 
transactivate a novel target gene to cause leukaemia. This model incorporates 
an understanding from published studies to interpret new data, and allows 
novel insight into the way in which leukaemia develops as a result of MLL 
fusion proteins. This understanding suggests new approaches to the targeted 
inhibition of the leukaemic process which will aim to improve survival for 
infants and children with this disease.
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Appendix
Table 10 Classification of highly significant genes down-regulated by MLL-ENL
Regulation of transcription
Probe set 
ID
Fold
change
Gene symbol Notes
1449333_at 0.7 Sf3al splicing factor 3a, subunit 1, nuclear mRNA splicing
1418730_at 0.6 Rnfl2 ring finger protein 12, regulation of transcription, DNA-dependent, protein 
ubiquitination
1418387_at 0.5 4930548G07Rik chromatin assembly or disassembly, regulation of transcription
1417892_at 0.5 Sirt3 sirtuin 3 (silent mating type information regulation 2, homolog) 3 (S. cerevisiae), 
chromatin silencing, regulation of transcription
1426929_at 0.3 Brunol4 bruno-like 4, RNA binding protein (Drosophila), mRNA splice site selection
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Regulation of cell cycle
Probe set Fold Gene Notes
ID change symbol
1420481_at 0.6 Cnnm3 cyclinM3
Regulation of apoptosis
Probe set 
ID
Fold
change
Gene
symbol
Notes
1418929_at 0.5 Esrrbll estrogen-related receptor beta like 1, caspase activation, regulation of apoptosis
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Signal transduction
Probe set Fold Gene Notes
ID change symbol
1449019_at 0.6 AkapI A kinase (PRKA) anchor protein 1, RNA binding, kinase activity
1424337_at 0.6 Snxl5 sorting nexin 15, intracellular protein transport, intracellular signaling cascade
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Enzymes or transporters
Probe set ID Fold
change
Gene
symbol
Notes
1451341_s_at 0.7 Cebpb ubiquitin-conjugating enzyme variant Kua
1421014_a_at 0.5 Clybl citrate lyase beta like
1424746_at 0.5 Kiflc kinesin family member 1C, retrograde transport, Golgi to ER, microtubule-based 
process
1417865_at 0.4 Tnfaipl tumor necrosis factor, alpha-induced protein 1 (endothelial) potassium ion transport
1423590_at 0.4 Napsa napsin A aspartic peptidase aspartic-type endopeptidase activity, hydrolase activity
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Other
Probe set ID Fold
change
Gene
symbol
Notes
1425030_at 0.7 Zfp622 zinc finger protein 622, RNA binding, zinc ion binding
1426503_a_at 0.6 Rnfl21 ring finger protein 121
1426835_at 0.6 Metapl methionyl aminopeptidase 1, methionyl aminopeptidase activity
1419471_a_at 0.6 Nude nuclear distribution gene C homolog (Aspergillus)
1427033_at 0.5 Dnmbp dynamin binding protein
1456772_at 0.4 Ncfl neutrophil cytosolic factor 1, superoxide-generating NADPH oxidase activity, 
leukotriene metabolism, inflammatory response, cell proliferation
144824l_at 0.2 Gm2a GM2 ganglioside activator protein, sphingolipid metabolism
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1452279_at 0.2 Pfc properdin factor, complement activation, alternative pathway
1423739_x_at 0.1 Aplp2 amyloid beta (A4) precursor-like protein 2
1419627_s_at 0.1 ClecsflO C-type (calcium dependent, carbohydrate recognition domain) lectin, 
superfamily member 10
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Table 11 Classification of highly significant genes up-regulated by MLL-ENL.
Regulation of transcription
Probe set 
ID
Fold
change
Gene
symbol
Notes
145232 l_at 6.1 Wdr9 WD repeat domain 9, regulation of transcription from Pol II promoter
1436208_at 3.7 Asbl ankyrin repeat and SOCS box-containing protein 1,
regulation of transcription, intracellular signaling cascade, male genital morphogenesis
142285 5_at 2.1 Cpsf3 cleavage and polyadenylation specificity factor 3, mRNA polyadenylylation, mRNA
processing
2 2 0
Regulation of cell cycle
Probe set Fold Gene Notes
ID change symbol
1454675_at 1.8 Thra thyroid hormone receptor alpha,
regulation of cell cycle, cartilage condensation, ossification, regulation, regulation of heart 
rate, cell growth, organogenesis, negative regulation of transcription
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Signal transduction
Probe set ID Fold
change
Gene
symbol
Notes
1422188_s_at 19.4 Tcrgv T-cell receptor gamma, variable 4
1420819_at 11.3 Sla Src-like adaptor, intracellular signaling cascade
1418892_at 4.0 Arhj Ras homolog gene family, member J,
cellular morphogenesis, small GTPase mediated signal transduction, regulation 
of cell shape, actin cytoskeleton organization and biogenesis
1421103_at 3.4 Bmp2k protein amino acid phosphorylation, regulation of bone mineralization, 
protein kinase activity, ATP binding, transferase activity, phosphatase regulator 
activity
1450298_at 3.4 TnfsH4 tumor necrosis factor (ligand) superfamily, member 14, cytokine activity, tumor 
necrosis factor receptor binding
1430640_a_at 3.2 Prkar2b cAMP-dependent protein kinase regulator activity, kinase activity, protein
2 2 2
amino acid phosphorylation, fatty acid metabolism, signal transduction, cell 
proliferation, organogenesis
1448548_at 2.5 Tulp4 tubby like protein 4, intracellular signaling cascade
143786 l_s_at 1.9 Prkce protein kinase C, epsilon,
protein amino acid phosphorylation, intracellular signaling cascade 
chemosensory behavior,regulation of peptidyl-tyrosine phosphorylation
1418594_a_at 1.9 Ncoal nuclear receptor coactivator 1, chromatin binding, signal transducer activity, 
receptor activity
Enzymes or transporters
Probe set ID Fold change Gene symbol Notes
1449136_at 448.2 Epx Eosinophils peroxidase
1427052_at 53.5 Acacb Electron transport chain
1448730_at 19.9 Cpa3 carboxypeptidase activity, proteolysis and peptidolysis
1420444_at 9.4 Slc22a3 solute carrier family 22 (organic cation transporter), member 3
1418989_at 7.9 Ctse cathepsin E, aspartic-type endopeptidase activity, neutrophil collagenase 
activity
1455045_at 3.5 serine racemase amino acid metabolism, lyase activity, isomerase activity
1454187_at 2.4 Pkdll2 polycystic kidney disease 1 like 2, ion transport
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Other
Probe set ID Fold change Gene symbol Notes
1441836_x_at 473.9 Baiap2 brain-specific angiogenesis inhibitor 1-associated protein 2
1419520_at 34.9 Cml4 negative regulation of cell adhesion
1459665_at 16.4 M rvil MRV integration site 1
1437886_at 6.3 Klhl6 kelch-like 6 (Drosophila)
1455493_at 3.9 Synel synaptic nuclear envelope 1, actin binding, protein binding
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